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~rgeted c:helotheropy. a pot entially cl inical l y releva'l t methcd of .
inc:easing the selective ~ellve'Y of cyt~lc agents . t o ' t umor e'en
populations has been evaluil.t ed. ·
.~ , lI'Odel ~ in .these. stu:Ues eatprised a ta .rge t , · tl1f! W:OOr
associ~ted ca[C~cyon.1C an tigen, ' vhich 111 ,"exp r eea ed by a wide tange
-. o~ human solid tumors , "and conj ugates ot ~inde8tne, a ~~t vinca
al kal oid , covaltiltly linked to a specific monoclonal anti-cEAant1bCxJy.
. . .. . '. ' . ~ ".
Olaracter16ation ot hanan tUnx:l[ cell l inea by iJmuncx;ytochElllilltry
am rad ic:bW ing 'assays established ' a range of Q"A expression enabling '
'. ' . .-
" .select ed cell . lines to be used for the assessment" of con j ugat e efficacy
in vitro , and t o be g rown as xenografts in nwe mice enabling a 'rel evant: . .'
pre--clin~ca1 m::del to be developed . '!be ' effect of conj ugate treatment . ' .
~ the gWorth of x~raft8 wl!=-h a range of a:A express !?" wu then
assessed., .
Theu<"iitucUes demons t ra ted the efficacy and bel ectivi ty of
~hBoother8P.r' both in vitro aa1 1n.V! Vo ~1(lg this model , cc nf thl1bl
theo retical ' p rediCtions', -rn addition, P~longed' su rviv al of mice t reat ed
wi th conjuga te ard r~ln!d toxicit:Y of calj~ated ca:pared to free drug
was d~trated in one exper iJrental protoc ol. '"
Furthe [' investigations and the cl inic al potential Of"1tu s approach
are discussed .
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cne of the major I1m1tatiOfl!!lof present day career Cherothe,aPY is
the lack of selectivity of cytotoxic drugs for mallgn.ant ~lls. conse-
. .
quently, ~ in therapeutic doses, toxic side effects are oft~ ' seen ,
~iallY vith ,r~idly .dividing cells of" the bone marrow•. gonads am gut
~ - . ' "
..' - "
Targe!;ed chmotherapy otfers a methcd of lnProving 'd rug ,delive ry .
to the tlmlOt, while sparing the host -toxicity, aoo has potential awl!c-
ati~ in the clinical setting. The ~oncept ~f linking cyto~ic agents
to antibodies directed against canc:er cells as , tutrOt specific delivery
agents has ~eJ.1ng theoretical sinpl1clty. \~ inter-relationablp of
. these factors l'l'lllY be represented in t:pe followinQ schene .. and these will
~ discussed in Olapter 1.
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1M resea rch of PaUx--Dlrlich ' (1854- 1915) (pl ate 1), provided rMnY
of 'the f oundations upon which mod'ern imm.unOl~, pha~coIOCJY and
haEmato lcqy could be based. By extrapolotJ.nq conc::epts he proposed f or
1Jmulology am pba:macology, ~ I08f attr1b~ the~ of tArqeted
chmother~ to thiA great sc ientist';" Ehriich Is " al~ of lntfIest fOr ·
his early work in onoology .ipd thes~ aspects of his research will be
discussed. \
I .
Paul !:hrl Ich was born in -March! 1854 at strehlen, -~r Sileo!",
(Gau!son, 1929~ BaldtY, 1976, leCheI:'al1er , SOl otorovs ky , ' 1974), now
known as Strzelin. Polaixl.. Although.an -indifferent student- (Garrieon,
19291 he dEJllOrl8trated II natural aptituJe for cer t ain swjects. while
• smw.1ng l :ittle ·talent f or others ~h~ Geru:an Literature -(~dry, 191&,
Lecheval ier et al, 1974). Dur in;! hi s Itll!dical training at the Ln1Yer-
s lUes of Bres lau, st~ Leipziq, he developed a profo.n:l.
in t erest in his tolOli az:ld i ndeed his doctoral thes i s of IB79 was entitled
· Contributions t o t he Theory and P ractice of Histolog'!C41 Staining-
(Lechev a.l i er et al, 1974) .
Dale has 8Ujgested that Ehrlich's research career be divided in to
three p~s ~ e, 1957a). During the first , Im-la91, Ehrlich 's work
followed his ea rly h1stolpgical interest, relating to the staining of
cells l!lId micro-or9ani~ with the newly synthesised dyes of the GenMn
·chemical Wustry. He made sever"-l contributions to th is area, iricltld~
the staining of the t~rcle bacillus id entified by koch in 1882•
-;
,
,.
-.. • .
Plate 1. Paul Ehrl i ch (1854- 1915)
. 's-
Follow ing a two year sojou rn in Egypt. to recover fran tl:be rcu- .
tcete, Ehrlich returned to Berlin in 1889. 'Ibe disc:ovety of the di~
eda ' toxin by~ em Yers in in 1886 and the toxin and anti-toxin of
~,r,
tetanus by~dnq and. !titasa to in 1890 stiJllJ.lated the next phase of
D1.rl1c h' s research. 'Ihus , be tween 1891 and 1903 t:.he centr al theme· of hie
rese arch becere the s ttdy of iJrIrllnity, the natu re of the toxin-ant i-
tox1n~ reaction, em the practical. aspects of treabrent of infectious
diseases.
The f amous -s ide-chain- theory, · ",as · lln at t eillpt to explain the
toxin-antitoxin in t eraction, and although many of his early papers
hint ed. at th i s concept i t was' first ful l y pti>lished in 1897 (Ehrlich,
1897) and presented at the open~ of the new Institute for the Invest-
igation and Cbnt:!ol of se ra , in Frankfurt (Baldry, 1976) aM as the
croonian Lect ure to the ~a1 Soci ety of London in 1900 (Dale,19S7b) .
r
~ -~ntia11Y' DlrlJch proposed that e~ cell of th e body exh~ited
. \
6E'Veral fi?e chains , wi th the MJeCific function of - • • . •attachi n<j to
~Jes ce rtain fcxd-stuff~· . During active infection, a tox~ would
bind to the s ide chain arx1 rel'der the cell susc eptible to dC!IMge infl-
. . . ~
ict~ by the toxin, ei the r di rectly , br by th e prevent~oo of uptake of
nutdeK:lts. He ~tre~ the speci fic nature of .the toxin-·slde--<:h81n-
reaction, and used thi~ to explain the origin lind action of the anti-
tOlli n.
-:
lX:ed "in excess durin;) regeneration, aid therefore pushed off fnxn the
protoplasm - thus caning to exist in a free state" '(Dale ,1957bl .
' . \
Therefore, binding of .t he antitoxin, o~ the secreted "adde-
c!Wn", 't o the toxin in the seM ~u1d represent a specific reecetco ~
- ---- render the toxin harmless to the cells of the host, -Ehdich later
referred to these antitoxins · asl antibodies, "or ' lI'IaI9i c bul\ets'", "These
. { " ' "
ant~ies are exrlUBiVelY 'pIl~ASitotr~hic" emS? it is "!1?t ;S.urp ris1ng
that~ seek, o~f their targets, li~e" magic ~ulle~~' In this way I can:- ·
explain the mirac:u1ous curee that are sanetimee obtained" (Br~ls., 1~61) .
If su:h substances could be mlde with the bcdy , reasoned Ehrlich,
It should be possible to prcdlJ:~ S1m11a~ific stbstances ' in the.
lat>c:ratory (Baldry, 1976, Lechevalier et er, 1914, Br~k, 1961),
·SUCh eceeeeeeee would then" be able to exert ~ir full action exclUs-
ively 00 the pIlrasite harboured with the, Or9ani~, and would represent,
80 to speak, lMglc 'bull ets , whIch seek their targets of their own accord"
(Lechevaller ~t al, 19741.
The) search for such eceeeercee st1Jrulated the final phase ) of
Ehrlich 's research between 1903 and 1915 . 'I'h1~ .era of chemo~rapy led
to the teSting or organic arsenicals developed by the German Olem1cal
I
.
It was ~ao during this f~ pMae ,that D1rli~h.am hiS co-worker
Apolant , coriducted t!XJ:erinents on transplantable murine tUll'Ors (D~e • .
1957a ) . 'I\)ey found that ' pre-1nOCulll~iOO of mice with certain~.Of
tlmlOr enharJ::e:J eeereeeece to 81.tlseq~t 1nocul.llti~ am .in sate cases' itid ~ · -­
to t UllJ:l r reg ression. ~e early exper~~ "l ed t o interest in"~
' " \ ' . .
·applicatUfl. of 1Jmulology ~ oncology, ..WhiCh/declined in lll.t~[ . years-.
when(it was found that these results we~ related to allogenic responses
( , ' . ". ( .
to b.!stocanpatibility antigens present' in fI?~ ,and tm:-or t1S8~. .. .
Just as Ehrlich extrapolated the '"Concepts of 'side ' cha!its· teM
, .
Kekule'8.~~1~R1ng Rypothes~, It . is justified ' t o credit. - Ehrl1C~
• with the first concept of targeted chemotherllpy. COnsidering .the ~
antibodY-dr1J;J. conj~ates as the magic bul~ets he otten referred to, the
.,jpa, rasi t ot rophic ' 'effe<:i would be ~~isfied if ooe considep3'41th':_'plu:as- r
ite' to be the 'neop l asm to which the aiJ.tibody is directed, while sparing
' f
the 1t cell. arit
IV '
'organotrophic' consequeneeA.
I .
'.., '
·. .~I . ..
Estimates of the irc'iden::e of cancer in 1900 fran the National
I~titutes of . Beal."th (US\l sugqest that of the 185,000 patients with
newly dleqriosed maliqnal)l::~ for that year, approximately 61l percent are
- - --;:ent i al Cand~dates' 'for C~heraJ?Y (DlllVita, 1983) . This figure
excludes the .445, 000 localised skin, or ·in situ· ·t llOOrs that are cured
~ local surgical excision alme. Of the patients receiving chE!'ID- - .-
, ~~apy! ' an estimated 46,000 ,woul~ ~t to be ' .~ur,ed either ~ dr\)]
trell.tmm~ alone or .as an adjuvant ~o, local cootrol of disease by either
surgery ' or ' radiothe~apy, Idth e further -20 ,000 Patients expecting
C signific~t prolonged disease-free surviva!,.-'while the rema!mer wOuld .
receive c~therapy for ~lill.tion. OJr~' in tMs-context refers ~
life expectancy of a treated cancer patient to -be s1mllar to that of a
'normal' .~tehed cohort ,~ ~ popUlation.
\ Altho\)]h chemotherapy has ha~ ~~~_.greatest impact upon the
prognosis of ~ted' haemato~ogical malignancies, su::h as acute
lyrrphocytic leukaemia ,.-where a SO percent longterm d~sease-free survival
is expected carpared to 30 perc~t in 1913, other tumors, too, are
potentially curable such ee . Hodgkin's meeaee, testicular cancer,
Burkitt's IYJlPqna, choriocarcinana, and diffuse rdst!ocytic · lynp!nna
(~~r, rtee; Allegra, Yeh , ~":: ~_1!~)' The percentage of patients :
. lrlth . ovarian am head am neck' cancet8 .showing a response or even cure
aWeatS to be iD:reasing also.
-I •HoWever, t;he use /Of . d ~:8 in the treatment of rMny eo11d tumors,
9
especially in the adjuvant 'setting, is 9en~rallY disaRX>lnting , ~t.HOugh
the re are a f ew no~le exceptions . Of the pediatric soUd tumors, cure
rat e ,for wUrn's t1JlJOr .i ncreased significantly following the add iUoo of
actil'lOI!!fCin./J ~ surgeryttxJ. ~adiOtherapy ' (D' Ang l0, Evans , B[esl~w.
Beckwith, Bishop , .Felgl ,. Goodw~ Leaper Sinks , SUtCJwi Tefft , Wolff .
19761, and similarly adjwant vi ncristine , actinomycin D and cyclo-.
plx>spharnide have been shown to inprove surviVal- for - emryonal rhabdo-
nyosaro~ (Maurer, ~aldson, GehM, Banroond,' Rays, Lawrence, Lind:>erg',
Moon', Newton ,. Ragab, Raney, Ruymann . Soule, SUtton , Tefb, 1978).
Ildjuvant' Chaoothe~apy fO~ Ewing:S sarcana has also been show to 81~ifi­
cantly increase length ' of. ~urvival ( ~en; caparros, ~Corm-
. ick , Huvos & MilrCOYe, 1978) although this ' has not yet clearly been..
d~t["te4 fo r os teosarcoma ' lRosek.,...,aUv09, Moseooe,-Beattie, ExeJJ:'Y'
ca~ros , xarccve, '1978) . The current stat~ of che:notherapy In ' :'th e
tre.atment of early Dre~t jcancer has recently been reviewed following an
atten¢ to assess the results of over eO prospec ti~ randomised stlrl!es
Addr essing this question lre itod al , 1984a, 1984b) . Although it is
sugges·~ that adjUv~t chem:ltherapy p,roloogs disease-free survival ?f ,/
pre-menopausal . patlents with stag~ II disease w.ith roe to three positive
nodes, inconsiatent pd:lllshed reeurte and."the need to further optimise
~regimens and dura~~on of . tr~a~t currently ,~~eclude an9 definit e
statement as ec its exact .r ol e in t~~~~nt of breas t cancer. (Bona-
, . donna & Valagussa, 1985).
\,~
By cCIltrest, cfie!r,)th(!t apY has not resulted- ~n significant benefit
for- 'patientB with g88'tdc, colo re<:tal or noo-small ..ce ll lung cance rs ,'
For small cell ILlllg cancers, ten to fifteen percent of patients are now
10
expected to ecbrece lfil'l¢erm survival, despite a reported increase in
respceee rate of pa:l~l)ccent in 1973 to 90 percent in 1983
(Olabner et al, 19841 .
A nunt>er of ~ of iltproving chenother'apy have been proposed,
lnclldlng- optimisation of dosages aM schedules o'f currently available
~ents, the devel~nt of new analogues with redoced toxicity , and, a
~roper eeeeeerene of reqi<:,"aJ. chemotherapy, which althouqh based O?
ecund phaflllacoloqical principles. has received inadequate evaluati~
,through poorly designed stwies lacking adequate controls 100000er et
al, 1984). In additioo it is 'expect ed that as the mechan1slra of action
of 6rugs and of drug resistance are better . understood, that this too
wUI influence the administration of chemotherapy_ '!be' recent establish-
ment of a panel of murine solid tLmlOrs and hlrllan tlJm:lt 'xenograf ts in nude
mice at , the Nationai Career Institute (USA), for 6Cl:eening drugs will '
allow better evaluation of new .drU3s W may also indirectly improve
resUlts. Screening previously ut~l ed the single P388 JItldne leukemia
model whose relevance to hl.lllan neop ~ia waS deb8.table. In addition, it is
. ;
likely that biolO!tic COIi;:ounds in the form of lynphokines, r lOOrloclonal
ant:lbcx1iea, and others will find an inc:easlng- role in cancer. treatment "-
over the next ten years and may eventua14' displaCe coovmtional cancer
chemotherapy (Oldham, 1983bl Ba1dwin~ ~?84; chabner ~t 81, 19~) ~
Although it is not expected that ta ,rgeted cherrotherapy ""ill, or
·sw uld , d~~ace current~y Us~ " dru;Js: i,t may well provide" a useful
method of ircreasil'l9 selectivity of drug delivery, or ··redociRj tOXicity,
and therefor~reciuir:es-proper and -'dequate evaluation,
, .
11
I 2.0 'INIZrS
'Ibe 8bility to identify and subsequently exploit dif f erences that
exist between eeece c~lls am normal cells would be of value both for
the dl~is of maligqancy and, f3C targeting, w~re ' s~h discrimination
, Is a necessary prerequisite of selectivity. However, many clams for
·t~r specific marker~~ have 8tDs~uentlY r~ned unslDstantia~ed in
. ,
the iight of fu~er inv~'.Stigatia"l, , altho~h·"tbl!se biological swstances
may ~ll eventuallt prOvide further insight into the ~ture of malign ant
change Mel the control of cellul~r dlfferenti~ti~.
• .". of}
StJ:h suggested ~~r markers, which may be detected in the sera of
cancer pat~ents- or as a cellular cmponent of the tumor itself, have
irclooed tUlOOr antigens: onccdevelqxnental prcdocte , inclt:rlil'l9 alpha-
~etoprotein, human Chodoo1Cgcmdotrophin and carcinoerbryonlc' antigeOl
irmunoglCbulins, as markers for nultiple .myeloma and malignant lynphomal
hormones, . incluJing ectopically prodU::ed calcitonin, insulin, glu::agon
.and c atecho.lamines l and , se veral non-SfEClfic enzymes such as lactate
'dehydrogenas e and acid phosphatase, where circ.~l!Itihg levels may be
el~ated in Ii v~1ety of malignancies. I t 1s apparent that many of "these
prClp)Sed cancer marker~ are too lbiquitous and non-specific' t o act as
potentil!ll targets, and attentla'1 has focused upon. the use of iJ'mono-
"logiCI!ll and oncodevelopoonW~kers for this role.
:- - -
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'11 2.2 '!moe Ant.1qerE
An immunologici!ll basis of tumor specificity was proposed by
Ehrlich in the 1900's, followinq the dBlXXUltratlon that ee[1,~ obtained
from mic@ inoculated with nece could inhibit the growth of s imi l a r
tUllOrs in other mice~ ' 'ltds WIIS thought to be a result of an J.Jrm\ne
response to tumor ~tigens and although s imil a r results en::ouca:je9
further studies into cancer :i1mu'lology and inrmmtherapy, sl.tlsequent data
.was re jsf convincing ,and it is now ~rent ~t BUC::~ results " were
obt~ fran allogeneicr~ to histocclrJp6tibllity antigens present
in ~ tm:ror. Inte'nist ~ t1li~e.:~~~id1y declined 'until the 1940's,
when a ntm'ber of fn~tigators ~re ~le to -deoonstrate the presence of
tumor specific .antigens in /~thYIChlOranthrene . indlK:ed ' earccees in
syngeneic mice amother tumor specific antigens were also slbsequenUy
demonstrated in a variety of chen1cally indoced experimental animll
tmors tcrcea, 1943J Prehn' Main, J.9571 Klein • .Sjogren , lQe~ & Hell-
strQll, 1960).
The distinction between tumor specific am tumor associated
.antigens is hrpOrtMlt as no 't!.mI)[ specific antigens have so fsr been
deronstrllted for human turrors with the possible exception of the hlmlAn
s-een idiotypes (stevenson, Elliot' stevenson, 19771 Q}.d, 1981). There
are, hoWev~r, II 'wiele range of tumor associated lIllti9ens, this elistipction '
arising fran the fact that Although elevated levels were ini~iAlly
identified in the circulatiOn of ~ancer patients, ,~rovecl ASsay tech-
niques later denonst-rated elevated leve'ls in healthy controls and
patients ~ith ~enign disease, AS well as In normal tissues also•
.)
J •
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Al~h the origin of these antigens is of f urdamenta! iD:por~e to ·t he
cancer or cellular bioIO;Jist, it has not been settled lIS to whether they
represen~; f~r ell:lIftIlle. differentiation ~tructures a r18ing as a res ul t of
derepression of fetal genes or whether they a re new 1I'101ecU.tea arl l!1 lng as
. a result of neoplasia itself. lb atte:r¢ will be made to address tMse
questioos, rathe r , to accept. their existence &r¥1 exanine their nature and
distribution as potential antigens fo r tarqet.1ng .
"'!be application of lIOOocla\al Illlt1bcdiea (see later) to th is eree
o f lIt umor i llU1lunol Oqy hA.II enabled ~ell s urface antigens t o be probed
with' a hi gh deqree of speci fici ty am has almet o:xrP1etely repl aced
the- use of absortled polyc lonal antisera. Their 'use hlls allowed v:arious
,
~ts of!f.~is~c eeneeure to ~ ~est1gated in addition to accu rat.e
quantitation of cell surface antig~ density in tllrOr ard no~ cells .
With the narrow ~arJ1e of epitope defin i tion by DX'lOClonals, lMl1Y normal
tissues IlIJSt be screened not only for the dlst r 1J:lution of ' the tarqet
. antigen, but also to detect any additiooal am W\eXfl!!CtedCrc6S-
reactions.
( ".
(
Altho ugh hetetogenelty of antigen exp ression has been desc[~
uslnq polyc lonal antibaUes (Sloane .. Qrerod, 1981) ita occu rrence has
been ·~onf1~d following the use of nonoclonal antibod i es t o def ine
cell a~rface antigens of breastt1l'l'Ors (Arkl.ie, .lor-P~~riou,
Bcxhter, Egan ~ Millis , 19811, colonic tUll'OrB (Areros , ~er6tynen , Bo8m!ln,
811ge r6 , Steplewskl, 19831, l ung tuno rs (w~ena.ar , HU~e r8, l'loul1n, .J'
SChol, ver atijnen, 8Ukena, CBanto I. v~emc:hue ren, 1983) , mel anana
-::ca.!!.el , s:~reyer, 9:hnidt-p:e~ , Kach, 19821 and between prwrY &I'd
1····
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autologous metastatic gas tric t:tIlOrs lBockey, stokes, 'Ibcrr{l6on, ~-.
bcese, MacDonAld , F,ieldinJ " Ford, 1984) . ' Many questions renain as to
the c4u.8e of he t.erogeneity. whether i t reflect s neq>lastic cellular
differenti4~ion or whether it occurs as II res ul t of variation in anti-
l' . genJ.c s tructure alone . The implic ations of heterogeneity .upon the
. lo:::ali sat:1on .of monoClonal antibodies are)1milar~y debated .
Difficulties with i~istoehm~al eecdtee '¥" tulrot .eec etcee
have already been . encountered in ,the ,s t udies referred to, which has l ed
to t he use of. paru;}s of lTOnocl~ -antibodi es' ~o roore .pr£cisely define
the range of antigens exPressed (GaU e r , l\bdUl~lz , Beverley, CO~alan,
Ford, Lane, Mota, Nash. Pulf~rd , Stein, Taylor-Papadimitriou, Wocdhowle "
HAsen, 1982 , Hand, Nutl ', "Colche r , 9::hlom, 1983). Similarly , ' !faa
sUjgested . antigenic het erogenei ty~ar8 to limit the overal~ effic~
,of antibody rrediated the~aP'.r"~"" the use of · cockt ails· carprislng several
monoclonals directed against the range of expressed antigenic deter-
y nants may prove useful . It has also ,been suggested however that the
~terogeneity of antigen, expression is not an ali 0[' none pMnanenon, &ld
in fact a cal1ge of anti9en expression is presQllt (BLlcchi~~~tin, .
Imai , reeeene & Waarner, 19821. If sLICh a differential expression
'ex i s ts ; c:arp!red to expression iJl normal tissues, Suffici~t selectivi ty
may al ready exist within sl.J:h a syst m.
Monoclonal antibcxUes ree:ocrusing cell surface antigens have now
been described for ' a variety of tumors inclu:)ing melanans (Bw.m,
WOOdbury, Hart , HellstrQ'll , Hellstratl, l~81 l, l ung '(Cuttit., Rosen,
Gazdar , Minna" 1.9811, prostate (Frankel . -rccee , Herzenberg, 1982) ,
(
IS
colon (Herlyn & Koprowski, 19811, pancreas (Metzgar, Gail14rd. Levine,
Tuck, Bossen , Borowitz, 1982), acute lYllPbJblastic leukemia (Ritz,
Pesardo, Notis-McConarty, La:z:arus " SChlossman, 1900), aro kidney (lleda ,
Ogata, Morrissey, Finsta::1, S2kLXllarek, Whibrw:lre, oettqM. Lloyd " Old.
1981) . Others may,al so show rellCtivity not only with the cells of the
~iZ~ tumor, but also with a vll.r~ety of ·ot he r !'!a1 1gnan t cells
(Drbleton, GuM, Byers , Baldwin, 1981), which may limit their
. . r .
usefulness in certain situations. In .DilUen, tlClllOClo~ Antibod~ea
with . differe~t ePi~~~ ' specificities may. ~ used to further defin~
e<XrilleJc macromoleCules .slX:h as carciJ'l?errbryonic , antigen «(FA) an:! its
rela.ted. glycoproteins (prirrus,. Newell, Blue , .Goideri>erg, 19~J w~r.
Petzold, Kohler' Totovic, 1984; KOllar Kurak! , Matsunaga, ,-S'ninoda,
Taklr;fasu , Matsuoka, 1985) .
Further consideration will be l}iven to carcll"lOE!'1Dryonic antigen as
it represents the mcx1el target of this thesi~, awlicable to a variety
of solid tlJm:)fS, making i t potentially clinically relevant.
"", .
, III /
-Carcinoefltnyonic· antiqens of the h.;nan digestive systm were ,I
~. . " ,
described in 1965 as... specific cancer antigens ' Of )the gastrointestinal:
tract end iT order to ~XP14in their . presence -in .fet~ tissues Ard
gastrointestinal tumors, it was proposed that they r~reaented c!llular
" j'P'nents which were repressed dllr~ nonnal ' cellular differentiation,
becaninq derepreeeed during neoplasia (GOld" Frec,iman, 1965"08) . Initial
16
ropes of using CEA. as a eusce marker for the diagnosis ~f qaatro-
• intestinal neore were encouraged by ~ s ubseq uent developnent o~
radioinmu,noassays capable of detecting . nanogram quantities of crA in
serum ('I'hortson, Krupey , Freedman & Gol d, . 19691.
~eve[. using inc reasingl y sophisticated irmlJnological techniques
it soon became ~[ent . that CF.I\ exhibited slbstaptial molecular hetero-
geneity CCOl1 gan , Renkart.~ Todd &- Terry, 1973; Vrba,Alpert & -rseer-
. "
bache r, 197!;il a1d with accl.ltlulation of data from 'clinic~ studies .
it was foum tha t eievated plasma , ieve ls of ' (FA or a.A.-like sl:bstances
. I ' ' ,
were detected itl ' a vadety 'of other malignancies inc:lud!n9' ~reast •
ueurence, Stevens, Bettelbeim, DarCy, Lees, Turberville, AlexMder .
Johns & Neville, 1972) ,~u[ence et al, 1972), percreea (Khoo &-
Mackay~ 1973) , nedullary carcinana of the thyroid (Ishlkaw~ &- Hamada,
~ . . .
1976), genitourinaty tract including bladde r (Guinan, ' John, Sadoughi .
,
AbUn , Bush , . 1974) I uterus and cervix (OlSai a, Mono.., - Hav~rback ,
Dyce, 1976), as well as for:: a.,variety of benign di'Seases . These in::ltrled
rectal polyps (0008 , wolff, shinya, Deqtabon, stenger:, GottliEb &
ZfmlCheck, 1975) , infl~tory bowel disease (Moore,Kantrowitz , Zmrchek,
1972), ' hep~tic c i rrho,:,is (Moor e , Dhar. Zarrcheck, Keeley, Q::lttlieb &
KupchiX, 197,2) , chroni~ b~hitis '(Laurence ee ,al , i972') i8nd in the
,erum of heavy cigarette seckere (stevens' Mackay, t'?» ' . \
SUbsequent identification ,of molecules antigeneically cross
~1Ve with CEA stimulated furthe r rese arch into de termining I1'Ore
precisely the nature of the molecule, obtaining II satisfactbry CEA
.'
-:
--'
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standaro. developlnq a [e lloble ",thrd of ....,. 1[ e-ev al .,.ting Its
clinical potential, am these .questions have been aidressed at
in te rnational rreetings (Alpert, 1918; auretn, Gold, 'OIJ., Karrlnaratron.
8!Insen, Johansson, von Kleist . !'tac h, Neville , Shivelef' St roebel.
Zarncheck, -Gol denbe rg ' Westwocd, 1978) • . 'lbe use of highly specific
.lllOnOC\cnal ant ibod i es has undoubtedly been of ' val ue i n helpi~ to
understand the o rigin, strlK:ture , di stribution w f un::tion of this
ro l ecule a1~h'manyquestions [main l1r'W18Wered twenty years f ollowing
i ts"d iscovery.
\ .
CEA was originall y identified by 1nrrIlllopr:eclpltatton t echniques
, us ing hig hly abao rbed ~tisera (Gold , . Fr eedrMn, 196Sb) I. and shown t o ' be
. a glycoprot ein of . lfDlec~i!Ir weight 200,000 (Xrupey . Gold" , Freeman.
196"7>, confirned by SDS-polyacrylam ide gel electrophores is t o be a
single dif fuse band (Banjo , Shuster , GOld, 1914) . I ta methcxl of
- - .. - .....:.-- - r- -
.ext raction fraa~c metastases.of colon1c ~r8 usin:;l percblodc
acid fo llowed by gel f~t1on ti rov id ed a a:A s tatldard for IMnY sttdies
~ . (ltrupey et al , ' 1967) ani an imImogen for the production of anU- Q'.A
anUbc:xUes fo r .use in. CFA 1JmLnoaseays. Pbysi cfoc:hemicai. ·stldies deoonst-
, rated the rolecule. to have a range of parent aiolecular weiqhts (SI~er ,
. . ."CoUqan , " 1975) and i t s carbohydrate conten t, whiCh
i
approx imates to
between 50 ,ard 75 per cent of the 1lO1ecule by weight is eatpd sed largely
of branched chailla of N-ac:ety lg l ucosamine . mannoee, gal actos e: fucose and
s iali c acid res idues (Te~ry, Henkart, Col1gan , Todd , 1972 , Terry,
Henkart . Colig An , Todd, 197~, Banjo et al, 1974). The variability of
these res idues , especially sialic acid. -bee been proposed . t o pa rtially
'"account for the heteroqeneity displayed by the rrolec Ule. By cont ras t,
..,.._--'"'..
' .
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each single ' polypeptide ~, stabilised by six disulphide bridges
'. .(Westwood , . 'I'hcrMs, 1975), appears to have a relatively constant amino
acid catp)81t1on, with aspartic ac,ld or asparagine, glutamic acid or
glutmn1ne. threonine and serine as pt~nant residues (Terry ee al ,
19721. ,
. \ \ -
5eqUencing of amino acid residues -a..l_~ ~terminal em of the
peptide backbooe has '~ perforned using Ekfrnan degradations (Terry et
al, -19721 OIu~ Bhargav8 & uervey, 1974), confit'Tlli.nq the terminal 5llino
acid ~e81~ueto be lysine. 'Ibe region also contains a sequence of
resldqes · c'ompria1ng leucine-leucine-leucine-vallne (residues lB, 19,
~O. 21) whic~ is identic~ to a hydrophobic sequence of an~
globulin precu~so[ am -Is thOught to be involved in menbtane attaclment
aIX1 secretion of the IlJ:llecule (Bu~tein, Zemell; ·-Kant or . & scbecneer ,
1977) . Interestingly, other areas of harology in the ~terminal region
have also been derrPl'lStrated between CE1\ preP5rations ard other Q;A-like
1T01ecUles.
-
. . 'l\le need to define the unique antigenic determinants ~ific for
a:A. 1s essential in order to 1Jl{lrove the specificity of its assay.
al:h01l9~ it is not clear whether these determinants reside in -,
carbohydrate or protein carponent of the lI'Olecule, or , possibly both'
(Kania, Wintzer , Uhleri:lruck, 1'978). Iecent stldies enploying tunlca-\
n}'Cin to inhibit glycosylation of the 1lJ01ecule in vitro by cultured
cells, leaving only. its protein backbone, foll~ by .llmunoprec i p-
itation using lli:lnoclon41 antibo::Ues, sUjgest that the main antigenic
detemdnants reside in the protein portion, whose IlJOlecular weight was
\9
determined to be 00,000 t 2.000 lkutoki. J(l.Icoki, Ichiki , Mats~kA. '
1984J . As conventional antisera probably react vith several deter-
mi.nants, i~ is in this area that highly specific mncx:lcnal ant1bcdies .
will fin:! i rx:reas ing ~licat1al (Hedin , Rarrrnars tran , LarSSCl), 1982;
Pr iJDJs, Newell, Blue , Goldenberq. 1983 ) .
COnsideration JlUSt rQI be 9iven to the CFA-like Oglycoproteina
~log~~ally c ross reac:~lt'e with ~. al thOugt) i t must be stated. at
the outset that it is still not known with ce~ainty_ .Wbether_theoj repres-
ent precurs?rs , cleavage produ::ts or inleed!irdiVidual screcutee (Pr1fiiis
Newell et al , 1983) .
The first of these ee tie described was -nonnal glycoprotAin- (rQ) .
(Mach , Pusztaszeri, 1972). found in perchloric acid extracts of 1009 .
and spleen and was of lcwer 1I01ecular weigllt at 60,000 . A eWl,r
. r .
. .-non-specif4: cross [~t1ng .~:_~9~~.yo...l) was also described with
widespread d i stribution In mal lg nan t ~ normal tissues 1ncl1dlng
tr¥do~d cells ani neutrophils ,lbut althou:lh' i te hIrunological aniphysio-
chemic al properties. were similar to Q'A. it ~d be dls tinqui shed by
vi rtue of i ts lower 1lO1ecula~ weight (Vm kleist , Olavanel , Bur t in ,
1972) . Subsequently desc~.~ antigens, inc lldiitg lCP have now been
shown to be identical to lQ-I, and the se were originally temed ax
(Darcr , Turber~le " Jll.mes, 1~ 3 ) or CCEA·2 (Turberv~lle, Darcy,
Laurence, Johns" Neville, 1973) . Simi larl y, t he cr068 reacting antigen
'TEX appe"s to be s imil a r , if ~t id~ntiCal, to td-l (Ke~sler.,...shit.te1y.,­
Pritchard" Todd , 1978).
A further family of cross reacting antigens ext rocted ..t ran · ·
....
C ' e "'-, '.
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' .
lll!COJl1un am f eces have been described which appear to be eore closely
related to . O'A, am have been designated 0CA-2 (BurUn, Chavanel "
Hirsch-Marie, 19731, normal fecal antigens, (lFA-2) (MaUillOkcl:, lI:uroki,
loga, Kuriyana, Mod & Kosak!. 19821 and meconium antigen (Primus ,
Freeman & .Golderi:>erg , 1983)•.
The CEA-like antigen CELIA iden~fied in the gastric juice of
nonnal individuals ~ara to reeesae ' O'A . closer than NCA, · although
, further · studies are req~~ed to ' characterise this ' mol ecul e (Vliento,
,~~..!k- Pih!to, svemerg, Ihal'l)aJd , Siukala, 1976). Bilia.tY glY'~'
protein-l (llGP-l) , fcurd in hepatic bile o~ nortI)U individuals appears
. '
distinct fran both CFA and NCA alth:m:Jh it is more closely ' related to the
latter (sve~rg, 1976;~tstrom. SVerberg,Bedin , &nful~, 1978).
Altb::n):]h anti~ m::moclonal ant~ies are disc~ ~ a later
section they are of . considerable iIrportance in characterisation of this .
1OO1ecule both in i1mlunanolecui~r' terns and in determining its 'distribut-
i on in tissues and tumor s, 1n addition to being used in CE:A as~y
systE!TG. Patterns of biriding reactivity of panel s of ~anti-ci:A nonoclonal "
• antibodies with differing epitope saecificities a re being used to
.: ;~ ~'Bt~€e the ismunologic41 het.rogen.ity of crA. and d.termlnBn~B
. , .~~ to a:A-l1ke glycoproteins (Pdrrlls, .Newell 'et ai , 1983; wagener,
'Petzo l d , Jl:ohler' 'TotoiiIC ·; -i9841 . Inrnunohistochemical. stu:Ues, r.e,
ilMlWloperoxidase , empI~ing specific anti-cEA rronoclonal ant1bod1es
with nU:nhw. or no NCA cross- reactivity , remai n essential for th e . '
evaluation of the distribution of CE'A ~ tUllOrs erd normal tissues.
tFatisation of the antigen haS been assessed in human tl.lllOr cell li~es
~
, )
I
.>'
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in cul t ure , grown a\ xenoqrafts in nude mice and In fresh. sl1r91cal1y
resected specimens (Pr imus , ' Kuhns , Goldenb~ , 1983, Motcy8ll'll:l , Watan-
abe, 1983; wolf, 'Ihmpson " Von Klei st , 19841 Wagener et ak , 1984) . A "
consistent findillg of these studies is tpe het~rogeneity of llntigen
expres~~on by tumors, whic~ has in itself stJJ:m11ated fU~her a.tuUes into
the syntheSis, dist~ibutlon ~ expreeefcn af . CEA. ,Variatloo i,?menbrane ; .
associa~ed ' CEA content is described for c'olonlc cancer ' cell lines;
dependin<j 'ttl the degree of tLlflOr differentiation, and aweMS to ~ ~19h
for well differentiated linea (LSl74T. SKCOl) end' low for (lOQ:ly dU:fer~ ,' .t
entiated cells. (!Hi20, RRl'18)'" '(shi, Tsaa -& 'Kim, 1983) . Whiie ~o--:
• • J . "€ ' . . .
chemic§U stuHes have shown that up to eighty percent.~f·CFA: i~ n:emrane
associated (Shi et al, 1983), further data on its stttellular localisat-
ion is scarce and atte~pts to inves tigat e th is usin9 1Jmunc?electron
microscopf have met with a nllltler of 'technical difficul~ies, (WOlf et.;U,
~984). The rate of synthesis and ' rel ease ' of "dA at'so ' appears to be
~El'pendent on ~ gl;O'<ith phase of ttese cells, decreas.in; witl\ ~!'1' and.
SKcoi as cell density increases . ' studies have also b~),~~tended t o
, . . . .. ' I
xenograft nmelsin vivo, and it has been shown that while CFAprodu:tfoh
. . .
per gram of '1'-300 xenograf t (htmm colooi~ 't unor l rerrainE.'lL const~t,
. .
serum c::EA levels' increased as ttmOr growth cccuered (MartVl & Halpern,
19~1 . Differences were also found for ~ clear~'~.of...pirctlat1ng 'CFA
obtained ,f ran patien\B ~era ( half~l ife, two. ana"a half, hou~[sl and t~t .
extracteq frCo ·.tumo~ ~rap~d), suggesting a differenc~ in' the , merrbrane
expressed and circulating rcere ~f the 1IlO1ecule. other at-Idies have Also
deIOOl'lstrated a rapid clearance of em by. the liver, which appears to
represe.:t the -major ereeeeaee pa~hW"ay, ;riv~;Ving'~ '~ecePto r mediated
· \~ocytOSiS by hepatic K~fer C~1l6' fOllOW¥'9~~ r~al of s.i~1c
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acid'res1d!JeB, the Jll)lec:ule is transferred to the hepatocyte for further
metaboliSlll (10th, '1hanas, Broitman , Z&lCheck, 1985) . Suc h studies
. \
attmpt:1ng to investigate the kinetics of ,(FA are stUI- SOlJ'eWMt prelim-
_ . _~ in nature altho\X)h they represent the first att~ t;o answer stX:h
fundament;el questioos. S1m1larly, stu:1ies · .at; ezpti ng to map the gene
~in9 for Q:A us:1ng sanatic cell hybridization in order to investigate
.t~~J - .genetiC control o~ .wafignancy are alISO in ' ~lr infancy (Sleet,
Brown, BobMW' 19821. t,'
~
~~ is litt~e doubt that 'Ul~'measurement of serum CEA revere -Ls . _ . .
. . ,
of 11tti~ v~u~ in'.~ diagnosis or screenin9'.of gastrointestinal
.~ (SUtrmary of mH CctlCeflE!ius .s t at ement , 1981) ~though it ~
been suggested that pre6petative levels correlate well with prognosis
..~ter curative BU1'9lcal resection for 9a.1itIQ.!~tinal cancers (Wanebo~
~, PinsJSy., 8Ofbnan, seeeres, SCt"Ma[bz & oettgen, 1978; Staab, Anderer, .
Brllllilendorf, stU"Opf, Flsche~, · 1981), and. for paUents undergoing rad ical
surgery for ILlll9' cancecs (Ford, Stokes , Newman, 1981). The rete 9f
Il'alitoring ' aA levels postoperatiVely in order 'to detect pr~linical
recurrence of~~l1(~iing curat1v~ surgical resection has been stLn
to be of value in eaceeeeei carclnana (~, 0'le1.ll9, La.! , wong, 1984)
-I al'though ~~ttern of rfee of CFA is 'of no pcacti.cal val ue In di stingu:-
ishing between local and distant recurrence" of these tumors (Hine , __._
. \
Dykes, 19B4a).•, Indeed t poetoperative elevated eerca Q'/'leve~s have been
proposed u a guide to further therapeutic interventloo, ir:a the selection
'ot patlent~ for eecced "l ook"1~ro~ in gastrointestinat malignancIes
~ :"
(Att1yeh , st~arns, . 19811 Staab, Anderer, stllT{lf, Hornung, Fischer " ~
lC1en~er, 1985) or for chemothe;rapy (H1ne \. Dykes, 1984b) . However
23
this is stUI subject to criticism and a ecee rewarding awroach would be
an lltt~ to correlate imtmohistoehemical grading of tumors based on
localisation of CFA. nus has been performed f~r lung cancer I where 82
percent of spec1rens shcMed localisation of anti-cEl\. antibody by iJrmuno-
~roxidase, WhiCh . although cor:elating with p~e ard Ttoperative eenm
~ levels;--waB-Of little prognostic value (Ford et al, 1981) . Sirnil "r
correl~tions betw~ !rmunohistochenu.cal ep. g[OO109 'Of colore<:tal t~rs
with serlJ1ll ~~.:-:~S have been reported , although progn08t~:. signif-
icance has not been addressed (~a, Yanamurll. , Hloki-, Yamamoto,. Nag~ra
, Watan~, 1985) .
\
!,
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I 3~O cvaai:Rs
Although '" wide variety of ce er fer systems for delivery of
therapeutic agents . to target cell popuJations have been proposed, the
theoretic al . pr erequisites of each 'should be simi lar . 'Ibat is, the
ca rrier should guide the warhead to its target am 41low i t tc .exert
i~ effect at that site with minimU or no Ineerrererce, while protecting
the host fran any possible toxic effects of the agent. Additionally,
- protection of the therapeutic Ct:jent from ~ host 's natural eeeeece
rreclWli8Iris would be -a desirable , pro~rty, thereby preventing premature
inactivation of the warhead, and redu::tion in efficacy.
I 3.2 Carrier SysteiS
/
AIthou;h not specifically addresa~ the problems of targeting
anti~neoplastic agents to tumors, a -recent rev iew listed seve ral carriers
of pot ential use in d"rUl targeting, "I:an9i ng f rcxn nat urally c:ccurring
cellular cooponents to a variety of synthetic c:oop;>UI'rls (GregOri adiS,_
198U; Present; experience relates to . a limited nUllber ofcarrfer
systems, in particular antibodies an:! li~, arxlapart fran isolated
case reports and preliminary in vivo st ll:li es, the role of other carriers
has nOt yet been def ined fully. It is .kely, l'loioI'ev~, that few will
have application ' in practical drUJ targeting, and even fewer in -the
delivery of anti-cker agents, altb:l\kjh they provide .models for t he
evaluation of the~~.Of drug t argeting.
, ... ,..
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As the use of Mt ibodies will be ccns ider ed In detail in alb-
sequent sections, these al ternative carriers wI ll be rev iewed fir st .
I .1teiest in the use of Upoec:mes f or selective dnq delivery has para-
lleled !:hilt of their antibody counterparts and their pote. n: lal as
~et1ng llgentB Is based upon a nUllber o( their characteristic proper -
t i es (Gregoriadls, 1976a,bl . I.s small sphe res consisting o f one or
ucre concentric phospholipid bllayers eepereeed by an eqoeccs phase, oil
variety of substanc es , 1ncllding drugs, enzymes and hormones, may readily
be incorporat ed within ei ther phase depending upon their::, rel ative . water
or lipid soh billty, whU e the . f inal size of the organelle may ~80 be
.. det ermined by sonication during the process of thei r prepa~at1on lnthe
_. __l llborato ry (Gregodlldls, 1980). Manipulatioo. of eeserane (:Oladty lr8'f
. .. .
result in variable degrees of merrbrane · poros i ty- allOW'inq drug Itak~e
to proceed at a set rate which ~ . also be __de.pendent upcn the loc al
milieu of a target ti ssoo, o~an o~ tcrnor .cYatvln, Kreutz , Horowitz ,
SJ:Iinltzky, 1980) . Bowever, despite t hese seemiD:11y advMltageous proPer-
t i es, th~. range of cells that associate aid f use with l1(X)601lES is
small MId appears to be · r~ated to the ce lls I int.rinsic endocyt.ic
potential. It. awears therefore, as if celle of the reticulo-Endothe li41
~t.em are chiefly re~~le fo r U~ ~le.arance in 'yi~ (Greqodad-
ia, 1976a) , although this rriay be advant.ageouS for . 'tIlE! eef ect tv e delivery
of agents to cella of the rronocyt~macrophage series involved in disease
(SChroit., Hart., Kadeen , Fid ler, 19831. In order to iIrFrove the eejecetve
t.argeting of these st[L:ctlJre8, incoq;orati~ of antibodf~s i nt o their i
out.er layers has been performed and iIrFrovement of uptake of l1p:l6omal
bl~1ri by CultUred ' ReLa cells has~ denOnst rated when ant:1-HeLa
~lcbulln G IIgG) 18lncorporated 1,\ th.. l1posane, c""",,,ed t o •
",
26
nm--specific IgG (Gregorlldis, ,"1976b) . Targeting of lipcl6alJeS to cells,
exprese~_~~. al so ~ achieved by Incorporati~g an a nt i-eEA
ax:rioclmal ant1bcdy ,into .11~ cmtainJng a nuo~ent dye , carboxy-
fluorescei n, WhiC~ could then be de:J'Jl'\St ra ted to be incoqorated wi thiif--- -
the cell by fluorescence microscopy (Qrldoni , O' Hara, Price. Shuster I.
Fults , 1984) . -
, . P~l~ with t4u 'arJoaJ::to ~cget1ng in vivo arise at ~
capilla.ry lev el , where~rt _of the se relatively . large et r cceuree
to target cells Is hindered by the capillary rrerbrane . and al so by ill.
~--IGP~uptak~ of the ' Uposomes by the liver and spl~. It has al so
J
/
never been denonatrated conv incingly tha t urue receptor-mediated t arget-
ing occurs using this llOdel in vivO,. and the lOCal release of Ieccrpce-
ated dr\J1s 1.0.suffici ent concent ratioo may be me mechanism of eeeree
..that wu1d prodl:l:e a .response indepenclent", of true t Arg.eteCI deU ve.IY,. as
would the ir capacity to act as a circul atI ng dtui depot p roviding a slow ,
even release of !:he drug over a prol cnged period. Eh::our~lng' ~tLrlles
using the anti~astic d rug cytosine .ar abi nos i de incorporated in to
. "l i posanes~trated~ro100ged SUlVlval -of edce ....ith the. ,LI2l0 leuk -
aemia (Kobayas hi, 'J'S~OShi ;, sak urai , 1975) . The overall r~uct1oo in
drug toxicity may~. redection of i ta possible mechanlSlb af -:Cti on, if ,
acting as , a eircul~ting drug depOt.
In add1tion to cytosine arabinoside, other Nlti-neopl:'Stic agents
su:::h as ac:ti1"lOll!fCin D, 5-fluoroUl'acil, methot rexate and b1eonrtCin have
been 'i ncorporat ed i nto l1 J?osanes (GrE!9?r1t1dla, 1976a,b ), and also a
" ,' nU!ber of 1lmlInanodulatora or irmmoet Jmulants (SChroi t et aI , 1983) ~
.:: .. . ~
.. .
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..., However, the efficacy of th ese lipooane-drlq cceprexee in the treatment
of cancer still ranail'l:S to be defined.
A variety of cellular carriers have also ~n prcpceee for drug
targ~ although it is difficult to elvlSage their use in the specific
targeting of ent t-cencer d~ tmiors at the present time. These
J~ystems i ncl t.rle erythr~s. o~ their ghosts, which have the a3vantag~
of availability and non-imwnogeniclty although they generally lac k true
t~eting' ability, unle6S 'specific Mltibbdies .can. be i~~rplrated into
. .
thei'= plasma menbranes as has been d~ribed with liposares . It . is
. certainly possible that these drug cont ain ing erythrocyte 'ghosts may ac t
as a circulatin9 store of drug as has al~o'been proposed as one mechanism
of llpcsorne action, and it is. conceivabl e that toxicity would al so be
reduced,
'!be localisation of neutrophils i n inflamnatory lesions provided a
model for ti'J> use of these cells in drug target~, and it has been
dem:nstrated that cells cOntaihing In-ill .,exi ne . will selp::tively image
• Inflamnatory le sions i n dogs (M:Afee, Gagne, Subramanian, crceanen,
'nlanas, ~kopf, Fe~ez , L~S, i980 ) and a s imilar rrode~ has been
U8~ to image pati~nt8 with acute pancreatitis (Anderson , Spence,
Laird, Ferguson , Kenr\edy, 1983) . Hc:loNever, it is unlikely t hat such
. ,
sys~ens will be of value in ttmlOr targeted cbemceberepy o r imagi~9
unless a significllllt inflammatory catpXlent is asscx::iated with , the
tllllOr.
Simibrly, a nOdel for ' the selective delivery ot vinb1astine to
rMCropmges has been aucceasfUl in vitro and iii. the treabt'ent of ' patients
.....
2B
with Idlopa~ic thratbocytopen!c purpura - (Ahn} Bymes, Ba[r~ngton. Cayer~
Snith, Brunskill & Pall, 1978; ~elli, DeCunto, Gresel e , ~i, Fedeli 0-
Moretti, 19841. It is aiso ~1kelY that this. m:x1el ;lo'OU1d find any,
practical awlication involving the tArget~f' the se c~llUla[ ~oop:n-..~;
enee to tlmora, although it prov ides an i nteresting awliCatim of drug
targeting in haanatology.
'1tle ta~eting plt~ntial of other proteins,~ or synthetic
COJrpOUl'ds such as dext rans has been investigated even Ieee ti}an thos~
systems mentioned. A model illustrating the targeting potential of
'ho~~S utilized a conjugate of dauOO¥in and ' tDelanotropin, a tropic
hoIllllne bioo.ing surface receptors of neuse myelare cells; to demonstrate
. . . . .
selective cell killing (Varga, Asato, Lande & LelRer, 1977). Fluorescen-
ce microscopy demonstrated that the coojug,ate was intetll~ised p[ef~rent­
tally by . mel~ ,Cel lS ccupared to control fibrc:blasts lacking mel~
tropin receptors and could be bloc ked by f re e mehnotropin. Free
dallllOIl¥cin "demonstrat:ed less toxicity to control metencee 'cells and
murine f1brOblasts ' ~{ similar ecnceneeeereos to those used in the
coojugate, although both cells were BJUaJ,ly susceptible t o th e free dru9
at DllX:h~higher concentrations. 'l1lis stlJiy also ?J stulated th e iJrpJrtance
of receptor mediated intemalisation of the conjugate ' fo r the specific
.
nature of targeting , as demonstrated indirectly by the absence of effect
upOO ~ receptor .defici ent fibroblasts and the c apac i ty of fr ee hOrrnorle
to block the response to the cmjugat.e. It is cooceiv~le that 8dvantage
could be ,rMde ,of the peeeeeee of bcrecoe receptors in ce rtai solid
tlUllOrs, notebly breast, In an effort to tatlJet antineoplas tl dr ugs to
"selected t\JnOrs ',
"
I 3.3 Ant1boClles l1li carriers
ni use of Mtibodies directed &go/linst tumor associated antigens
to target Ch~the!apeuticagents has great theoretical ~A1• . Althol.qh
11, numer of criticiE11'16 of this approach were raised following their
early use, these are becaning less vali d as work in this field expands.
Criticism regarding the nature of the target t o which they are directed
has been discussed in - the section On tumor markers, ' and criticisms
rt;9ardirg the na;ure c:: ~~..~~~~ation process i t sel f and its sequelae
in vivo will be addressed in the later section on conjllgates .
Until the mid-19iO's:; · ·ano~~ major cdticism related to the
techniques used to produce ant~ies of required spe(:ific!ty . Convent-
ional methods of antibody prodll:t.ion essentially often in vol ved the
imnunization of unrelat ed species with a preparee icn of the antigen
in question, follOoied J;ly collection of the animals ' sera after an awrop- "
Late period during which ~lobulil}_was being pro:luc':d by -the process
of active imnunization . Refinanents of this bas ic technique inchde the
administration of a suitable adjuvant an:l determination of th e optinun
period following antigenic chAllllllge 'at which to ccnece ~ greatest
yi eld of antibody, in accordance with ccnvenUonal 1mnunoloqlc technique.
'!be iJmU10glcbulins present within these sera were of a va ri e ty of
cl asses , predom1nantly'IgG sl'bclasses with a proportion of IgM, resulting
. '" . . '
in 4 heterogeneous antiserum, of vad~;e specificity am ' affinity. In
additioo, the poq:ortion of specif1~ _~9.9~~1n could not . be guar-
anteed when the prtlCess was repeated . In otder to !Jrprove specificity of
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l:heae ~lyclonal entisera, extensive: absoiption of the se ra was required.
al~h it is ·e~~that. the absorption p.cocG its~lf is not( / . .. ,
excessive and is stopped prior to the non-speclfic loss of the :umor
specific antibody (Davi es' O'Neill, 1973) .
'!be developnent of hybrldo/'!l technology, with the productioo of .
rnonoclooal antibodies, has largely alloweq. several of ' the limi\ations
JJrposed by polyclonal antibcxUe s to ~'~¥ome, in aklltioo toprov'iding
J . •
tools with which to further pr~ the structure of , eatplex molecuJ,essoch
"as the tlmlOr ant.lgens•
.
'lhese bi otechnology products .have also led .to further interest in
~he use of antibodies as therapeutic tools in thi!l !: own right (tmnuno-
. ther8F./) I in alHitlCX'l to their use as carriers by linkage to cytotdxic
agents eoch as toxins (immunotoxlns), drugs (immunQChell,l0thera py) ;
radionucl1des (illllUJloradiOthersPf and ' iImunoradiodiagnos!k) aOO other
potentially biol ogically useful agents .
I 3.4 PIcnOclmal Antibodies
In 1975 r Kohler and Hilstein reported a method of p~odtx:ing
moncxlonal antibodies in large quantities folloWing t he fusion of
spleen ~el1s . f rom an imrunbed donor with cells from a mdne lJ¥el oma
~ . .
cell line (1975) . Their methcx1 ess entially inv olved the fusion, of
iJmune ntidne spleen cells with cella of the ncrfne rryelana l?ell line
PJ-x't3-Ag8, utilising i nactivated s~ndai vi r us as a fus-ing age tlt ,
c~eatlM' hybd~CX\l8S that, contain genetic material from both pare nt cell
I
.,
Ii
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lines. The parent myeloma cell line lacks the :nzyme h~aQthine
phosphoribosyl transferase (HPRT) and therefore yies when gtovn In0
selective medium containing hypoxanthine, aninopterin and thymidlneL-.- .\·
(HAT) while the unfused spleen cells die spontaneously in culture. 'Itlis
enables the hybridana cells, which are not HPRl' deficient , (lIB these
obtain the HPRt' .fr(l\l the SPleen) fusion partner) to grow in culture. in
which they may be detected ard"screened for antibxly p[od~tion. It
\
has been estimated that only one tt¥elana cell in 1000 fuses with a
spleen cell to produce 'a vi able hybrid and that an aver!lge fusion will
yi eld up to SOC 'hybrids i f the dOnor is well 1nrnunh:ed (Seeber, 1980). It
has also been estimated that only · half wil.l produ::e irrrwnogicbul.in and
of these, one to ten per cent will produce specific antibody that reacts
with the J.Irrrmizing antigen. 'I\lis umerl1es the rationale for using high
ratios (10:1 ) of spleen to II!felana cells in later fusiooe, in cQ'l'{larison
to the original fusions which used equal cell nurbers.
SCr~ hybrids for antibody activity is usually performed by
. either. radioillffUl1OASSaY (RIA) or enzyne iinked ~rbant Maay
(ELISA.). Intere:sting hybrids secre~antibodies of required specific-
ity are cloned am maintAined in tissue culture, or injected intra-
peritoneally into mice to produce an ascites with grea.ter antibody
. . .
yi el d . Alternativel y, clones may be frozen and stored for sOOsequent
use. 'I\le method of fusion has changed little in principle al,though a
nllttle r of trodifications t o the . technique have beccee est!lbllshed I for
exanple , the replacenent of the 'inac t i vat ed serd~i virus "'ith pOly-
ethy l ene glycol (PEX;) as ,the fusion pranoting agent . Although the basic
technigue is successf~ for the' majority Of awl1cations, addit.io~al
/\ '" .
\t'
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ptcblems have arisen.,. "
.. In qeneral, vi ral or Pm i ndll:' ed ' tusiens exhibit scce dE=9ree of
- ..... .
rapdarness and poor yield of spec ific hi gh af fin ity antibody i s not
lD:CIlm:Il . Attetpts to hprove the yie.\d of high affinity antibody haVe,.,
. I"
inc:l lded . the use ~ electrically Jndu=ed c ell f usl oo, which promot.e.8
. cell ' aligrmlent and Irc reesed ~iomerrbrane peme abUity prior to fus ion,
an:! prntdsinq jBults ho1ve been ob~ when t his procedure Irecrpcreees
ce~6udace receptors to l~rease fusion selectivitY (Lo, 'rSCJl9. Coorad,
stdttmatter, Heater' snyder , 1984).
~
Yield of nnoclonal Mtibodies to weak antigens remains a persist-
ent problem and a promising 'aw r oac h is the t t ansfo'hnation of suc h
antigens into hi ghly 1mtU1ogenic speci es by coupl!Jl g them to adjw ant
proteins or foflowing c:hem1cal no:liflcatioo (~ato , E16en, 1915).
Hore rec ently a fu rther appl ication of DNI\ tecmology has been
described in , the prc:doct1oo of monOclcnal ant ibodies (Roth , SCuder i,
. .
westin " Gall o , 1~ a4) . A transfoming oocoqene, N-cas, f rom tur.:u;,
acute lyn:px;olastic l eukaemia AIL 1-69, was shown' t o t~ansform NIH J'l"J
fibroblests which then exhibited a tumor- associated entigen , to which a
DUrine monoc:lm& 'ant 1bcdy ' 19 M) was rai s ed . . 'St udi e s t hen rehted '
. aht1b~ bi nding specificity and pattern to the distribution of the
Q'lCogene-lnduced cal l au,:t"ce molecule among th e parent cell ' l i nes ,
transfeeted ftbrcblasts and a range of nome.l and malignant tissues,
using ELl~ and ~operOXi~e techniques. I t was deua\Strated that
bi~occur,r~t o the parent ALL 1-69 and. the seccnda ry t ransfectant,
.J
Philips, Watson, 1983).
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but not to the parent fibroblasts, and a::Hitiooilly, the antigen was
also deroonstroll.ted to be present in a variety of tmct1! MId sese normal
tissues . The iJtp::lrtance of this study relates to the potential use of
DNA. technology in the, generation of selective monoclCf1~ antibodies to '"
oncogene produCts and ' the use of these moooclooals as probes for the
.~er elu::~,A~i.o.n of the 'nature of oncogenes.
Most hybridanas are the [eBult of lI1Jrine or rat cell fl.!SiOOS 'Md a
.nl.llber of aIPr~hes ~e been investigated for the prodlCtion 'of human
m::noclonal 'ant UxxU es . A nunqer ee human mye1~ cell lines h~1rK:Jw
been established In c~lt!J[e although rate of ilnounoglcbulin produ:::tlon
Is poor cCJrIl'<lred to their murine counterparts and loss of human genetic J ,_
material is ~ problem follow'ing fusioo (Olsson & Kaplan, 1980: I
Pickering & Gelder;, l~82). It is not generally feasible to itnnunize
no~ hanan subjects with the antigens in quest~oo. AWroaches t~4t have
beer'l"explored include the use of the E[::6tein Barr virus. to transform the , I
peripheral lynphocytes" of patients to prcdcce ,monocl ona l antibodies.
although the yield of clones p-roducing sufficient antibody is low
(Bteinetz, Klein, Kookimiea & Hakela,19n) , as well as fusion of pedph-
.. era! blood, intra-tunoral cr lyuph node lYJlilhocytes from patients with
cancer with a human rt¥t!lana derived line (Si~ora, Alderson, Ellis ,
...
Using the hybddcrna techl'lology described in the preceding sectioo,
A nt.lllber of investigators have atterrpted to produ:::e Itt:lnoclooal antibodies
J'
against, carc inoembryonic antigen •• The reescea for this 1l1ustr<l.t e
clearly the potential applica.tion of monoclonal antibodies . and are
essentially twO-fold : os i ng these highly spec ific ant 1bodi es , the
molecular and inmunoloqical carplexity of <:FA, or indeed other hetero-
geneouS macromolecules ma§be probed, which in addition to the cha rac ter-
isation of thia antigen. o f f e rs the potential o~ dev eloping a standa rd
I
CE!'> assay whi ch may eventually ~rove to be of \ value in ~ C,liniC al
evaluation of lM1ignency. sec ondly , they o f f er great potential as
~ifi~-~arrie[s i~ s nUn:ber 3£ targetinq systems~
'rne . first Ilu:::cessful fusions yielding m:moclonal anti--crA anti-
bodies were reported b y Aeolla, cq::parent:1 y following a l ong series
of neq at1ve results IAcolla, carrel & Mach, 1980). ~ing standard fusim
)
technique. spleen cene from mic e 1mnun1sed wi th 15 ug of purified CE'A
.and Freund 's adjuvant were fused with Il!fe1oma c ells , to Obtain some 400
" iJYbr~ ·!'rom 7 different fus i;ns- A radiobmunoassay was us~ to scr~
for anti-a:A ac tiv i ty and of 9 positive hybrids, onl y 2 retained activity
after subculture mil we.re sUbsequently Cloned~ ' ~e I gGl and IgC2
moncx:loous were shown to recogn ise different antige nic determinants
of Q"A following a carpetitive inhibit1m binding ,as s ay . ~ s ame group
haS stbaequently utilised t he IgGl roonoclooal antibody in an enzyme
irmuloassay and demms trated. good correlatioo of (FA quantitatioo with
c:onventiooaJ. red~ay, for 300 S~J;um s allt'l es f rom both patients .-
and normal 1ndi~1dda1s (Buchegger,~ Rivier, carr el, Acoll~ & Mach ,
",.
Using . moc1i fi~ irnnwnisation schedules, ot~r g roups hD.ve also
<II'
/
Jsuccessfully produced monoclonal Mti-CFA ""intlbodies, each rec og1Using
differe.rt epitopes of CEA and , exh.ibiti~ a rMge of c r 08S reactivity
with OC'A or other re l ated antigens (FDge rs , Rawlins' Bagshawe , 1981,
Redin
j
et ea, 1982; ~rimus , Newell et er , 198) , ilDgers , Rawlins , Kordana .
G~ , Bag~, 1964) .
I"
As a'iesul t of. a, c ollaborative project between the~·5I.Jr;r.lc.u
IDIllUl'lOlogy unit , Birmingham, Eng land and t he Li lly Research ceeee
lj1ndlesham, &lgland , a nurrber of ' ~rine monOclonal anti..,CFA an\ibodies~
we re prodU:::ed by hybridana t ec hno l ogy il] the . early' 1980.'s (to-land,
sinmonds , co;;-ai~MarSden. Johnson, Woodhouse" Ford , Newman , 1982;-:
ccrvereo,"'Axt on , BrMdcn, snitit &: Woodhouse, 1964) . ' BN.B/c . mice were
'-....irmnuni sed using .pur.ifi ed CFA with Fr~Und'B adjuvant • . or as an alum,
precipitate wi t h BOrdetella petussis adjuvant or using the CFA producing
cell }.i ne Itt 29 . spleen cells were harvested' and fused wi th the p)-
NS1-l-~4-1 rouse Jl\ieJ.~ cell line in the stane;la~ ~~r dC·acribed .
B'ybddaMB were B<:reened f or an ti-<FA acl:1vity using an enzyrre-l!nked
. " ...
~oassay (Wocdhouse, Ford &, Newman . 1982), and intere sting hyb rids
wer e clmed - and-- i~estigated further for CFA or ~birding" and . aga inSt
a nunber of ~urnors ard normal tissues, using hiSbx:~cal me!:hOOs: Of
the 14 or so anti-<EA ecoceicoere obtained , t h r ee , designated 1~-285:"14
(IgGl) , 11-35-75 (IgGI), . 14-95-55 (IgG2a) , demonstrated bind i ng to
co lorectAl carcirioma ~ssue sections ,but no reactivity with spleen cells,
• and conpetitive inhibition binding s t u1 i es performed us ing ELISA htrIe
demonstr8. th8t different epitopes ~CFA are recognised ~ e.a:h of
t hese IlI'Itibodies t<:orvalJ'et al , 1984) . FUrthe[ h1ntochem1clll charact-
_ / edsaticn ot 11-.285-;14 and the di~tributicn of i ts target antigen, ~,
. .
( ,
.'
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demonstrated positive . reaction in nocmalland malignant qastric and
coloolc epithelium, and interestingly Also in the superficial ncn-e-
ke,oti.ising ctypt epithellum of the torisil7Gattet et er, 19821.
M;) bind.1ng was seen for a range of other normal tissues BIXh as brain,
GUn, spleen, kidney, pancreas, bile duct, liver, lung etc. nus
paper also sU9gests the potential use of paneltl: of specific roonoclonal
. ~t1bodies ~'., adj~ to ~~~;:1s of ~asia "'hen histological
exami"ttiOO awears .lIlhelpf ul , in addition to their potential use for the
, r:charac::te~lsa.t.ioO and" distribution of potential t8.rget antlgens. ~e:-
.~~ s.ections w~ll dl~u8B the potential of U-285-14 for targetihg
stwies.
.. \'
. ,
1'3.6 tmoclcnal Antibodies iii ~r Diagnosis .m:l 'l'reatlllent:
• It . 1~ theref~re ~rent tha~~e highly ~if1c antibodies
Mve-f~ ,a wide range of awJ.~catiais, f~f~ing Kohler~ Milsteinls..
. ... 'c106ing tement . that ·such cultures could . be valuable for rredi.ca! and '
. use- '(1975) . severer SU:::h~licatioo8' exist wlth~n tJ:!:e'
orC8ncer. d18C}JlOSis ami therapy in additioo to helping answer
fundr.mental questicns r~ardiw cellular differentiation . and control,
, ~ ,
and the 'atrtrture of~~ variety of cell surface molecules incJ.ooing
oncodevelcpnentAi. ,nt'igena. · 'l'hese-'aw11catiooa will ,now be discussed '
W.I,th ,t he excepti~ of the~r ~",licatioo to inmunochemotherapy which
""~ll be cOns.idered In a l11t~r B~tion.
1- .
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t"
'!be [01" of the irrl1lJrie systE!1l in the developnent of · cancer MIdde
. .-. . ' \./ .
use of antibo::Ues in its treabrent !MY be traced back to the turn oil-
E.he century when:' the~ first atterr()t8 at passive and active irmunisat10n
to tmnors veee maSe by Bericourt , ard Q:lley respectively (Newman, 1978,
Mastrangelo, Berd , Maguire"', 1984). _Since then, interest in this area
has been cyclical, altOOugh liith th e a9Vent. of monoclonal antibodies, II
• better epprecia~ion of tUllOr inIJnology md the host-turror relation-
ship , the pessWsm that was preSent ;n the 1960's and eady 1970' s has .
been replaced with a renewed inbl[l~st in this area .
J
lb'ltil ~hi9hlY specific JlX)floclonal antllxxlies beccee available,
only hete[oqe~s antisera we re available ' to iImu'lotherapists and
early resul ts, ~ often inawropriate aftima;l mo:iels, were f[eq~tly
disappoi nting . In addition , th e use of polyclOllA1 an tilx:dies i n the
clinical s et t ing l ed to /I va d ety of toxic [eact~OO8 along with tlimilllrly
consis ten t poor overall [esul~. qther factors that contributed t o the
~;~'ivism~t shrowed this .approach ir~"tlD~ ,the often premature ard
Irccerece ext rapol ation of ea rl y preclinical stud ies and case reports
which often faUed to shOw lJrf'j Significant inprovement USing ~~iJxdies .:
SOroo degree of ccrceneue regarding the present status of itmuno-
therapy is found i n 4 nunber of recen t ' revi ews dearin;r with r!his ~\t)ject
(Levy , Miller , 1983r Oldham, 1983., Hastrll"lge1o et at , 1984, Dillman ,
Rpyston, 1984, · BaldWin, 19841. 'ItIe role of antibody in tumor c elld~8trUCt10n ~as. initially focused upon a ' d l rect Mti~ nedlated
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reactioo although it is now being apprectateCI that antibodies may exert
their effects in other ways, in particular in the requlat!on of the
irrrmrle response and thr~h their interactioo ",ith the various cellular
c:arponents of the .i.Jmune system. Indeed the 're has been a greater recent
efltlhasis 00 the. effect of these cellular con'p:>nents upon t~r gra.it.h,
thr0U9h both ~lfic and nOn-specific mechanisms, although much is
': . _~._..t-.
still speculative. BiOlogical response mcdifiers, therapeutic agents or
awr"",,"", t:.od directly. to augment. or to _ity the hoot's bi ological
response to Its tumor, are also being .r~al~ted in .the light of :ecent .
biotechnologiCal advances, and this term has now,care to inclooe the use
of egents such as Bacillus caImette-QIerin <Rei, eff~'r cells soch as
macrophaCjes or natural kill~r cells, ~ynphoklnes aod interferons (Oldham,
1983b).
,.
As mentioned, the results of .ea rl y stldies using polyclonal
antisera were disa;ppointing, both in the laboratory and clinical settings,
(~enberg , Terry , 1977). With the exception of eercre loooced by the
}t)loney eerccea virus and the polyoma vrece, m~rgrnai therapeutic ·
benefits were seen ~y when l&:loratozy . an.imals were treated prior to
.'lIlCr lnocul~tiQ'l (!Jmt1noprophylaxis) or just following .tmor challenge,
USually within 24 hours . Another hctor''that awearoo to be iupnt.m1t. "i n
determining response to trea~nt was the tunOr burden, which aweared to
exhibit an almoet inverse relatiooship ' to outcome "and the "SUbsequent
expianat1~ offered was that immunotherapy co~ only deal with a
cdtical tlllCr burden . In the trOUSe, this was estimated to be 106 cells,
and therefore miclt with tlllOrs o~ 9reate~ cell mmbers would not be
expected to show a Desponse to il'l'l'ltlnotherapy. There are also additiCX'\al
'.' .. ' .
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iJrplications arisirq fran this corcept regarding the host-turo[ relll.ttprl-
ship ard the theory of irtmJne surveillance, which pr~e8 that &(X)lltMl-
eoualy appearinq tumor cells are destroyed by the host's 1tmtme system.
provided tUllOr burden is below a similar critical value_. The role of the
iJtrra.lne systEm in neql1asia in man 'is at best_ C.iJc:UllSt~tial. Several
well docurented observations are often ql¥)ted in 8lJAXlrt, for eXo!IlPle the
phenomenon of spontaneous turror regreSsion, regression of metastases
following surg ical resection of the primary lesion, the inc,reased
in cidence of tumors with lIge, In immune deficiency states, and in '.
imnunosuppressed renal transplant patients, aithough the precise nerce e
of cases in which such phenanena have been recorded ' l s actually quite
small am inconsistent._ 'l1le question of whether or not ~tient8 with .
cancer are itmulO81.Wressed is alsO open to speculation. several etucUes
have reported this to be the case although others have failed to dmon-
strate any significant suppression , following cri t i cal Malysis of
peripheral lyrrphoc:yte levels in career patients (Baldwin, 1984).
Ant ibody destruction of tUll()r cells may occur in a nl.llber of
different w~, altho~h. the actual. nechanism operating in vi vg 18 not .
, .
known wi;h ce~ Complement - ·med i at ed cytotoxicity , invo1v1n'i!
bir~Ung of antibody to the cell surface ~~get antigens, followed by
fixatio~ of complement throug~ the Fe portion of the antibody with
subsequent:--eell-iysis is tho~ht to play a minor role in tlll'lOr cell
killing and animal st,:x,Ues have failed to ~emonstrate that eatP1m:nt
fixation is essential (Dillman et al, 1984). The role of antib"ody
depenc1Eint cell medill.ted cyt?toxicity however has . a&stJrled a greater
iJrportance And t hi s rrechanisra has also been suworted by early studies
•
..
..
-=---.
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using fDOnoclonal antibodi es ; which have ind ic ated the ~~e ot
. , -
Mtibody i sotype. '!'he IgGla isotype has been tOLnJ to be tooBt
effective .in.vivo (Berns tein , Tam" N::Iw1.nski, 19191 Berlyn , Koprowski,
1982) whereas IgK, a at rc:ng carplenent f ix er , has . been "s hown t o be
pract1call~ in effec tIve i n tumor c~ ki lling . Ctiler I gG isotypes .
• (G2b, Gi , GJ) were shown to have a range of ef ficacy, alt ho ug h all
required the binding of IlInOnUClear effector cells to their F~ p'rti~
in order to prodtre cell lysis.
Cl.ini cal. trials invo l ving treatment· with monoclonal antibcxUes
have only beccee estm>Ushed within rece?t years and ·although patient
n~rs are small, sane lendmark respons~ have been reported. Baemato-
logical malignancies su::h as leukaea.ia and lyqthoma are ecee lmIenabl e to
.
th is Bi:F--rcacFi 4ltMugh it has also been used to treat a I1mJ.ted nurbe r of. . . . .
~tienl:8 with solid b.mJors (Seacs , Atkinson, 'Hat tis , Ernst , Se rlyn,
~€~ePl ewsk i ' Bayry , ltoprowsk1 , 19821. Levy , Killer, 19811 Gcxdnan,
Beaumier, Be1ls t ran, rernyhough , Bell8t~, ~98S). · Ole parti cularly
encou raging report · 11 f rem Killer who ~ a JllJdne IgG2b rcnoclon al
I " "
anti-idiot:ype antibody to t .r:eat a patient with advanced &-cell l yqlhana .
(MUler, · Maloney,!1lamke , Levy , \ 982) .Ca:p1ete remlssicn for ove r four
.ye:ra has been obtained; although there is still specul.at~reg arding
the rnechanl6lllby .which this response was obtained, through either di rect
cytotoxici ty or as a regulatory response. Other: i nve s tigat o r s have
ut1\.i&ed na'loclmal ll1It.1boCliea ~irected against the CCJ!lllCrl acute l~
bl astic leubem1~ antigen (Ritz, Pe~, sauan, Clavell , Notis-McCooa-
tty, benthal ' . S::hloe sman,. .~9Bl) . Followi ng adminlstratiCfl~f , ~l.ICh
Mtlbodies to patients with. leukaemia, a fall in peripheral . 1't\lkaemiC~
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c e ll level s was " not ed , althoL)~h the res ul t was often of II t r&\81ent
nature ard l eukaemic cells reappeared wi thout expression of the antigen.
Thi s has been attrib ut ed t o a t~rll~ in itial etear erc e of ~eu.k4emiC
cells fran the bl ood , followed by II number of SecOnd4 ['y r e sponses
1nclLd l ng antigenic II'OdWlltion (likel y) , antJJx:dy 'b l cckirq by circ~"t1ng .
fr ee antigen or u a [@sui t of the pati ent's iJmu\e response to tbe
, .
nu r ine monoclc:na.l antibcxJy.
J " .Simil a r brief t her apeutic res ponses have alao been ~r ~n
patients with" T-<:ell l eukllemills treated with monoclonal antibodies
. . .
reacting with mal i gnant ~cell surface antigens (Mill e r, Maloney,
!'t::KUlop , Lr!NY, 19811. ~ response to antibody has ~ shown i n the.
s kin pla:J\Jes~ lynPl rcs ee of a patient with T-cell lyq:tlc:rna (lillier ,
Levy , 1981). '!be fesponse to other so lid tl¥llDra generally awears to be
l ess en:ourag ing (sears et .ef , 19821 Goodman et al 1985) . Nd adequate
evaluation is s t lll awaite:l (Dillman et al , 19841, Al..t.hoo:ih the presenc e
of an tibody i n t umor has been demnst ra ted after antibcdy 1nfual~
(Oldham, roan. Mo~an, woedhouse, SChroff. Abra'rll, Fer , SChoefi;)ecger ,
Far rell, Kinball , Sherwin , 19841.
Earl y cli~cal 's t udies~ as thes e 'have r:~~ed a neeee
of inp>rtant furdarren~Sti: ceqa~ing antibody lK!m1nistcation i n
vi vo. It is l108t likel y that antiq~nic modulation is t he reason for
th e reappearlll"J:e of leukemic cells not e xpress i nq target. antigens
following se rothe rapy and it appears as it this 'IMY be\ ecre fnquenUy
cceur r inq ' cons equence t o treatment t han was i nitially. ant1~ipated
. .
(Hast cangel o et al, 19841. The ~ec reased expres s ion of .1 surface
"'.
l '"
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antigen following antibody treatment occurs rapidly but antigen will
reaweal when ant1bcdy is reoovec! fran the system with no apparent
pet"lMnent cellular sequelae. It has been deooniltrated that following
antigen antibcdy interaction, the carplex l ocalises to one portion of the
cell surface (·cawing-) followed by a precess whereby the cCftillex is
internAlised by the cell (Pesardo , Ritz, Lazarus, '1'cInaSell & SChlOSSlMn,
1981) . 'Ibis property i s also dependent on the nature of the cell surface
antigen ttseif (~ et ~: 1983). 'Ibis phenanenon also stresses, the
1Jrporta,nce of antibody bin:1ing in , order to prcnee an effect upon the
t~r celio , lUll several stu:1ies have.,.atterpted 'to rejere 1JmIunothera-
. peut lc reepcese to'antigen saturation.
Cbviously many other factors will inf~l:I~e this i n a:3dition to
antigenic rncduliltion. '!be tumor cells thenselves will , gener~ly exhibit
a heterogeneous population of target Mtigen5 andtheretore therapy with
. . .
one rronoclonal ant~ recognising one particular determinant may in
itself be s lboptirnalj and this !MY be cverccee by usiD] 11carbinatl~n of .
rra'loclonals each iqentifying separ...~ determinants or different surface
ant1gens . The use of murine IlIOnob1.cinals in this regard may offe~
therapeut'ic : benefit if ' the dete~nants recog nised by ontibodies of
Mother ~1e8 ar e unrecogn ised by species specific antibodie s , or the
host's own iJlIwne system (Oldham, 1983a) .
It is generally agreed that in order to achie ve anl:igen sat uration
of .a cr ,ltical level , and hence 'therapeul:1c ~ffect , larqe quan~ities of
antibody must be gi ven. '!his was qUMtified to, be in the o~~er of
mll11gr5l1B for the treatment of murine leukaem.ias (Bernstein et ~, 1979)
4J
am. irdeed doses used in clinical sttdies have tang 'ed from microgram
quantit~es ~rartEl (Ne'onMn, 1978).
Theoretically~ problems arise in the t[eabnen~ of so].id tl.lllOrs
using this awroach , .where targ~t cell ~ations are acch more inacce-
ssible than for the disseminated haenatoloqlcal malignancies. Thi s !MY
. be overcome by using much l arge r doses of ant~ to ecbreve saturation
, '
or by the use of tw. or IOOre antibodies, as has been SIlg'les t ed by animu
studies (Cspone, ' Papsidero " Qlu, 1984). ftlt mly would s~h ~1~be
reiativel~ . _lnaccesSible to antibody, the in£ll~ra~iOn of tl.DOOr"bulk -by
' - e~fee:tor ' 'cells may also prove to be a ptoblet'i. : However despite these
theoretical objections, indirect evtderce of antiJ?cdY localisation is
ava ilAble f ran stooie~ ' using thl~ approach in the di~8 of tumors
(imnunoscintig[ap~l. both in animals and in patients . Fuker optimis-
ation of this approach in the t reatment of solid tAmlOra may be achieved \...../
if it i s used in an a:Jjuyant s e t tincr f ollOlortni;( t unor debu1king or iil t he
treatment of s ulx:l in ic al met as t ati c deposits. Although the use of
imrunotherap;( in these settings .in presently not adequately 1,efined, it
may weli prove to be a roost -rewardi ng awroach.
The shedd ing of tUllOr antigens . in to the circulation IrI!lYaffect the
in vi vo response in two ways. Antigen antibody conplexee free within
.
the c i r c ul ation may account f or dim~i8hed thertq)eutic response as
antibody will effectively be bl ocked , ard in order to cverccee this,
larger infusions of antibody would be reqUired. 'l11ecirculating cOlTPlex-r
ee also present a potentially toxic threat as they ' will be renoved from
the circulation by reticul~Othel~al cel l s, inclldlng the liver ar.d if '-....
I
. \
"'1984).
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renal excretioo also occurs, it 1s possible that a glareculonephrltis may
also result, althoUgh these side effects have not been .s ee n in the
11m!ted ~unbers ~patlents ,s~~ed to date (Dillman et et , 1984).
/ '-, ....
. •_'J:11:E!__PQt:ectial toxicity of 'flmtni s t ed ng monoclonal antibodies
. \ .
received much attention in early stlrlies. True hypersensitivity has
been noted in ten to .f ift een percent :0£ patients who hav~ received this
mooe of therapy so he, ranqing from fever and chills to urticada,
b~onchospasm and anaphylactic shOck. other toxic . s~de effec~B noted
~r .tc relate b? the 'nature of the treatment itself, and possibly
occur as a result of the relOOVal of target cells . from the blood. When
given as a rapid infusion in the presence of a large ci~u1at1ng tllnOr
load, respiratoty distress has been seen in mice (Dillman et al , 1984).
'lhis ~ be explained by W:te t.rawin9 of cell ant!bcdy carplex~ by the
~ung which would then r~t cha.;acteristica11y prodocing a respirat0rr.,
distress type picture and ultimately respiratory insufficiency. Similar
puJmona.cy syrrptaTlS. beve. been ~eported -I n patients i n'{olved in some
clinical triale (Dillman et al, 19841, but not in others {Oldham ec er,
I
'Ihe regulatory effect ~t antllxxUea may exert upca the irmu.me
,response , in particular through idi~ anU-idiotype interaction, has
been better lIfPrecill.ted since rrcnoclooals became avail o!lbl e and these
cmceptS have also been aw lied ' to the fie1d~of tliio·r· -hmunol ogy. An
ideal target would be the kell tlll'lOr ,Idi otype s., the cnly hlll\flll tT' ~
specific marker presently know, .and the use of anti-Je.~~ antibodies
In the regulation of prolifera~ion of mal1gn~t, kel'! clones has ,been c'
proposed (DI111lWl ,et al, 1984). Irdeed. this mec~1sm of actioo has
----
;'
been sU3Qested as an explanation of the socc:easful 'treatment of a patient
with e-ceu lytrt:lOOna (Miller et al, 1982). Monoclonala may also act as
iJmlJne regulator s if directed against a nueer of growth factors or their
receptors , such as the transferrin receptor 01;.that of epidermal qrcwth
re eecee, but fu ll evaluation of this mechanism at a:tlon re stHI
awaited.
'ltLe antibody indeperXlent cell neCllated response to tumors haa also
received increased attention recently and this approach . broadly enc:an-
. " pas es adopt~::.e. _cellula[ immunotherapy: _ utilising specific cytotoxic
l~~~:' or enhancement bf'the non-spe<:if l ccytotoxic cells, the
Il'aCrophage or natural kille r cell (Mastr,sngelo et al, 1984, IOserberg ,
1984).
Early esperurenes transfusing large nUllbers of iImune lynphocytea
into tumor:-bear1ng rats ,were able to demnstrate tUllOr regression
(Delorme' Alexander, 1964) but the unavailability of suitable cells
,for ' hlmlllll use largely prevented clini~al. s t udies. )Tumor-immu~e pit]
lyrrphocyteS have been used roe the adoptive :in'murlOtherllP'i of 24 pa tients
'wi th recurrent blar:xh1r cancer , \lith , resueeton reported' for 11 patients""
(Sy!res, Mitchell, Eckert. a:;bertB, Feneley,· Tribe , La! , 1978). fleCent
work has beenencouraged "by the denx>nJl(~at10n . that suppresso~.....-T-cells
could inhibit a cytotoxic, ~ell response in '8 tlJOOr bearr host and
therefore by controlling the suppressor r-can popui"ation. illDlluno-
. j therapeutic reeponee would be facilitated (Mill e , North. 1983 ) . In
OOdition. expos ure of T-cells to interleu)tin 2 in vi t ro could produce
l arqe nL.:Tbers of cytotoxic T-cells (Mor Cjon , R1scetti " Gallti976) that
. '.
4.
would be required for successful adq)tive 1llmJnotherapy, and using this
tecmique, laenberq has derrmstrated that l}'IIPhocytes obtained from
patiCflts with cecee have ant1t1Jl'lCr activity in vi t ro fOllowing expansion
of cytotoxic kell clones by exposure to 1nt~rl~1n 2 (19821. Altb:l1.qh
it isslill too early to assess the practical use of such fWings, it is
quite. poesible that su:::h teeMiques would enable the production . of large ...
nlri>ers of "cytoto xi c T-cells to be obtained f~ iJrlividual .patients,
which could ~ be used as ~ive :inmunother~t[eat the donor
\
patient's t1Jl'lCr.
The role of the non-speciflc cell mediated iJrmune response 1s even
more speculative and there is ~o generallY·..accepted vi e-" regarding ~
!Jrportance Of each ~11 l in e pcoposed in this capacity . '!he macrophelge
}x:Iwever awea~ to have sev,al roles, inclLding an antigen presentation
function, as the suggest ed effector cell ll'Ediated sp;cifically through
the IgG24 traloclonal antibody (Be r l yn et er, 1982) am awarently al so a
non;-spec1fic cytotoxic function (Mastrangelo e t al" 1984) . Its activ-
ation by Bacillus cal.9'tt~uerin (BCG) atd co rynebacte rium Pl\tyUJn
(C.Pa.r vuml has led to trials o~ these agents being ~ed in cancer
.the repy. In Sllllllary it ~CB as 1£ systemic BCG administrll.tio.i is
ineffective in systemic ~ropMge activation, lind this t ransl ates into
no over~l effect upon turtJ:l; grovt:h in expe riment al an i mal modela .
However, . although its l ocal application has been dEll'lOrlStrated to prcdcee
tllllOr req ress i on 1rf some settings, sllCh as in the treatment of malignant
melanana (Mort en, Eilber, Holmes, Hunt , Ketcham, Silverstein' Sparks,
197.) and intra-pleurally for luncf clJfCer (!'t:Itneally, HAver , xeueej ,
1970) . It h4a never c:""!nclnglY been"i""",,"~ Is 4 «suit
. ----~~
;, '""'.l
of specific NlCrophage activation.
Natural killer cells beve been proposed as one of the principle
. ~ cell types responsible for host eeeteeeece to t\R)rB or llll!ta8taseB in a
normal individual. althool;h there is atill no conclusive a~rt.1n9
evidence of this (Baldwin. 1984). In vitro they appear to exhibit
cytotoxicity but to what extent this is inportant in vivo 18 not known.
Present research 18 directed at ways of au:penting natural kUler cell
activity, including the role of interferons, in an a~~ to s\Wrea
tllDOr gr;cwth.
In StJllMry, the role of 1JmtJnothero!lP,( in the treatment of cancer
. remains controversial and Is to a great extent unproven. 'Itle availlbU-
t ty of IlDnOClonal antibodies has not only provided a renewed interest in
this a(yroach but has . alao helped to answer fundamen"tal questions
regard1Jq uecr iImmolcqf am regulation of the 1JmLIne &ystE!lll, ~~h
this too is f~ fraa c:arplete. Additionally, interest is also being
focUSed upon the role of the cellular ~t8 of the 1Jm'I.me syat8D in
~r cell killing but this area of ~capf Is even more speculat-
ive at pcesent.
,.
48
I 5.0 x.RJ)IACXmB
Radiolabelled monoclonal antibodies have also been used for
ilnaging which, in addition to inrrUlohistochanical am 'birding studies.
provides indireCt supportive evidence of antibody, localisation at target .
. t\D)r sitee, ~ also offers potential as a new di~t~c llICdality in '
ita own right. As this targeting syston has now seen use in patients,
it i s hoped that experier:e of dninistering such anti.bo:Jyo-radioisotope
conjugates may well define pioblems that ~ ariSe when antibody drug
conjugates are 8~uentlY admi.niste~~ f~r therapy . For exarnple ,
t his approach has\a1ready· provided interesting information on the
percentage of intra{~lY admini~~re:i-~tibody that actually lccalises
in tllllOrs, which"may have great relevance to drl.l:J targeting eyeeece,
' . - \ l:l
As with fer .antibody targeting systE!nl3, early In vest!gato"r\J
utilised polyclonal antibxlles raised against turoors. In 1953, pr~sman
reported that ra::l.iolabelled rabbit antibodies to the mGlfine wagner
osteogenic sarcana local~ in 'mice bearing these inllianted tuners,
although localisation in several of the normal tissues su::h as liver and f)
kidney was also noted (Pressman , Korl'M10ld, "953) . SUCh early studi~
etphas~~ the .requi recents of high sp!Cificity of the lUltibody carrier ". .
and the presence of tumor associated target antigens . Despite the
I ' · I
similar limitations 6f polyclonal lUltibodies ref~[[ed to in preceeding .•
secti~/_1!!!t..b.sve successfully been used to localise tJ.mdr:s· \~th in
l abOrat orY animal roodels and in PGtients, wi~ over 00 per~t' ~r~
beil"il!._~ rted (GoldertJerq, .DeLand, Rim, Bennett, Pr1JTos, van Nagell~
Estes, DeSiJnone , Rayburn, 19781 Mach, Carrel, Forni, RiteehArd, Donath ,
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.....· ~ 'Alberto, 1900; i¥t'es. Hine, Bradwell,' Blackbu~, leeder, Drole " Booth.
1900). AltMUgh cr.A was the target antigen for these studies', other
9r0up3 have utilised antibodies raised against alpha-fetoproteln ' (lim,
DeLand, Nel son. , Bennett, Simoons, Alpert, Goldenberg, 1980), bUJM.n
coo'rionic 90nad0t'r~~ (Gol deJi)e r<j. Rim, DeLand, ' van Nag°ei1& Jav~
l!>OOl and f~[ 1mag~ eeeeseeeee of renal cell cancer (Bd.it.s~~, GhoB~,
~, Tai _"~d, 1918) .
.. - --EStfiiia~ of the porporti!Jl1 of injected an~ that ~tua11y
..
~::, :~I[: ::[:o~[::ooO:O~~~:6:r~~:~ : ~C:::l:;::::. ,
GranilWSka, Tayior-~apadl~itriou, Ni mmon , . Durbin ~ Hawkins, Malpas "
Bodmer, 1982) . Thi s, in addition to antigen present ,!lthin 'the cireU1a~-
ion am in nomal ' tissues , acCb~ts for high : bac kg ro und nvels of'
radiat ion detected when conventional SCanning' 'procedures are~ ~ to ' fIII".
, ) . \ c .
~e the distribution of labelled antibody. ;this has lar<J.e}Y ·prevent-
__ ed its wideSpread clinical evaluation a dia;nostic t~l and rapid
~eveloprents in the oth er dl~tic ~it of c::. scanning ~d.
ultrasourd at the sane time have dimini shed sane lTIIest~gators' enthus-
i asm to .pursue this diagnostic. approach .
.,
In orde r to Overcome these P~.cb.l~, a n~ offurthe,c awroact=. ,
ee were' explored inclu:1i ilg the use of lOOllOCibnal ant tee; fragments or - ,
~EIons ot.J8r'l.ti~~Ues to trcreeee ~ifiC;ty, , ,
subt rac tion sc~ing techniques. the admi.nistra~~ol'i'
t o pranote cr eerarce of the primary labelled an
rll:lion~lides with irrprovedirnllging ctiaracterJ.stics -eccnee "I l'xUlllt-lll or
, , ' ~
\ ..
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In vi,YO expedJrer'lta ~inq radlo18belled ~noclonal antibodies have
~~trAted localisatiOn of h~ tumor xenografts in eeveeer model
. _ 8Y8~ema (~u8ton, ' Nowinski' Bernstein, 1911), ltlshakis, ~Ilhinney,
····~havan · ' Nevll:i't; 19m, Sfuhlmillei, Sullivan, verlaert, Croker,
karriS"~ seigler, 19m.; ~ne~ e~ er, 1?J8:21 ~lcher, Zalutsky, Kaplan,
Kufe, Austin .' . sC~T !98J.;, ~,. FInan, Lenncx , RitsOn,. ·Takel,
)i'rllight r. Slko~a, 1983) lU'ld~of these' stldies Mie l'IaI seen ~cal
evAl~tio.;~ ~llowing ~ dena\etratio'n. of~l~ antibody lqcal-
lsaUon in H1'2'9 (colorectal) xenografta In .mi~e', SOD microgrars of
' '? ." -. "
labelle4 tll)nocIMal Antibody (Iodin~) waS edministered to !I patients
. with '~~l~r'~tal cancers with ~~ , correlation be~ til' exi~t of
clinical disease aid scanning 'after~u[S (~ey ,et al , 1983). f -
simua,rl't, a ll'OOOClOOll1 ent1body raised against an osteogenic sarcoota.
' ce~ _ l~e h~ "al so been shown to looalls.e in a n~r of ttrrCrs ~luding
colcirecW pr1Jnaries, aBi has been in,vestigated in 60 pa~eht6 of w~.4 1
Ml .benigr\ colorectarlesions ~ 1%rco-ccjontc gastrointestinal cancers
U'u'randa, Perkins, ;1Jml, ~ Hardy, Qrb1eton., .•Ba1~ , fi6rdcastle, 19821 ,
hrmitage,. Perkins, Pinn" Farf~' Baldll~ Haroca.atle, . 1984). In ,this
8t.udJ,&. 200 'mi~tlll6 of 1-131 labl!ile:1: antibody was qinistered and*
imatglnq. ~rf~rmed tJ~ 48 am 72 Mum poet ...injectia'1: . COrrelation
~. vas at~ 'tie~ r,eo'uttB obtained frm seaming and c~ts ctltained
trart rese9~e<I i;pe(:~,mens . o.f patients who were treated . 8u r9'iC,~lY ,
Localisation ' was shown for all 29 Patients witl1'prmry coiorectal
• p . ' .. . .. /'c:~r ,i n 'addi~ion to successful iJMging of metastatic depos.its , in 13
~t ~ "l 5> patients ~th di'sseminated diseAle . - Ib poaltive scans were
•
),
\
J
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obtained eee the patients with benign disease or for 10 of the patients
I '
wi~. non-eolonlc gAStrointestinal maliqMnCies . Although encouraging
resUlts have been obtaJ.ned'lfran eoch stt.d!~s , little 18 JtnOWl:!..l!bQut the
actual Ilt!Chanism of localisation of su::h anUbo:Ues, and furthe r inves -
tigation into the pature , ext~t, ~ distribution of the target antigen
is wllrranted .
I
By contrut. studies "taz::getincj tlmOra expr~8~ rele.tJ'lely ~1l
characterised antigens such as aA may provide ecre Worma~io", . Of
. " ~ .
partlcule., interest are stud ies .utilising the highly specific 4J1tl-a:A :
nOOcclonal~ 11-285-14 . I-131 . ~lIbelled 11-285-1.4 h4s been srown
to localise in nwe mice. bearing a.A. express~ hlmlan t1mI:l.t · .enogr~ta
.(Macoofial d, Lazenby, Alilml & . ~ie11tiJg! 19a5) iJt' addit1~to current
evaluation in Patients -88 a guide to seccrd look laparotCll!i ard in the
. .
staging of gastrointestinal and pancreatic tUllOrs' (Alllll'l, AndersCfl,
... .
A nUll'ber of investiJtions have utilised ra:ilol.abelled ' F(ab 'J2
fragnm~ to enhance localisation in tmx)[ tissue, am this has been
confi~ in studies with mice xenoquftec1 with hlrMn tUlfJ)r cells
(Hedyn , Powe, Alavi, Kattis, Hedyn " Ernst, Val.1ll& Itoprovski , 1983) •
. , . . ' .........
'qthOUjh, it has been SU}9e&ted that sUch fragments , tray "'show ,great er
intdnaic selective,a¢ ~ifiC ~irDing ~ed to the intact an~,
.I?the r f aetors Bl:JCh lIS inc:relloSed clearance fran ~' blood IM'J 4180.~t
for the 'better irMg.1JxJ as ttM:re awears .to' be less eOaplexing ' of thpe '\
F(ab',)} COnjU9a~eS with clrc~at~, antiger;: ..wl~ s\tlsequently lees
uptake by ret1~~~Ual c~l~l in~lver, lll'lg', aoo spleen. ,
"
.,
.'.
JO.,: ,
--
. ,
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LoCalisation of a . 1-131 labelled mnoclcna.l antUx:dy, which was
[ w ed against a Ulloolc tll%lOr antlqen. in a stuiy of 52 patients with
colorectal adenoca rc inoma , yielded 1DI1t ive 8CM!I -in 51 percent of
CMeS. wi th l o: al1 aation confirmed trOll as&eS8llleflt of radioactivity in
reseqed spec1b!ns where the aver ege antibody ccncentration vade! .~
3 .6 to 6.3 ~1mes hig he r than in normal t188ue (K!Ch. O'latal. Lu:Or08O,
BuchecJger . ..Forni, Ritschard. Betcher DouUlard , carrel, Berlyn , Steple-
d U . ' Koproweltl, 1983) . Althoug ti ooly one th ird of patients received
labelled F(Ab'12 fr~ta. the yi eld of positive scans ctItai~ "' oIlS only
IMrqinal ly' inc reasecL...t:g_ _~~~percent, ,a1~ugh · i t w~ not stated whether
th is wM a s tatis t1ca llysigni f icant dlffererx:e.
\ .
In Orde~ to werecee the prtblem . of ncr.spec ific uptake of -Ieo- .-
topes , totaich creates the hi gh -background rlll:Uoacti vity in the circulation
. ' .
am [etiCuloerdothel1~ t issues, Golderberq uti~lBed a :eeord labe~led •
antilxldy to · iJMge ' the bloc:d fOOl an:! using a eatpJteri6ecl stbtraetlon
~tnique. !:!proved the ntItio ~f tumo r detection (Golde~e [9 , 11. ,
DeI.an1,. eennet , Prizrus, 1.98lJJ. However, fu rther evaluation of th is
." teeb'dque has ~81.qJe8ted that precise bac:kgr~ co rrelat ion i 8 rEqUired
to prtrent f al&e neqat i ve or tal&e pSsitive ~esu1ts and tMtndth a low
tl.nOr/background .count ratio, the tecmtque is qu.t..te , unreliab1.e IOtf'
Grey, ~iv4novlC " ~lower, Trott, Moshak18, Coarbea, Neville, Onrer&J"
Westwood', )t:tready, 1983). Deapl t e 'these '~ 1n)1tations , Sate variati,:,"
ot t his computerhed sl.tltractlon tec hniqud bee , been ado pted by IlO8t
inve atiqatoi. in We f1e1~. · \. .
. . . \
Ot~r methods 4imtd at reClLCing back9~ "radioactiYlty ~e
/
. ":
,
. ,
. ~.
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includbd the use of second antibodies directed aga1net the primary
ndiol~ed antibody in order to eeeereeeee its clearance from the
circulation. Thede may be adpl1nistered in the fOrtll of l1poeanally
entr~ secon:3 antibodies (~t. P;eep , c reen, Searle, Bagshawe,
Jenkes, Jones, Barratt " R;yman, 1982 ) or directly as free, antibcdies -
into the circulation (Sharkey , Primus " GOldenberg, 1984). '1b@ latter"' · ".
awroach "'~ invef3tigated in hansters bearing -hlll'latl colonic xenografte
an:!was found -t c enN,:nce the clearance of the pr imllry antibody without
slb6equenl con::::entration of r2ldioactivity in the liver' and spleen, as
",as noted usi."":g l1~ly entrapped secord ant1bcdies . '!he clear~.
'of the l~lled antibodY fr~tl.e ..~r was -'loot seen Until' 24 hours
""after inject.ion of the second antibody, alt:b:l~h ma:dJfUll association of
the primary antibody with the t.lmer rrI1'j not have occurred as a result
of i t s npid clearance f ran the ci rc ul ation . c...
,
The studieS outlined in this section have atteJ,ted t o dem::mstrate
ant~ loC~l1sat1on ,at target t\DO~.sites, which as indica~lier,
p rovides onl~ i ndirect ev1denc~ that. other ant~ conjugAtet will
similarly localise I However., 6~~CU~S ha ve aleo di Feetly addressed
the probl,811 of ant~l~ conj ; ate localisation I1j labelling ei~er
.the antibOOy or dFlJ}di'rfeUy with radioisotope. .. _._.
us ing a 1-131 labelled po1yc~onal anti-a:A antibody lvirdesine :
~jlJ9ate, 8 pll;t1ents with .a::wanced metastatic ovarian old colorectal
' c enceee were inveetigat@d for conjlllJAte localisation }FO[d# NllWlSn,
Jomson, woo;house, Reeder, blan:3 , ~, 19831. Poeitfve ecanA,
using subtractiop technique, eeee obt:ained ' for 5 pat1enta up ' to 48
, .
....
..
-,
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hours foll~ing the o!lCh1nistration of the bbelled conjuga~5 suggesting
that drug conjugation does not: i1rpJ.r the ability of antibodies tQ
localise in vivo, end carplEmentary in vitro studies using ELIsA.confirm-
ed the anti-CF.A binding 'activlty_~_ the antibody following conjugation.
"
AlthoU;h ilm'tmoradiodiegnoois repr~ts an area of research fa -
its own right, it is hoped that information obtained fran sttdies siroilar
to those . described "'in this section may ~e relevlll)Ce to the targeting
of antlbod:f"'drlXj conj\J3atts \It.en used for therapy.
\
"
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I 6.0 W\IIIBM:6
'6.1...-J
,Frcm t:he...Pt ev ious section. i t appears ~ if llntibodies, espec i ally
1II:lNX1onal antibodies. of fer the grea te st ~ti41 as target s pecUlc
deli Yet'Y aqents in order to rr: the selectivity of the nmber of
c:ytotcxic agenu.'_ 1ncllXllng toxins; radi~Ude8. which may "be used
for 1Jmunoradlcdi agnosis in addit! orr to iJr1rImoredlotherapfi llf'lt1~er
drugs, ard a vari ety 'Of o\.er cytotoxic agents .such as Venan- md phospbo-
lipases. SUchwarheads ",Ul be discussed in the- following eection. \11th, . . .
the exc!!ption of ant i -c ance r drugs which will beiconeddered under .
J.Jaruxicbem:ltherlPj'. &eetton I 7:0 .
I 6 .2 :r-motadJlII
J •
'!be advantages conferred upon a targe~ &yst E!lll by the use of
toxins as war heais res ul t {rem their extreme potency, which theOretically
of f ers the gr eatest chalce of a ja1 eeli "" of )l'411qnant t~r «11
populations that are either inacCessible to ~entlonal d[l~a or lack
8~f.1c.ient cell surface antigen density for iJIirmotherepj',or bmmochmo-
therapy to be expected to be beneficial ('1bo~, Wwards, Daviea'" 1tle8,
~9B2 ' Ra&o,_ 1982, s~r4' SI'edley ' : TOOcpe', 19841. : HoweYer, the pot~~
tal for Mn-sPec ific toxicity alsO exists using stich IIlOleculea,~ia- '
~ . Ing ).he need for highly ~ 8pec 1f~~ delivery agentB. Althoogh 8Uch."
iDmJhotoxins have deroonatrated selecti ve cell' kUling in in vitto n:x1el.,
there have been rdatively few in vivo studies 8\.HOr ti.ng thl1 to date, "
and fea rs ~ non-sPec:1iic toxi city Mv"e,;~eo preclu.1ed ~'lr uee in the
,:) .
clinical setting to date. __
)
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A relatively I 1Jn1ted rnrrbet-tf toxins have been invest i gated fo r
potential con jugation to ant1baii C:S in targeting sys tems ,. ~ the,s e
1nclme di pt:.heria tcn:in , and the plant tox11l8 5:irin and ric.in. in
addition to Othe r plant ooderiwd polypept.1des which al~ ~lad:in) in
{Oten::y\ appear to exh~~t &are deq ree of - tox in-l ike- effect in vitro
('1'horpe et al . 1982r Siko ra et al , 198").
I .,
The struct ure of , the toxins of diptheria, abd n am r ic in . i s
essentially eimUar , cons i s t ing of two' polypeptide chains , A and B.
eech having specific functions , and linked through a" d leulphide bord o
TOXi n int,.!cactiai W'ith cells Is noliated th rOUlh the B chain, whi ch
bi nds to tb iquitous cellular receptors , which for ebrin and ricin have
- - - ...~ . .
~ Iden~led to be lflrIJ surfac e carbohydrate~ teBinatirq in. a
gal ac tose ' r es idue (~ger , Fl et e, 1979) . '1lUB recElpl:~~....~*llated
interaction Is responsible for ent[}' of . the A c hain into t he cell , I
although the precise all!CMn.1SID is stUl urc lear . I t Is thouqht that
. , ., .
cyto todClty ari sing trca ~e A chain ent ry cccure fran i ts inte.ract l an
with rtbo8cme catponentB, thereby inhibiting protein synthesis ,yd it
has bee!t es~ted . that the - entry of me CDlecU1e into acel i is >suffi c i -
ent to ki ll "i t (YaMh:~ , Heka14, Uchid a ' Ckllda, IS7S ) . A e illl11a r A
chain effect has~ seen >with the pl1yPep"t~e gel Cll.in isolated f r<lllthe
seeds i f Gel oniwa mul U florum, - whic h inh1b~t8 isolated erythrocyte
r.ibosorres with eimilar potency to other plant toxins, aJ.tooug h its low
. ~ overall in vivo potency arises lra'll ,th e absenc e of a B cl\a1n (Sti rpe ,
manes' Pihl , 19(0 ) •
..
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The properties of antibody tQxin conju<j8..tes are essentially
similar to those required of lJrrj conjugates used.for targeting pcrpoeea,
namely retention of antibody target antigen binding ability, stabilitY of
the linka;e in vivo, maintenance of warhead 'potency and the ability of
the conjugate to allow the warhead to exert its acttoo at the target · sIte
without interference. Early conjugates using coupling agents su:::h as
glutaraldehyde resulted in pol~rlsat1Q'l of theeoojugate with conseq-
uent loss of toxin pbteney, .tb:lught to be due to the. formation of
. .
irredUICible _balds be~ the ~xin ~ and, B chain . . &bBe:l4eflt .inp rovoo
\ methods of conjugation using coupling agents soch lIB the anhyddd~ or
ester. derivatives of chlorambucil, "SPDP" reagent - (N-succinimidyl
3-(2:1'Yridyldi~O) propionate), or £011ow1,n9 oX,idaHon of B chain
res~ues into .-aldehyde!\. capable of , r~acting . with aunO groups ~ the
an~ibody molecule, have proved ' to be successful "for the production
of ZlCtive .inmJnotoxin conjugates (Carlsson, Drevin & Axen, 1978, Thorpe,
reee, omter,. lIins<ln, ·"""AId•• oJ.., 197., 1bO"", ee Ill, 1'.2). TIie••
_ haV~ "1'" allQWed a ntmber of available toxins to be linked to
POl/cloo~ and ~l~a:. antibodies .and even to hormones (Chang, Da20rd
, Neville, 1971) •
. In1tial stooies. perfooned 1n the " early 1970'6 us1ng ~tox1rw
~E!fOOMt;ated selective cytotoxicity of cells bearing v1ral or c~m1cal1y­
induced .antigens 1n vitro, when treat;.ed w1th ill conjugate of intact
dipt:heria tox~ and .~tibody' raised against these induced antigeno
(Hoolten , CbOpl!rbanc'J, 1970, Philpott, B:9'fer , Parker, 1973a). .DlCour-
09i.~ res~,~· frau early aJ\imal stlilies were erec "<:OWned ~. it was
demonstrated that 8urvivai of hBrMters bearing 'aubcutanoous sarcOOl/J
ttmrs expressing chem1CallY"'"indlJ:ed antigens, could be pro~onged by
: ..... ..
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treatment wi th similar conjugates canPr'l.sing intact diptheda toxin an:j
. ..antibody directed t o turoor an~igens (Moolten, eawarell s . Coope~baOO ,
1972) . However there is, presently little e'lidence that such conj~ates
can ac t upon human t~rs ~ten, SChreiber" Zajdel, 1982).
,
,
Immunotoxin conjugates utilising intact toxins inevitabl y show \
ISi.k.Qr8 et al, 1984) •..
cmsiderable non-specific tox ic i ty in v ivo as < a result of bWing ec
normal cells through intact B chains, in addition to exhibiting a h igh
II degree of potency. Attmpts to redcce these urdesirable toxic properties
of obrin and ri cin conj uga tes -in vit ro , have ut~USed free galactose or
l actose in culture to block non-speciflC binding, by eatPetition with
cellular receptors for the ,avai l able Bchains (Thorpe, Ombet, William;
Mwarda , ft:)Bs ', Davies, 1981 1 Si kora ~~ al, i9B4) . Al.te~tivelY, '"b)e
use of IlDl\9Clonal ant!bcxle s directed at the bimlng s ite on the B ch ain
would also prevent non-specific todcity wit hout affecting effic acy
\
Direct conj ugation of the effector toxin A chain to antibexUeo or
their fragments , has erec been perforined in orde r to increase selectiv-
",
ity,..~~~h in gene~al potency of such conjuga~es lS.fml1Ch les s thMl
that seen US!n9 the intact toxin. 1IlmJnotoxins fO~ fran coupling the
A chaina of diptheria or ~icin toxin to re2lbit Fab fr~ts directed
r aqainst the U2l0 m.urine leukenla have been1enonstrated td shoWselect-
ive cttotoxic:ity of target IJ.210 cells in -vrerc a:rthough potency was
d1m1.nJshed ' (Masuho , Hara, 1.900). selective cytotoxicity of imnunotoxins
corrpdsing ri cin A chain and a po1yclonal goat anti!X'd'J raised .against
the hlll'M tUD:Ir associated ~ti9~' 0lA, has .al so been d8lOOSt rated ' for
, . . ~
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colonic adenocarcinoma cell lines expressing this antigen (Griffin,
Haynes & DeMartino , 1982). In vivo stu::1ies using ric in A cha i n and
in t act anti-t;tm:>[ antibodies have also cawincingly been shcArrm to reduce
tunor growth in mice (.Jans~ , Blyt.bnan, ca r r iere, casellas , eros, c rce,
Laurent, Paoluc ci, seu, Poncel et , Richer , vi dal , Voisit:'r-l~82) •
./ l
-,
'!be uae of conjuga~es of g~lonin ha ve been Invest~ated in
attempts to reduce tOxicity while maintaining selective ecereo,"~ it
has been demnstrated, in C;;-omoon with A chain coojugates , that potency of
such irmun~xins 1s also reduced (Thorpe e~ al , 1982) •
.....
V!tetta has demonstrated that" separate del1very of .ricin A and B
~hain antibody ~oojugf!ltes coofers advantage in cell killing, even when
A. chain conjugates have been demonstrated t o be ineffective etcne "
(~itetta, OJshlef &. Uhr, 1983) . It [~ns, ro,;ever, to be eeert whether
~· hls synergism seen betweencoojugate's ~""'V'itro, can be reprodoced ·in t he
in)vivo aniJDal rDC)l;je! . A further approac h to iIlpco:.,e efficacy of ricin A
chain iJmtmotoxins has util ised tb~_ addition of standard 'cijemot he rape utlc
agents (doxorlbicin ~ cyclophosphamide) to the treatment ~egime of mice
with 1.1210 leukemia. CClrbined .trrmm<?toxin and chemotherapy was ahcsn to"
be more effective in prolonging ' s urvival of mice than "'wi th either
treatment no:1al.ity alone (S1rooi, caneg rati, Ib'rano., \recchi , spceer-
. ", Icc, 1984).
In SUJlIlM,ry, the efficacy of immotox1ns has been well dem:::n-
strated in vitto, although problems related to the intrinsic potency ~
intact toxins have l:!flerged fl:Ol'll the 're l a t ivel y -l imit ed m.rbers of animal
/ "
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studies performed. Methods of increasing selectivity which have been
COOBidered include increasing the specificity of the carrie, in add! tion
to rechl::~ n~specific binding of tox.ins to oomW, cella thro~~ their
B chains, or di[~ OOuplf"'9 of the A chain to a carrier. '!'he 'l at t e r,
however, has in general also resulted in reduction of potercy and
selectivity of ~ese conjugates must further be ae\tned in experiJrenW'
nmels prior to clinical application .
AlthoU9h, radl~t1on therapy 1s a well established treatment
. ./ ,
rrrdality for certain cancers, . the .systemic adminls .tration of; radio-
isotopes has fcurd limited awl1cation. Ole pa~ticular exception is in
the treatment of thyroid cancer where the selective uptake of ,r ad ioact ive
iodide by thyroid tissue, PJth mall~t arxl normal, is exploited. 'lbe
concept of conjUgating radiomx:lides to antibodies directed aqainst
tunor llSsocloted 'anti~~ has~ potential for . ~r~ing the range of
tlJllOrs that II'IllY be treated using radioisotopes in addition to the
S~lec1:.~ve'b~t1ng of these .~ents to radiClSel'lSitive tlm)c cell popul.at-
ions. In addition to this therapeutic awroach limnunoradiotherapy)
radlonU:lidee·have also been conjugated to antibodies for the~- of
r " "
diagnos» (irmJunoradiodiagnosis ) as ~ been discussed in other secti~.
As with Illi potential targeting 8ystBll6, there are a nllIber of
~rent advantageS ard diMlvahtoges in using hi9h energy r~li~
.180~ S as the warhead. I80tcp!S ,l!lIit t ing alpha partiCl~~h as
Bismuth--212 and LeaJ-212, have been used infreq~tly ' ",", to~~eir
" '
- \
·"
gene r al instabil ity , although Astati~21~, an allOO8t puc.e'alpha ESllitter,
has soccess f ull y been conjugated to a roonoclonal a ntibody 1Bloomer,
_~ Liputein " Dalton, 1985) " an:! ther,efor!'; attention has been fOCus,s~,uP""
such beta emitters 86 IodiJ'l~131 or Phosphorus-32 (Sikora e t al, 1984) .
'!be abil i t y of beta rlldi aUon to penetra te several ce ll layers te of
advantage in tr eatin9 tumors with poor vaB).ularity arrl generally inacce s-
sible tar~t;, cell~ . 'Ihe antigenic hetel:ogene ity of a tUJOr cell populat·
ion is ,theoreticall~ le~ of a problem using this approach a& i t would
require relati vely few cells expressing antigen t o t arget the [adier •
isotope conjtJ;late t o ~ tUlOOt' where a cytotoxic effec;t would be exerted
upon surrounding cells regardless -of 5ltig en expression. 'Ihe D'll!jor
~isadvantage of this aa;proach is tha t of non-spec.1fic "i r rad iation ~f
normal tissues during th~ distribution of the conjl):Jate throughout
the bcx1y, an int r ins ic property of the warhead i ndependent of the
specificiq. of the carrier.
•/
Prel. iminary stLdies investigat tng the potential of 1Dm.lnor61:U~ • ~.
ther apy in t reating human colonic tUllOr xenografts in an anilMl mc:de1
# . '
hav e been encouragi~.~~..!:atge t anti gen being a:A (Goldenberg. Gatfar,
Bennet t , Beach, 19811. Po1yc10nal g oat a.nti tEA irlmunoq1obul in,
-? .
conjU3ated to 1-131, still retaining CEA binding activity, vas -used · ~o
treat.!m18ters bear!nj a:A expressing t;lIIlOr xe1fl9,afts and. /I; single
injection of 1nCi 1-131 was shown to J.nh~it tutOr gr CMth in addi~ion to
incre/lSing survival of hamste';; teeeiv!ng conj ugate.
SU!=h an approach has also been applied :o . l: re~ '/I; limited nJ.mber
of patients for whan conventional treabnent has failed (Order, lQ.ein,
\. 62
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Ettinger, Alderson, Siege1JMtl , Leichner , ~900). Based on the "llili ty of
. . ,
radlo1abelled antibOdies to lo::a1iBe 1n antigen expressing t\ll1OCS both in
animals and in patients, eOOjugates of }anti-a.A or anti-ferritirl an~­
bodies and 1-131 were administered to 9 patients. ~i9nificant tumor
{ . .
regression (CiT ~,an.alYSi8) was seen in 3 of 4 patients .witl! hepatic .
cancers within_one mmth of treatmant, ~eleas no therapeutic effect was
seen in 5 patients with non-hepatic t.unDrs (COlpn, lung, flOOr of ll'DUth).
When up tQ 100 lI'ICi of radlo1~ed .antibody 'was ~istered in.nilt.ton
\. . .
to ~~0Ml "?" trea~t (T1neCI irradiatipn ard c~ther8Pi):
cnJ.y 'ooe ,pati ent tr.e4~ vith n~iOi~utloglobUl1n. de.veloped rever,
suggesting rei~t1ve lack of . tOxicity as.~jated-with : th i s ' treatment
administered at these doses.
In ord~r to prevent potential- systanic toxicity, a 1-131 lllbe11ed
nonoclonal antibody cirr~ted ag~t .a. · t~~ ~lated ~t1q, has
been ~ster~ ut the intracavity route (int"apleurally, intra-
pericardlaJ.ly and .1nt raperi toneal.l yl in th~ee (M,tients (hrrnersmith
Q1cology Group, 19114) . Selective deliverY of radiilt!on to malignant
. .. . .
tissues WlSS d~trllted with evidence of pericaroial tlllOr reqre~ion
en cr scan seen in one patient, aOO aI::¥Ience of tlAllOr cella froo ral
or peritoneal fluid being fo\1ild follOWing' trelltnerlt in remaining
. _; I
pat~ent8. Abllerce of toxicity ""as 11.180 .c::;7 fol-lowing this trea
5lX:h sttrlies s\q3eat the poteptial of te,rl]eM tlldionuc:lides to
. . _ . ~
tlllJOr cells tor thetepy.,. and encouraging res~ts are owarent fr~ the
limited ntarbera of patients treated using this aWroach. A further
l!Wrooch' to ilmun~ra;liotherav.f has~ 1~ea'i:il]ated by Go~denberg who
",'
:~
,/
" ~ an ~ti-<:E'.1\ antibody t~ .tar.9~,t ~ron-lO to ~ ~['ealling 'h~.
colonic: xenognlfts in h_te~ where s eiec:t1 ve lCX::ali~tion was • .~,
n ique i s investig a t ed further.
I 6.4 Drugs
. ' .
.-rn~ri~, to the . r imge of aite~.tive war~ descdb~,. a.~
r elatively Iarqe mmber. of ' an ti- cancer d nlgs have been utJ"lised in, a
() . . ';
v a riety o f ta r g e ting ~ystems, inel ud~I\9 " ad damyc i n" methot re:JCa.te.
ehlormbuc::il, V1ncJes uie; allwlomyc~" ~l~in, C·~Bpltllt1n, . ~tlIrz ino­
atatin, pheny~~ diamene-llIJ8tarCl rlD'ld the range is" expected t o increase
as new analOl;lues .u e d~~. 'nIis lIfPraach may well ' r:e flee t 'th e
op inion o t: several , J.ovesti9Iltore · ~t 'dru:.l~ currently represent the rlI)8t
CIwcail; r;,el evant wA.rhed as ~ have ' gener:aHr al ready ~. wiae- . '
spread ciWCal use and inu::h infot"ll'llltion on the kinetics ; ' d iatlr ibut i on
~ "toxicitY.lItIf the i-ree" ~ r:u9S is 'avaUabie . p~iding Il Ueef~bMeJine
, for ,t he e e eee eeene ot' , '~nj~ate ef~icacy. By Cont~ast , the . lim1t~ : . .
inf~{ption availab l e Dr! the in vrve . e!!ect _"o~ ~.I;m!'~ de1ay,ed .lhe
• administration of immatcxin conjug~tes to petients : Howevet,:. ,.whereaa
~ P;tenC-j of '~pm, ~' :adJqi~I1deS .~~. thes~ ~ml~ .appeatJhg' f~t
targeting, it ~"bee!;' "e~ge8ted that a rel at..!:!-eiy 18('lJllr, nlriJer: of dtug
rr: :
," - '
... .
..'
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",.ecul~ woul~ rec:1iJire .d.ellve~. to. . \a~'t .celle in. cede r to prodoce a
~rable ef fe: t: Alt hough the~irE!Sfll!:P ,_~f. ~tibody drlX] ~oojU3ates
w11l be d~~ in fOllowing ~~ons t is ~[ent that tbe use ot
"""""t;he .lII:» t highly potent \0£ U.e . .would be advantageous. This
. ' . . '. 1 ,
~e[lie8 t Hfl r a tionale _ ~or(~uS.{ of the vinc a alkalO~ds_ in ~e
8~le. in thi~. ,J-bests , which ~ ~lar bM,i\" lin the most.-potene
'anticancer dro:lB in cl inical use. Aspects of .thevinc a alkaloid will'
'. nowbe discussed.
" , ,
\ '1 6.5 v~~o~
.l ,·
, "
.... ,,/
" ..
.'
, .
Vi nca rceee or comm:::n periwtnkle, has' seen widespreaS use by
" . ' . . . ' , ..
herbalists re e sevecal -yeeee, especially for ~ healing of c hroni c
woirllS~, in ac:ur:yY, : and fo'[ the relief of tootMche,. although its antl-
neoplastic POtential -waS not d1scovered \Dltil the 1960's, when inveatig-
' " ~t~ona. int o . i ts ' ~leq~hypl;Jg~YC~C pr_~rtles w~e um e.rtak en by. LUly
,? (:em~rl 19m) . Of 70 alkaloids 's \bsequenU y extr~t~ .fran tto.ib plant , ' j
. ' ~tPe a ~e ·~toxic ard of these, virtll aot ine and vin::r1stin e have been
\. " , I '
~ wid.ely · jn the drtq J r~at:lrent o~ ' cance~. They hiebeen fourd to be
be parUcU!\.r1y ' useful 10 the treatment of haenatol ogical malignancies , .
. _ al~h activity 69~~t many aO{i~ t\.lflOft. has als o been reported, •
InelUllinq Sreaat cande r, t esticular cancer, renal c.,-w::er, 'rnaIiqM.nt
D'II~,ardBa~.
' It, " .. --/
.~ 1l'O.l«:ular a,trueture 'of these' alkiloida Ie eesentially sWlar,
consiat.1hg(of tvolinked rrtl1t!-ringed o:Jlt'Ourds, virdoUne am 1
• CIUlaranthine; which' in ,1aolattd; prfpa raUone ~ lJPP8ar~' :t o hav~ ~ anti-
"
-,
65
. .. \ t~r actfvlty (~e[, 1981). Virdesine (deaacetyl Yinb~asti~ amide).
one of two semi-synthebLC derivatives of virtllasUne , appeA[$ to have a
different ~rum of anH-tLlllJ)[ l'lCtivity o!M on a milli9r~ per
, kiJ.ogrambas is. exhibits less ~xicity ttlaJl the ,othe r alkaloids ; maJc.1ng
1~ ..an attractive a9~t fd~reli.m1na~, clinical ~trialB (Creasey, 1981) .
It has been _erown' to be · .~tive . in ' patientit~'p[eviOU$l~ . unrespons ive to
vircristine~ suggesting lack of cross reslstNlCe between- theBe agents '
• • t •
(Valdivieso, Rictrnan, Burgess, ~ey , E.'reire1ch. 1981).
. . . ~
At the ectecurar level, it ,has been derroostrated that these agents
. ,, / .
require an energy..(leperdent active tr~rt s;tBtEll\ in order to cr088
the cell rnencrane to enter the cell (Bleyer , ' Frisby , Oliveri~975),
am i:'lwJ been SL,XJgested ~t re:::eptors for the vinc a alkal~lds. in
'. . .
putlcUlar v~esine, may be present on certain hlJllM i~aemia ce]J (
~es ('IOtsuka\CBhirn! , HizOglJihl, 1982) ....~
plasm, , these 'acf;: are thought to . exe'rt their effec~ upon t\bU1in,
irmibiting i~ p:tl}'tl'l!dsation, And ther~fO[e ptevent~t:t the fOC'l'llatiOn of
... m!crotlbules, essentitU for several cellular functions 1ncludirig"mitosis,
structural integrity ard transPort of 8olut~9 (Berder , Halrel, 1984). A
notable feature is that ver:y low concentration of drugs Are reqUired · to
. inhibit microtlbule fOrrMtion an:J hen::.1!" prc:du::e cytotoxicity (Jackson ,
Bender, ' 1979) an:I it is nQl ~rent that ,cells may be killed at MY
.
phase of the cell cycle, although they ~at to be rrost susceptible
'du ring the late S phase (Stoht ·' · Fisc:=hinger, 19781 . - In ' addi~ion to ttAs
direct cytotoxic action the alkaloida also cause delay of ptol1feratShJ
C~ll POPUlations at G2 .ard it ~ been 8~~es~ed t"t ~ rrtri be I
incorporated into chenoth&rapy reg1.mcns tor synchtonielng tWDOrc:el1"~
.. ' .
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p::lpUl'attoos, with . akIltiooal agents ~lng used td' achieve max11lum cell
kill at the phase preceedinq the b~ock (Hill' 'Whelan, 1980)- Within the _._
'kinetic: Cl~fication 'of anti-tllllOr. drugs, the v.incas 'are regarded as
class II (cell cycle ~~specif1cl a9enu:.
The. toxicitf of ,~':;'~ incas ~ars to "v~ J:>etween In!ividual .
. " agents , with neurotoxicity &:curring in greater than 30 percen~ .of
> >
patients receiving up to 2 milligrams of vinc rist ine as 8 single 'dose,
. but being . reeeiy seen with vinblastIne or vW esi ne (Creasey, 1981~1
Although dose dependent, these neuropathi es (notor , sensory, autonaDicl
\- are often t 'rreverSi.ble. By contrast, it i s ll¥elosuwresl00 that is the
-' --limiting toxicity. ~ vipblastine, with a revers1b~ leukopeni; and
thrOnbocyt.openla seen in greater than 30 percent of pat~nts within -10
'" days of treatment. .
'Ibe small doses ~n which these d~s a; UB~• •1.arge~y priluded
pM.DlOkinetic stlXlies of these agents untU a sensitive ' radio- :" "
1Jrm.JnOassay was developed ((),oell1n, Ib)t ', Hairls, 1971; Sethi, Burton &
Jack~. 1990). 'nle phamlaCokinetic pattems~o~e alkaloids awears
.essentially similar, with rapid drug distribution \nto extracellular
> • >
COIlpart:fnen~ fran plasma and biliary mccretion foUO'oIing hepatic metab-
" , , ' \
oUsm of these drlJ3s. Extensive reversible binding to blood elements has
.al so been noted, in the order of gre~test binding to plasma proteins ,
platel~tar"ed and white blood cells (Bender et 8.\L 1984). 'lhe relatively ;
> ?'
short plasma half-life of these lM]enta has stinallated seyeral ,stu:Ues to
invflllltlgate the value of long term infusion of theso drugs, especially . •
for vinblastine end vlOO. 81ne, which as mentioned, ere Ie.. l~ted\ by
neurotodcity (Bender et:. al, 198C)r and encouraging reepcneee have been
~ ~~ted in pa.t1&n~ . wi~_ advenced bteaat. cancer (Yap, Blumensch\ln,
\_rtobagyi, Tas.=: ' too, 1979) . , stt.dies by Mathe ~~l~rlY 8"e8t~
the, value of -infusion of .Y~ine over bolus injectioo ~or haematOl~-:
ieal IIlAlignancies (Mather Kisset, DeVassal, <buveia , Rayat , HlICho'Ier,
Belp::n,e,' PiCO~~enber9~ R!bov9, H~~t, Jasmin 1 DeLlx:Il, 19781 ,
• .and simUar ~thOugh~~~~ry stlllies 'have ~so .conf i rmed ~~Value
I and relAtJve safety of t hi s awroach (Bodey, Yap, .Yap , Valdivie80, 1980,
Gllby~ 19(0) . . r ,. ,
'!be use of y1ndesine in the treatment ,of solid t~.cirs i s being
eval'uated' further bY 'many phase II ~udie8, and enc:ourllging results of
ita effic<K:Y in ~ treatment ~~ na;ignant me1l!nOll'oal (carmichael , Atkin-
l
Sal, ,calman" Hackie, Naysm1th ~ Stlyth, 1982), a1Yanced breast ,c anc er
(Walker, RaiCh~ F~tana, Sl'tj~~ian , adgers, Knost 'Denni~, 1982) ad
ncn-SlMl1 cell Itrig' cancer U~rnas~ Wi111.a:rs~ Einhorn' Cobleigh, 1982) ........, -.
J have been reported, Although its use in the treatment of ·renAl cance r has
not been r~ed (Fossa, Denis , vail. ocaeerce, DePauw , .St ot e r ,
1983) . Although these ·s t udi es have utUi6ed the c1rug as a single &gent, .
given. weekly by in~rAVenous bolus injection, it has also .been 81JOCeSB-
fully used in seVeral rrulti-dru; regimens, and even pre-operative.ly, with
cisplatin and bleollrfCin, fOr the treabrent of carcinana of the oeaop~us
(Bains, Kelsen, Beattie' Martini , 1982) .
I 6.6 MJ.seell.meoue tra!:beada ' -* (
Alt;houq. h the ma;or ~\a8a@8 of warheads invest-igated in t arget i ng
• '" " I .
ayetem have inelt.ded to~l~, drugs and; r"'rlonucl1dn, a limited nllrbar
ot other cytot~dc a9~nt8 hav~so been report.ed ,f or use In this
\- Ilttlng•
••
•,
.,
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A covalent carP1ex CCIl{)daing a murine ~lonal 8Ilt~, raised
'II&1.nat a huIMn ~lmx;ma ~lated' Mtlgen, an:! the C3b-l1ke ' glyccr
protein of c(lbr.ll venan, ' was' eOOwn by~ vogel to "exhibit selective~
toxjfI ...;"'t ~.·1~. cells When mixed with Othe~ cell '~ ~ne8 ~ ln '
~en::e.,of ~N'lI, dete~ by a 51cr-releae:e ~W::IClty ....assay
• (V&:!'el , Eberhard, 1981). The · .~tlve verlC?nt factor, itself non-~iC,
ts · thou2ht to 'be targeted to ;~el18 ~res8ing" appropdllte antigen:G,
whic~ in the pr~e 0; eatplenent faStors of ~e- alternative patlway
within the seN1l, cause cell l~is• . An advmltage of this, approach 'is
that the' conjtJ3ate is active at the surface of target cells ard does
not .require internaliB4tion. Reports reqardln;J the efficacy of this
awroach in the animal iPodelare'awaited however• ./' .
'1tle tatgetlD1 of the enzyrre glucose oxidase to ';t.l.lDOr cell
~a.tl~ 'hM el8~ been pertornEd., the· rllti~~ of ~ih1S- ~-aPP[;;~
being that ' freeradiC~ formed frClll. reaction pr~u::ts between
~idases, end CatflOuOOs eech as iodide, arsphenamine ce luminot will
\ ~
c4uN'eelective cell kUling (Philpott, Bower , Parker, .1~73bl Philpott,
Bower, ;a;;er, Shearer' Parker, .19741 Parker, Aac~ · '.pott, 1975).
S1m1larly the ta,rqet~ of- the enzyme '~l1pase C in~ been
II~ t.~ lyse tarqet leuka~c cells without ' killing nol:1M1 SPleen. cel.J.s
' (F1~r , Trost, 1976). . ' . .'
. .
<
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I' I7.0~
The cdteria allided to throughout thi~Chapttr regarding tacqst-
"'" Sfst.... and their """;""ts fore "lUO!lY ""lIcable to ~ ~~;Ing
of drugs ' t o t,~r8 1 iJmiJnochemotherapy .
-1hese. n q uh eaelts ~6'e sl.mnadsed as follows l one , that s~le
~onjU:Jate.s C&\ be prepar~, using ' covalent I1nklqe between the cytotoxic
drug am its antibody car ri e r. '1\10, that the proper ties of e'a.:h cmp:m-
ent art.-rE'~ follOliling C'Snjugatioo . 'l'hree, that specificity of the
" .conj~ate relates to the spec'ificity of the ~tibody carder. Four, that
the cytot oxic drtJ] IlUSt ~ sufficiently poten~ard must retain activity
at the tacqet site•
--....
. .:'Wll!lrlY; suggea~... Umitatl6ns of Other ~eting syst\WI a~~
also rei;;ont. to 1ltiIunochemo~rapy am rMnY questions remain 1JMlIfl\rer-
ed , 'l1leae inclu:1e the abil ity of ' Buch conjugates to reach target cell
populatLOl1B by vi rt ue of .vaecuia ri t'y ' of tumors or .t he i r ability to
e9CllPE! f~an .th l .~lood ~8selsl the mechanism of action of th ese conjugat-
es , whether ..they di8~ill.te . in the regl0~.Of the tumo,\o r ,r eqUi r e
l~teml!l1isation of the conjugl!l~ in . orda'to exert tbei~ IIftiooJ the
effect of c i rcul ating antigens in reduotng con j ugat e efficacy, t.he,.
role ot antigenic lJe:e~r.,99eneit.y and the possibility of the host ' devel~ .
J.nc1; an 1trroorieJeB~G. such conju:Jates .
0\.
With the widespread use ot ItDOOClonal ant.1bodies, targeting "Wi th .
. dr~8 may well prove to be a , practic,al addltionaJ. mode ot ~anc.r eherno-
,'"
•J •
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theupy and the present stat us of iJmuncchett:lther~ wil l now be dtecues-
ed,
'n)e rrodem eta of ' targeted cherothe~llpf.began with a report"~ . ~.
'Mathe in 1958 (Plate 2 ), of the erfect~f an antibody d t U}- coojU1ate
- •OJ 8. Dllrine ~eukemi~ (MAthe, tee , Bernard, 1958l . ADti.bo:li~ .~fiC
. . '"\
f9C the U2l0 leukemia were ,coupled by di4Z0ti~t1on to rrethotrexa£e
ft!ld the ·res ~lting conjugate used to treat mice "inoculated with the .
'\;~eukaemia. A significant len¢hening of ~urvival 'was fourd in the ,group
.- ot ~ce treated, with a single ~us injection of conjlJ3ate cClt'pared "to
those treated with di~ or antibody alone. TheBe e~r~ing results
were followed by other reports of dr~ targeting in the 1970"a,
I
Gho8e utilised a ' coojugate of chlorllllbucil am antibody against
Erhrlich Ascites 'l\InJ:)r to destaUJtrate sUppression of ' tlDlOr growth an:J
" . . . ' ,- ' ., / .
survival of mice treated. with ,the conjU3'ate~ C~[ed t~ mice .-!'£.eat~
with free antibody . or wIth chlormrbucil bound to '. non-sp;eclfic protein
, • (Gho6e ~& Nigam, 1972) . 'l'he method of ccnjlXjation involved adsorbing
the drug physIcally to the ant~ ~the cold, ' res'ylting in the •
't:rmat.ion of 'a non-covalent corrplex. USin9 this nethod, the alky1atinq
pr:ope~iea of chlorarrbucil were retained am ant~ activ.ity dmoost-
rated by imrunofluorescenee on smee.r:s of Enrlich Ascit~8 carCi~~ma
cella . Rowever, despite , the convincing anti-tutrPr effect seen Iri these
experim!nta. the use of non-eovalent bourd ~tibody drug conjl:Jlates as a,
drog targeting system .has been criticised following the deroonstratton of
. "eaJt:llex cUasociAt,ion in vivo (Davies, O'Neill, 1973, Rlt>ena & "Dulbecco,
1974)0. , Therefore, despite lack Of, true -hclning- or tarqeting of such
t.!l El':I.'E E Xf' U II\l F.:liTAU:. - I:"(} " Jll r Ia Irl(("rllll~' 1:!llJ de I., ",'Jllr'-' '{IIII,
combinuison l}flr din:;u/tff;"" ff'·('II/,'t!W/,lt:,.if/(! rt Iff" -:-,:;Ifflmlinn .I,. 1" -"II.lr('.
flurll-llri ,1,- r,'(l~ ft'fl l'h uic / Hl r lu't,:ro,!;rrt!l'. Xct c de .\1 \ 1. (;t U II "l ' \1 \l lIi~
'I' ll ' '" B, I.. lt: et .It;" B r U\\llU, pl'l' H'lll ec Jl.1r ~ 1. Leon Ilillel.
Plate 2. Photograph of Title and Abstract of rlathe's
1958 paper.
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conjugates In these s~udles, it was SlJ39estedthat the adCIlti ve or
synergistic: effects of drug am lUl.t:~ daoonst rllted, likely resu1.t~
frCD~tibody destroying drUj af~ecte-r£!US (Davies et ~, 1973! .
.. .
J
' .
using II. simUar ~n~alent chlorarbuCil anti:-tumor antibody
conjugate, Q)oae also demonstrated suwres8i~ of grOlrth of E;.4 lynphc:ma
. - - ~ .
in .mi,:,e ocmpared to gt otp! t rea.ted with the antibody alone {inmune ratblt
g.1.tDJlinl. ch!ormbucil ercoe, or chl orarbucil bound tl? non--f1mune rabbit
globulin (e;b"se, Norvell, ccau, cameron, Bodu~ & MacDonald, 1972).
However;, 'th ese l!xperi1rents did not .1n:lude a.group of mice treated w.ith...a
idxture of unbound druj "or antibody., an inportant control if ~ dissoc,i-
ation of non-covalent c~exes dOes..indeed c:ccur in vivo.
DeSpite these cdtici6l1S, the paper do!s also report the use of a.
conjugate .i n the treAbn~nt of '" patienT .w,~th me~ta.tlcmali~t
melanana, who, despite surgery, cherotheraP; ~ direct sa; injecti~
of metastatic cutaneous nodules, shc7tried no evidence of tlJDOr regression
~unl,il treated with ~he i ntravenous chl,orambucil-goat ,ant i mela noma.
an~ibody- conjugate •
• The me,thod of coupling drugs to antibodies to form covaIent
~ corrplexe~ ' .18' ther~Ora" ..of.. ilrw~tanee, ..~ alth,Ouq'h ' Math~~ 8' o·riqinel ·
paper (1958) rei~rreci only fleetingly to the 'process of diazOti~tiOn" _
. • • reports 'as early ~. 1964} ~ttmpt~ ~ define the cherni~~ pr~leir.s '--;;"-".._.~ " .
., ... .
coupling such agents 8f!.me~t;exate to iJmuloglobuli n mo~eCules (DeCa~"
.al·ho,- Rard .,· Lewl s; ' ·1964).; The'" range'of chemic!'! reOctiions bas been
.wlde~ to ~ irel~, ' In·<<ku .t l;' to .a1Uot(~t!on; ca~~1JIdd~.~ensI;-
t. ~ . " ... ~
1)
ion between carboxyl and amino group;, glutaraldehyde coupling be~
amino g[oups~ oxidation of sugar residues ard ester fomat1on of carboxyl
groups (P.owl~, In Prees). It was thought that direct conjugation of
drugs to imnunoglobulin rolecules would limit the efficacy of such
• J
conjugates as oil ref¥1lt of phys!cOCherdeal c~ea irduced in the antibody
am the ~ility to -l .ink sufficient drug molecul9S ' (!bolland, O'~Ul ,
Davies, 1975). 'Iherefore in eeeee to minimise interference with the
antn>oc:'lY. and increase the nurber of associated drug_weculelt.ti.e. con-
juga~ion ratio), ine·rt;,.....tntermediate canters were mployed, such as
~1Y91utamic acid. ~henyleneCUaminemustard carpl~ei:J via . pOl~~utam1C
acid to ral:Jbit inaunoglcbulin against meine EL4 lYD{lharla cella was shown
to prolong the ndian survival time ' of mice inocula~ .w~th · the EL4
lynI:hana (lbilard et aI ., 1975) .
Cbnjugates obtained frem the direct coupling of "desltCetyl vinbl as-
tine hydrazide, 'a precursor of vindesine, to polyclonal Mti-Q".A Mti-
bcXIles have been evalUllted for targetin<j efficacy frl Yi~!"O , in a 72 hour
.exposure microcytOOtasis assay, using caJ.u-6, a h~ tUDOr lung cell
iine as ebe taiget (Johnson, F~rd, Newman, WOOd~, b'~mJ an::!
. " ...
. Simrorda, 1981) . 'Ibe results clearly derronstrated the ~fficacy of such
conjugates over free antibody, drug, or a ~ture of both In thi~
: ' ,syst~. ' This radiol$>elled conjugate has' also been administeted t 'o
'~Pa'tientB With'\\vanced canc~ 1ocallsati~ has · been conf1~ with
," 5 of the B patients stu:Ued (Foro, Newman, JOhnson; Woodhouse, Reeder,
, .'
R:lW1and , 's1immds, 1983). . In addition, no obvi0U8 toxicity waS seen
even witl\, the ' administration !If 'up to ' 42: ~' of a sing1edose otconjug-
ated antibody, fU39e8ting the fe~1bility of this awroach •
. ..-:..-....-.
t...
)
.,
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Such s t udi es stinulllted further wor~ Jl:to the Coupling of - the
vinca alkaloids to lOOnoclonal ant ibcxUes, ~;~;;ent carplexes were
~ ..---- .,?rep~r~ betweel:\ the drug anS"""the. anti-~·'monOClcna.l, 11-285-14 1
anti-melanoma antibody, 96.5 (Brown, Woodbury, BArC, Be11st ran' Hel l s t r-
om, 1981) I anti-neurot\lastoma antibody . ,.. UJl3A-.(Kems~. Fr itschy,
• Asset, sutherland , ceeevee, 1982), and anti-oateogenlc &arcana: eeoc-
clonal, 791T/36 (Dlbleton, GJnn, Byers , Balpwln, 1981l .In general two
nethcQs of cen j U111tion have been . 8l()1oyed , azide cmjU3 11tion am active
ester conj ugation, th e latt;.er . being mor e effici~t· in idJitlon to
achieving hi~r conjug at1?fl 'ra~ (a:Nl~ , In Press) •
'Ihe efficacy of these conj ugat es in 'suppres sing tumor growth has
~ investigated in ip vi vo Bysterrs utll,18ing the ~til)(rlies mentioned
above. Of particular i nterest are targeting stooies 'us ing the (FA ,
eXpress~ colorectaI~; MAWI, maintained by s...eria1 ~ssage as r
xenografts in mXle mice (Rowland, COrvalan, Axton, ceee, Marsden, smith
& SJ..rmm¥ls, 1984). Mice bearing these xenograftS were trea~, on the
day of tumr inocul4tion,. Vith ' free antibody, (175 ngkg-l twice weekly
for "f i ve weeks) am conjugat~ of 11-285 -14 8nd virdestne (6 rrgkg-! with
respeCt , to vird,esine concentration using a B1mllar~hedulel , the
latter ' res ul ting in , suppr$!8sion of tumor 9ro.rl:h for .~'90 days of the,
experiIrl!nt, whereas free ~tibOdy, him ~Y slight eff~ct. Parallel
Sped,mente ua!ng the ant1-<FA rrOOoel~ 14-95-55 (4Il IgG2a) am ita
vi rd es ine 'conj tJ;Jat e: also confirned conj\tjate ~tticacY~' 'al t hcH,q h ' suw'res-
, sion of tUflK)r growth WM alsp obt~e::t 'oil':' free ant:~.
" 0 .'
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Drug -targeting ~.~~ies teve also beef! PJrsued by other investigat-
ors alCll.9 similar linea, ~ a rec~_t CClf:t)rehenslve review 81.1lrNl.riaea
experience in -vreec and in vivo with coojugatea of W1yclonal Mel
~lOOal ' ant:1bo(U~s dl!,ec~~t rat tlXOOr ant~9er'ta, and :~.lpha­
fetoprotein, . using daunomycin and its hydroxy-derivative adriaJl!fCin
(Amai. , sela. ' 1982). Targeting'.of dalInOl¥Cin with anti-<:E'A polyclonal
antibody conjugates has also been ~trated in vitro using human tUTOr
cell lines, where .conj ugate -efficacy~~ also found to be greater than
that of free drug, antJ.bc:dY, or a lure of both (Belles-Ilea' Page,
1981).
Mrismycin coojl:*3ated to anti-Sp 4 1l'OOOC1onal an~ibodies, shown
to localise in vivo in tUllOr be~ing rats, has'~so beeh shown to ret.ard
tumor growth eatt>ared to free drug, a conjugate of , adriamycin and a
n00-8pecific inrlll,ulO;lcbulin, or a mUcture of fr crug and anti-sp 4
mc:noclonal (Pm, Jones, Price, H..iddI:, Enbleton r. Baldwin, 1982l.
r
I
Clinical studies utilising anti1:x:dy-drug COOjU9.8teS are f-:w-=-~._
have generally involved I1Jn1ted namber of patie;'ts, ofteil with advarl;ed '
disease. , In «Idi.tion. to demonstrating clinically the .s ynerg istic
.ef f ect between d~ug:end 'ant l booy:...in_f iv e patients with rne'tasta.tiOOo \ , '
malignant melanoma, prolttlged rredian su[Vlval time of ' a patient treated
intemittimtly over , a ' year with a covalent melphalan-imrunoglobulin
conjUgate,haa also .been reported , { Evera~:',- DOWd , Davies, 1 O'NeU'l '..
JV.Iland, 19771. Using adsorbed ; noo-c~. alen cmplexes of chlorllll'bucll .....
and anti-melanoma ant-!bodies, Ghoae was so ~e to obtain prolonged
surviVal times i(titnts with CCM, cCIT'p&red,....t;o .those rec~iving
' . / ' ?
/ . ~. ·4
.r.:
\
76
conventional chemother apy (Ghose , Norvell,. cceru, Bodurtha, Tai ,
l<ac!lalald. 19nJ .
However, further clinical studies usPlg covalent carplexes of drug
&XI antibody a~ sc~e, and none ~e '~'Pblislied to ' dat~ where
. ~ , ...
. ~lonal antibOdies have beerll.lsed as carders.
' .
' , ': .
I ' ,
r ,
'" .
J .
11
I
. Prom the ~oing MCtlcns,-u" awe ar; as 'il targe~ chem6-
. . . ' ' .. ,
. thenpy oU efS potentral as a ~thod of .1q)cov1ng ~ selective d.el.l.~ry , .
of d~U':J8 to tlD:lrs, . whlch IMf be clinically relevant.~ . • . .._
" ./'
, .
18 part of the @valUation of this, appr~~, the . a1JnB of these-
s t udi es -,ce as follQ,l~1l
.>
"'"
1. osf,-q crAas 4 ~el, to -Ch8r«:t~dse a r~e. of hl;lW'1 t~r . cel~ ~ "
lines for. the ~xpre8sion of . this target" ant.1cien with an arlt.l-<v. "
monoclon&l Mtibody, using i1rm.mcytochemical ~ radiol«iell~ .
,Stud i es . " ~ • \ ( .
2. To eveiuatl ta rgeting efJicacy ~ ee~~eV1ty ~ anu-ai. .
1lI:inoC1onal antJbody vlnies1ne oonj ug:ates in vitro'UB~ sil~ted '
, \ .
. cdl linea (frem 1) in a mic r0cytc6tasi s Uuy••
. ~ . . . .
3. 'Ib es tabl1ah a xenogr~t pte-clW c41. rodel ~or the in vivo : r . •
&SSeSSlDellt of targeting using the l 1nes:'lte1eeted ftCIIIOl above.
C. To eeeees the etU~ aM se lectivity of 8I'\~i~ -~l~'-O
.. . '---
ant.ibody vW es1ne conjugates -on tfe g rowth of hmM tUtOr
, x~rafts~~ ',8rang,: 0/ta~et(~tlgen. la.A) exp~esBl~', in the : . ' :----. '
\..x~raf~ lfDdel (3;above) " • . ' • •' ~~ . ~ •
'5. In addUioo to these principle ah, the ge~rat1on 6£ ~edJ1ti~
anU~ 'llI)rloc)onai M~ie8, Using ltib~idanll .t:e<:tv-b~~ ; -~~ ." ;·i}·~~
J
\
; . .' -,~' f !
attetllteJ.
\ .
... ' \~"-. :- '1'
. .
' .. ~ .
:.. ....:
~ ' i
\
\
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' fi~1d of oncology (S)'kes, 19751.
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II 1.0 . 101M 'ftKR QIlL alUtJRE
II 1.1 IntrcIhictJ.a,
_ . J us t as a progrEeS ~ mic robio logy vas slow lmtil 1881 . ~ la:tl
p roposed a a! thcd of se lective bact erial cul tu re . sUIUbl~ methods of
• culture of tunan t lz.O r8 have all owed npid progr ess . to be inade i n the
""-,
. Si nce ' t he fi rst pe~ent cell cu lture was prepared J rm 4 .
cervi~~ neop lastll in ,1952 (Gey , ,·()) f fman " Kt.bl~k , ,1952), O~~[ 'hunan,:':"" .
. '. . . -...... . .-,
BOlid .turrors .~e been grown 1n vi t ro as nonolaye rs OR '"91~s and pl dtic ... -':
Thi"sohAs ' not been wi thout prooleu hoVever , and at terpt s are still '
be~: IMIde 't o' ov~r~ 8uch . f~anen~ diificUttf~~~ ini~t~tiI~ the
cUlture, selective 'growth. of t urror cells fr ee of. ~~tfb!.!Sts arK! othe r
' caIt lllllinant cells ' . suitable nutritional cordl.t:!.ons."fo r optiJMl c ell
9ro.tth and characbrtzation of the cells . Against these 'difficul ties ,
the t hreat of infectiort [ eJ:la!ns a potential ha;ard an::! techn,iques of
MRnt.ng these cul t ures order s te rile ' conU tions, with jtdicious use of
ant ibotlcs ,. have' also requi red devel oprent.
,
. 11 1. 2 Qell~
< ,
('
HI.Inan tlDl'J:lr cell lines, ut ilised In this study Are listed in Tabl e
1 along wit h the type of tUtOr, ard were A1re~ es tab lished in ~~ture
in the Ch::oloqy Resear ch !.4bor<1ltory, where they vere undergoing cnerec ee-
riSlltioo. 'Ihey were obtllin~ initiall r-.frcm; th~ Alrerican '1YP! CUlture
Co~ection. Maryland.. U. S.A •• wit h the exception of BENN which WlIS
obtai~...~rpm Dr . M. Elli~ at the L4.dwi9 ceeee I~tit.ute , London; U.K.
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TABLE 1 . aieen 'IUror ceu Lines used at Olc:ology ~gearch. with scc rce
. ,
aLL LINE saJRO:
LSl74T Adenocarcioona, colon
SKa:n Pdenocarcinana, colon
1/1':" Adenocarcincma, colon
CXL0020DM Menociarcinana. colon
\ " . "
LoVo . Adenocarcif\Qll!l. colon '
. SWl116 Ildenoctrcinoma , colon
SiB37 -v , Menocarcincma, rectum
AS49 Lung .cerc tncea
calu' Lung carcinana
SENN Lung cerc tncne
~ ... .
. , i
,.
"81 '
The ,cell lines "were grown as roonolayers in 75 cm2 perspex til!'sue
culture flasks (Falcon , Becton-Dickinson), am mintalnedat 37 deg[~s'
. ,
Celsius . Selected cell . lines Le, BENN required inc:cba.tion in a, 5\
carbon dioxide eerospbere alP were k~ in a sepereee gassed h~dified
Inclbator .
cell growth was checked daily by viewing the nonol'8yer urXIer. an
inverted viewing phase 'mic roscope ([)101lve rt, · ~itz ) . Characteristic
. . . ,\ . ,' . . ~
pat.terns of. cellular morphplogy ~re seen, Le , epitheloid, plearorphic,
fibroblastic, am th~\p[oportiOn of the JOOnOlayer coverin;J the s~[face
~ . '
of the flask was deteoninM , in Cddition to :other char'acteiistics"such
. ' . .' " ' .\ ..... -.
as cl~in9 or pUing.,.up of cells . Plate ~ illustrates grovt:h of a tumor
cell line 1n culture.
II 1. 3 Media
•
'1'~le 2 !Jets jihe media and suwlenents required by "each c;iJ
• \ f"$ "
line. 'Itle addition of the s~lerents to the basic stc4: 8O~Ution was
performed in the laboratory umer sterile corrlitions.
Medie.was lidded to the culture flasks or replaced as necessary,
but, on average, 30 - 50· ml of ~ium w~ changed bi-weekly, depeooing
on cell 9w.rt:h. 'Itlis w-as performed under sterile C?nditions«, using a
(Jl amiM r ale f1~ ~los.ure (con~t.ion cOOtrol Ir-=.) , sterile equiP-
!lent and standard · micro-biolog!cal tetlv'liques eocn as flamin;J the - Open
f!lQuth of a container prior to pouring.
Plate 3. Growth of cell line SKeOl monolayer eight days
post-trypsinization , as seen under an inverted
viewing phase microscope (nt ever t., Lei t z)
(Eye pi ece . xlO ; Obj ect i ve . 10/0. 25)
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TABLE 2. Hedi-'i r~ired for cell CUlt ure, J.n:lwlng slfPlanents
• ( 'All ~terfals 8uwr~~ nOW' Labo~ato ries )
-~-_._--- --~--~-~-_._ -----
1m,
LoVo
CXLC020DH
&/1116 / Si837
~
.... .
It:COy's
(500 mll
HAM'Sr- l O
(500 m!)
RPMI-1640
(500 mil
L- 15
(500ml)
"
100 ml fetal cal f seD.D\l
. (15 .6\)
~ ml 91utamine
6 m1 noo-essential mdno acids
12 ml pen~CHl~etJ:ept:Ofl!r'C'in
. (. 60000 U penicillin ,
6Q nq streptonr/Cln)
, "
15 ml IMH~ Buffer
100 ml fe tal calf .s e nun(16 .1SI )
6 ml ,91utanine
12 ml penlcillin-streptO¥in
50 ml ,fet Cl;! calf- semn(8.8\)
6 'ml glutaridne
12 ml penicillt"":,streptanycin
50 m1 fetal calf serum (,B. at) .
6 ~ glutamine
12 ml penic illin-st repto¥in
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Table 2 -c ontnnued
' Calu 6 Dulbecco's
(SOD mil
•
Ml99. (250 roll ·
\ . '100 ml fetal calf se rum 116.02\ )
6 ml gl .utamine
6 ml non-essential amino acids
. ,n ,"~niCi)lin-tpt~mjOin
50ml fetal cCl:1f setun (S.S\1
.f Dulqeqco '.s (250 mll . 6 ml glutaMine . ' "
.12 -~ :Pe'niCil~in-streptany~'
A549 .." Dulbecco ' s 500 ml 50 ml fetal cal f se rlDn(S. S\l
"----- --~----~ 6 ml glutamine
12 -~ penicillin-st~ept~in
rsl74T I SK001 Mininun eS8e.ntial
medium (SOO,mll
50 ml fetal calf ae rum(S.S\l
6 ml, glutamine •
6 ml non-essential amino acids
12 ml _petlicillin-~trept~tn
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When cell growth in the . tissue culture flask reecbed confluen::e,
a een suspension was prepared by t~izirg the ' cell monolaYer . . 1\rls
enabled a cel l count to be performed and based on the nt.U!t>er of v i abl e
cells pre~t in suspensioo . aliquots of known,cell nurrber were prepared
for use 'in . . sl:bsequent experimltts:
.~.. . ~, ~.
r
, ', : ' .
Ph?sphate: buffered saline , (~~_~ piih~t 0.15M, prepa red h ffiS):abTets
(QcQ!d Itd. ', ·.E;nglaD3h dis~~lved iil "distilled" water as Fer man 4t~re['s
, I .: . '. ' :: :... : , ' . . - •
instroctions , .and; :acerilized by autoclav!ng•
. ", .t ·.".:., . ." ,
Tcypsin-EmA lOx (~ibco) 1/10 dil~tion. in F9S
, "
\.
. ~
....
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.• III ... (b)~
1~ .I :Ond E7 [' s t e r il e '.'Condi t .ions . the rredium in the culture flaS ks was
. poured off: arrl disc~ed. . '
2. '!'he c~ll ~l~er~ was washed''twice with 20 mJ, sterile PBs. at [0QlI
. ' ~' . ' tmper~t'ur~, ~ .~~ PBS ~iscard~~ . .
~.~ 5.0 ,ml ~,rypstn-:EI1.l'A. soluti.on (l.l~ <\llutl~ 1PBS! was added to
_ . the flask , which was: then incLb~f~ 37 J:I~r' celsius . (0 C) for 5 .
minutes. . I . . ,
4. 'J.'hI 'ttlPSiil SOl~U~i~lOcontaining \the~~l1S " , ~en poured i nt o a
'st e r il e ~~en~df~e ' t~~,.w 2.3 ~ PBS}cdded 16the f~ask 't o ,"wiil
any rernain~ ~~uC~ then poUred into 'th e' c'entrifU3e
t~al'''• .- ' : "1 .
5 ~ ~ cells' ~e[e then.centrifllJ'ed for 5 minuteB lat 2009.
6. 'Ihe superna tan t was carefully poured off the t ell pellet 'w the
cells re- s uspended by tawing the tip of the ¢entdf U3e tOOl).
7. 10.0 rnl of tredium was then a:1ded to the cells ' and a cell COlZlt
parforrred, i
. I
. • I'
II 1. 5 <:ell Q:lmt . ' I
lb. ccecentreercn of colla In .llon J; calculated using •
haeno:ytoItEte r. cell viability was ass Jssed bY u,81n9 a sol ut io n o f
I i~[idine orange . .(Whi Ch .s t ains villb le cells br1l1rant gr~) and ethidium
bromide ( ~h1ch stains non-v i abl e cells orange or ldull green) when viewed
witli 1!I fluorescence mrcrceccpe, ' . :
I
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II 1.5 (a) Mster1al.s . '
, -
Raeno::ytcrneter lNe\bauer ) . wi th coverslip
k r 1di ne Oranqe (Sigma chBDica1s, USA) •
Ethidi lb BraUde (GJ.t[ . LtnJon, U. K. ) •
*used as a 0 .001\ so lution ALVEB
Fluorescence Micro scope (Ortholux II, LeiU), v1th a 50 wat t
. mercury vllpOur br: ll.
": II 1. 5 (b) · Met:.t03
O'le dr op of ,t he cell suspenetcn, at appropriate dilution,
, I
~ed with one drop AQlm soluti~ an1 the mixture placed, beneath the
~e[S~ip of the haenocytcmeter, . Which was then vi ewed UJder the fluor-
escence microscope • . Viabl e and no n- viable cells were counted and
the pe rcentag e of viable cells calculated.
II ~. , <Jell D~lng , /
FollOW'ing ~ preparation of a ce ll S~ion and deteLur,#l
of a viab l e cell count , aHquots of cells at: known ~entcaJons ~re
p repa red .
At every ttypeinlzation , cell srears were routinely
illJWllocytochemist ry . A cell , euspenetcn of 106 ce lls in 1 1\ bovine
ee nm al~~ (Si gJM) in rss was pre~red and SO' ul dispe ed onto each
of fifteen. al cohol (:1e8Ooo , edcrceccpe s lides . 'I'hese
. \
latJoratory. For this purpose ; a 10\ solu~ion of l ii neth yl -SUlphoxide
(BDH Q'lemicals ) in fetal calf serum (Fl ow ~[atoiies ) was· sterilized •
liquid ni trogen'. (Liquid nit rogen cannister : M'CLW SX 35; MIlE) .
-,
,
8S
New flasks were established usirJ;j' a minl 'lltJf1'1 of 106 viabl e ce lls ,
which were in itially placed in 10- 20 m1 of medium prior to Inclbation .
Slbsequent maintenance of these cell cul tures has been described.
zxtre cells were frozen i n o rder to obtain a s tock sUW1y for the
,
\ by passage th rough it 22 urn micropore f ilter . an;:) 1.0 ml of this solution
'- -. - - ', '. 'lrlded t o '-4 ~ 6 J[ 106 viable cel1~, . pr tc r to , t ransfer to a ~ vial
(Intermed ): Thes e vi als were coo led ,f 9' 24 tccre in . a -70OC ' Reyco
'''--. .. . .
freeze r (Bleern 'Manuf ac t ur in g Co., Ashevi lle , -N. C. ) pr i or to stor0ge i n
,
cells were [~deved by rapidly th awing th~ vi al in a 370 C wat er-
bath unt U a litQle .Ice ~enained aId then acHing the cells , under ste rile
conditions, to 9 .0 ml of rredi um .in a sterU~,centdfuge tooe. 'Ihe
s uspens ion was then cent rifuged a t 2009 fo r ' 5 minutes , t he super -
natant disca rded, 5:0 .er of f resh medium added ,an.1"fpllOWing A ce ll ., +
eourit , ~ s~pension was added to a tissue culture flatlk.
The con cent rations of cells used i n .Ind Iv ldual expedrrents ,
urid~ne assay, fusions , . )C enog r~t i nocula t i on, e tc . will be desc ribed in
the awropriat e section.
II 2. 0 GI!H'JWl'IQil' a ARl'l-cErA~" MTIBCDIES
II 2. 1 Int..n:dLctJaI
\,
as
r "
The Ih!thod of fus ion outl ined for the gene ration of an ti-CFA nono-
claW ant 1bcrli es foll~ tha t of !tohler (1975) arrl~ 119B2)" ;
The NS-1 mouse myelana cell line was otit ai.ned from the 'HUnan'
• Genetic Mutant cell ~sp08itory ' (Qmden , ~.J . ) It was grown in
suspension -tn ?Scm2" tissue culture flasks (Falcon, aeCtOO--Di~kinSon) .-t
~70 C in a SI ceeron dioxid e h!Jmid1fied-abnoSFhtlre. I~ med~UIl'I, RPMi-
1640 (SOO ml ) was suppletented with SO ml fetal cal f BerllP (FCS) , 6 .0 ml
gl ut am1ne, - 2. 0 ml penic111 inlstr~Cll¥C1n ( 10000 U ~niCillin , 19.. ng
s t rept aJ¥Cinl, 10 .0 lIl1 gl ucose (4.5 gl-~ ) " and 1..25 iill thioguanine. (All
mat erials supplied by ' Flow Laboratories ) . '1b maintain "exponential cell
g rowth, rredi llil vas decanted frm the fl as k urder s te rile co nH tions ~
replaced wi~ f res h Jedi\lll at awrox~tely 2 day in tervals• .
O1e day prior to fus ion , cells were diluted 1:10 · following a ee l'!
. . ' . .,
count am asseSsr:Ent of Vi abil i ty, .'iq orde r t o tnaint.a1n exponent1~
g rowth at ~ tim! of fusi on. A cell count was repe ated on the day of
fus ion and ~O~lOw.ing · a s t e rile ms ~h, :~ ' 8~ion ~~ " i07 vi ab:!e
cells ml-l w~ prepar~.
.- ~
. <....
II 2.3 ¥eerl osu Donor
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consisting of s~;en C~18 i n suspension• . .
". • t o
Tab~e 3 l ncUcates the i1mun l sa tiOn 6Che:lUles for spl een ce~~
~u. •
To . harv.est the sp l een ce lls, mice ve re sac 'r U k ed ~~ ca.rbon
dioxide ard the spleen [E!IlOYed~[ s t er U e anUtlons . 6-ceH sl1SJll!N>'"
i on ;6S' prepared by ~h1ng tie sp l een through",oa fine ste~le Si eve •
using ,a rd:be r 'fiwed syringe Plunge'c . The spieen cells, were collect ed '
til s t er ile PBS; ard the s~nsion all~ t o 's tand in o'eder t o allOw
. . . . . . .
large. cl~ ,til settle. "A plpe ,tte was used to [~~ the supema.tant ,'
....
, t.' .
..
.· f
"
".
/~ '~ ,
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" iabir, 3. Itrrrunlsation SChedule for ~leen cell ~ors
(pe'dormed by rnenbers' of the Olcblogy Research Laboratory) I
/' ruSICN DAY ' IGEttr O~'l"{ M>JINMT =
,tug, cells )..
-
_ 1. . CEA
•
,0 ' ALlJII/Il.P . IP
3I CEA' ' 0 ALUM I P
42 CEA · 20 ALlJII/Il.P. IF
129 CEA 20 ~Un:vB.P. IP
.
346 CEA 26.6 ALUM/!!.P, IP
355 CEA 20 ALUM IV
'409 CEA ' 20 ALlJII/Il.P . IP
.. 454 CEA 20 ALU>VB.P. IF
" 465 ciA", 20 ALUM IF
469 CEA 25 ALUM IP
·472 ,FUSION
."-
z: O· Wlo 107 B.P . IP
" ~2 ' tcvc 107 PIlS IP
" ~ 355 IDVo 4 .S8xlO6 PIlS I P
-., ,377 .. ~Vo 3 .4SxlO6 PBS IP
- 386 CEA 30 ALUM IP
:.~ f'USlOO
"II 2.4 P\18100
II 2.4 Cal Mat:er1al8
Sl"I.E:m au. SUSPEN5IOO 107 cells ml-l
!'OlSE Mn1.CJo\A. du. SOsPENsIOO (NS-i) 107 cells ml-l
RPMI--GLN: RPM! 1640 100 ml
•r GIA11'AMINE (ern) 1.0 fill
PENlCXILnV'S'I'REPI'CHlCIN 1.0 m1
PEXHlkSCrRPMI (4~' pro) : PCLYE'nriUM: GLYaL 8.0g
..DlKE'11IYLSULPHOIDE "i . s m1
RPMI-CW 8.5 ml
RPKI-Gt.N-FCS : · RPf'U~
rcs
RPMI-GLN-HAT:
¢ >
100 ml
.11 ml
100 ml
HAT x 50 2.0 ml
RPMI-c;m-!tI\T-FCS: RPMI-<:I,.N.,FCS 100 m1
HAT x 50 2.0 nil
RPMI...!GLN-HT-FCS : RPMl-GLN-FCS 100 m1
HTxSO 2.0 1lll
TIS&JE an.'IURE PlATES, 96 arrl l24 WEU (L~[O. Flow )
All mater.i:aIs fran FIC'ol tebcreecrtea, except PEXJ t. tIlH, Poole,
England ) arxl OMSO ( BOH, Toronto l .
HAT : Hyp::»tanthine Aminopterin Thynddlne
HT :- ffypoxanthine Thymidine .
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II 2 .4 (bl 1IetIo:l .
1. spleen cells and myelana cells were lIlixed 1n a ratio of .IO :1
and centrifuged at SOOg for 5 minutes.
2. FOllowing rercvar of the supernatant, the cell pellet was
wat'll'led in a beaker containinq water at 370 C which 1n t um was
placed within a. larger beaker containing water a~r
eeepereeure , .
3. 1.0 ml P~RPMI was 'added to the cell ,pellet dropwise
over ~. minute, sUerin;) gently ~ith a pipette tip. This was
continued for a fu rther minute and 1.0 ml RPHI""'GLN-fJAT added
over one minute in a s imilar ~er, ' followed by 'one further
. minute of gentle stirring.a.O ml of RPKI-GW-HAT was added
over ] minutes and cells then centrifuged for 5 minutes at
20".
4. Following renoval of supernat:ant,~ cells were resusperrled in
25.0 ml RPMI--GLN-HA'I'-f'CS and plated out into five , 96 well
plates whi ch were inclbated at 370 C in II. humidified 5\ carbon
dioxide abrosphere.
5. The plat~a" were unlisturbed for 5 days. 1he trEdium was then
changed by USing a 19 gaug e sterile hypodermic needle (Yale,
Be<:ton-Dick inson) at tache::! to i!l vac u\lll line "eo rercve half,
~hich was repkeced by fresh RPHI~HA'I'-FCS. The rredlum was
changed every 3 days and lifter two weeks, the hybddoma
selective medll.Ull (RPH!-GLN-KAT-FCS) was retroced by amino-
p~.eri~ depleted medi um, WMI-GLN-Hl'-FCS, for II m!r\11UTl of
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three chang es. 'Ibis was then replaced by RPHI-GU}-FCS.
6. Microscopy using an inverted vi ewing phase microscope was
performed on a-d~ily basis after the fi ra t medium change i n
order t o detec t growth of o;lonles . Supernatants fran
pranisirx{""'lJells were rE!llO"leCi under sterile corditions ~
tested for anti-<:FA 'activi ty by EI.ISA.
7• • Positive hybrids were either exparded"'t,y t ransfer in to 24 well
cult\lre plates or cloned iImediately by limiting dilution
(10 and 5 'cells ml-1) , follwe::1 by dispensing lOOul b.1 quots
into the wells of 96 well culture plates .
!
I
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U 3.0 fHZYKE ...tr«m lJ'IIXBmlNl' AS5M (Ei.I.9.)
II 3.1 In trahK:ticn
'Ihe detection and q~t1tat.lon of strdll mDUnts of b i Ol og i Cally '"
active stbstane es, even within the nanogl;am ~, Ili llil i t re range, wi th
a hi gh degr ee of specUicity , sens!t1vi ty n ..reprocJlx:1bil i ty has been
achi eved using met:hcl&-that utilize the unique llll tu rt:' .ef the ant~9en­
antibody eespcnee , Radi oi munoas say has 'been . widely 'used fo~ such
. . \ .
purposeS ~ince i ts Introdl1Ction over 20 years ago (Ya! ow & Ber.~on,
1959)" The us e of racUoiSo topes however has ' several d i sadvant ege!>,
relat~ t~ ~ handl ing and, safety of ~se reagen~ . the~r 'cost ,
avail~ility .and limited shclf life (O' SUllivan, Bridges , Harks ,
1919: Deins. 1980) .
'Ihese di sadvant ages have been 6Vl>t:cQne by usinq _~zymes as
alternative l abel s t o ' radiois ot opes ' i n an enzyme !r.mJa'?aSSay. Horse-
rlldish peroxidase and aikaline ~tase are winely ,-"Sed~
labels, ai though othe rs such as 9~ucose oxidase, &-D galac to-oxidase
.. and 91uc~lase have Also been used (O' SUllivan et al , 1919) •
.f)u yme ac~ivity may t hen be assessed in a'quantitati~ or se mi:'
quantitative manner following catalys is of a sinple reece t ce , 'which may
1nv~lve a col or change ' or th ermal response . sev erer t echn i q ues of
enzyme iJmllJrloas say nave been desc ribed with reaction sequences .rel at ed
. . .
to l abellin g of ant igen or ant i.l:xrly, phase of reac tion ~ t he nurter .
ot s tages involved.
.The ant ibody .ELISA. used 1n sc reen ing hybridana supe rnatants i n .
this s tlrly was essentiall y a rrcdification of the sandwich ess ay. . Dcesa
,
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antigen was bound to a solid· phas e and rea~.ted wi th lII'ltiOOdy, which in
tum was detected bY an anti-mous e immunoglobulin - enzyme l a belled
antibody . The col or reaction was t hen quantitated specerceccptcany ,
and i t has been .shown t hat 50 pg pe r cuve t t e of anti":'CFA monoclonal
ant~·may be detected using t his &SS~ (WOOdhous e et al , 1982).
II 3.2 llntihody 1Bsay •
On 3.2 (a) Materials
Carbonate Buffer la.1M, pH 9. 8)
\ Sodium O11or~de . ~ . 76 9 IIi
. '"""\Sodium Carbonate 10 .6 9
SOdiun Bicarbonate 8.4 9
U BSA. Carbona t e Buf f er '
BSA (Sigma , USA)
car bOnate Buf f er , a.1M, pH 9 . 8
Citrate Phospha~e Buff er IO.1M, pfl 4)
Cit ric k i d ' 0 . 9069
DisodiU'nHydrclgeri Phosphate 1.017g
Dissol ve in 100 ml distilled wat e r
BSA.- PBS---'IWeen Diluent
BSA, It .
• PBS liI 7••2
'1\Ieef!. 20 (BOH, Toron~) 0 .1\
Hydrogen Peroxide , 0. 0024\
saline 'l\Ieen
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S6dill\l Q1loride O.15M
'I\ieen 20 0.11
cr.A - E;at:h cweete requrree 250 u1 of a 2.5 l.J;l ml-l
corcentration.
2,2' azino-<ll IJethyl-BenzthiazOl1ne sulphonic acid) (ABTS)
ABT5 Stock, 27.8 ng ml-l (Sigma, .St . Louis)
PeroxIdase ~jugated rabbi t anU-rrouse imttlnoglobulins
(Dalto , Denmark)
Gilford ElASO -proceascr , with Reader .and 'nIermal Printer
OJvettes lElA OJvettes, GU£ord)
1. To coat cwettee , 250 ul of a 2. 5 ug" 00-1 soluti on of
cv. in carbonate bUffer was di spensed using the Gilford
ElA ~O at appropriate setting i nt o each well of cwette
strips . 'lbese were inclbated for 3 bcure in a water bath
at 370 C, followed by storage at 40<:. 'nle s upernat ant
was decanted prior to use .
2. To bl~k non-specif.1c birrling ; 300 ul of U ~-
. carbonate buf fer was"di spimsed lii to each cuvette followed
by 'an inclbation pe"riodof 1 hour at 370 c .
3. Test reagents were . prePared in awropriate dilution in
BSIl.-re5-'IWEDl, and following reroval of the 1\ ~..:
c~rboniite buffer, 200 ul was pipetted into each l~lled
cw et t e , with appropriata controls. A.f ur th er
inc~tion period of 2 - 3 hours at 370 C fol1ow~ •
.'
I .
/
sa
4. Rabbit entr -eccse imu10qlcbulln horse-ra:Ush peroxidase
at 1 :1000 dilution was prepared ard 250 ul added to eac h
cuvett.e af ter rlm:lVa! of the test reagents and cont rols.
1'he cweetes were 1nctbated for 3 hours in a water bath
at 370 c . :rhe subst rate was prepa red to prcvfde II
concen trat ion of ? u gl -1 AB'I'S "in cit rate-phosphate '
buffer , wi th O.Oq24\ hydr ogen peredde,
5 . The Gi lford E1ASO was set to p rodu::::e an absorbance
read ing:. of zero ,and stllbllized. Conjugat~ WlIS reecved
f~m ~ cuve~~;;' , foll~ by 6 .~~ wi th sall~~
am the subst rate dispensed' into each cuvette (250 u1).
'!be tiu-e of rellCtl 00 vas not ed , and the abeorbance . read
~[~iC~llY uSing oS 405 n:a fil t er ~ d isplayed' ~
the pJ:inter : \"
6 . For calculation of results, the blank absorbance value
I
obtai ned when AB'I'S was . iilitilll1 y dispensed was ' alb-
t rac:ted f[QlI the final absorbance reading for eac h
/ -
cuvet te.
n 3 .3 Antibody Mally fo r~Qnj~ate8
'I1le assay outlined above was used to .t es t antibody activity of
iodinated and vindeaine conjuga,ted 11-2 85""14, with 11- 285- 14 as a
""' co ntrol .Con:ent rations t es t ed were 1000 , 100 , "lo , 1 ng ml-l and eee ee
were pe rforned i n tripl1cat e. Stward CUtveEI of abe orb4nce (Abac!s s a)
with .ll.l'\t ibody concentration (ord i nate) were const ruc ted .
99
For quMtltation of cr.A, the initial sequence of the assay was
mcdlfied. CUvettes were coated using 250 ul of a UlnOO dilution of
rabbit inm.lnoglobullna to hunan a'JIr. (Dalto , DeJ1llark) in carbonate/
bicarbonate buffer,and inclbated at 370 C for 3 tocre ,
Following the · inc1.b~tion with 1\ BS.Vcarbon~te. 200 ul of test
sample d~lutions were ~ ' t o ~ cweeeee in triPlicat~, .with CEA
. . .
starda$ as controls, and inctbat~ for 2 hours at 370 C.
11':'285-14 at a ~~entration of 2.5 U3 er-i was dispensed into
eech cuvette (2S0ul ) as the next stage,' ard following a 2 hour inctbation
at 37OC, the ·assay was as for stage 4 of t~ antibody assay. outlined
lbeve.
standard curves of ececeberce (abscissa) against ciI\c.oncentration
(ordinate) were eonstru::ted to quantitate CFA.
\
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The' ilmllrloperoxidase technique utilizes a specific in'mlrlological
reaction to detect a variety of cell products inchd~ once-
develqmmtal antigens such as CEP.. Although several methods have ~
described (He'jde~, 1979) ,. the es~.tia1 £:j.a1: Uc.e of the test involves
the polymer~tion of a sL'bstrate e.q, dillll'l !dine at the site of
II I . ,- -
antigen-antibody interaction 1n the presence of [oxidase and hydrogen
~rOxide. . - . " . ', I. " .
'nle test used.Jn this thesis was an irxHreet method (Heydennart ,
""'ille, 1977) with """ificatlon (Fo,d, Stokes.! _, 1981) . ;"e,
"f i rs t antibOOy (11-285-14) . was a IOOnoclonal anti~ antibody while the
eeccrd antibody was a r_ahbi~ enet-acuee immunoJ~ObUlins (heavy and
light c~ain) oorser"";lish peroxidase conjtJ;;ate.
With appropriate controls and highly speciffc antibodies , the test
is extr~ly reliable, w~th the~itional adv~Ja;e of its permenarce
I
-aM pr.eservauon of cel1u1~r ard tissue motPOOlO9YI(DeLellis, Sternberg-:
er , Mann, Banks & Nakane, 1979) . I
,
II 4. 2 Materials
SPECIMEN
,
either methanol fixed smea rs of hl.lllMl tUlOOr
I
ce lls prepared following ~ryp6inization, or
for~alin-t1xed . paraff1n ~ errt>edded tissue
sections.
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stock solution-,
Absol ute: 7S~, 60', 30\ :, at
BOlI NE SEKl M AlBUMIN 1% in PBS (Sigma . UM )
PERICDIC ACID 2 .28\ in d i s tilled wa t er upp lied as 95%
solution (BDlf, Toronto) .
POI'AssIlJH BORCItYDRIDE 0 .0 2\"rn d i stilled water (
prepa red f resh.
, PHOSPHA'I'E BUFFERm SALI NE ' pfI 7 .2
. s toc k reagents
sodium chl oride (NaCl ) 36 .09
potassiun di hydrogen
2.1Sg
BRIJ 35
!'DIWU. PABBIT SE IU M
Dissolve in distilled water and make up t o
~.o l Ures, a:1just pH to 7.4 as required .
O. OOlt so l ution in PBS pfl 7.2 suwl).ed as
30' sol ution (Technicon, Ne:! .."!orkl.
1 125 d ilution i n 1\ BSA.-in~
11-285-14, 10, 1 ug rnl-l
. ~IT IINrI-MaJSE~INS.
~00ImJ)- TO HOfISF:IW>ISR PEROC~~ (Dako, Denmark )
CXNl'RCL ASCITES (BRE. JIILEOJlAR DIJlGNCB1'I CS) 10 , } ug ml-l
3 ' 3' DIAM1NCBENZmlNE: (Sigma, U. S. A.) prepared fres h
10 rrg Di am1nobenz id 1ne (DAB)
20 m1 J;'BS
10'
20 ul ) 0\ hydrogen peroxide
Mayer' s Haenalum (Ha rl eco Diagnostics. IDH )
O'le lit re con t ains :
1 . 0 twHsnAtoxylin
~. ~ It~}odate
-509 aIInO\ium i~
Lithiln Carbonate - Satutatoo Aqueous SOluti on-
PermJUtt ,( Fi sher , til)
IX 4. 3 lIetbod- 001.l -...~' . .
1 . ~l f ixed ce ll • ars were ble~hcd by cOveri~ the elide
wi th 7.5\ hydrogen pero ide for 5 minutes , f ollowed by II tap wat er
\M6h. I \ • ~ . \ I I · , ' , ' .. .
2. flrlogencus pe[OX~~ "'a:s blcx:ked .U81J'19 2.28\ period~C acid f or S.
lIlinutes . follO'a'«! by a tap wat er wash .
3 . Alde hyde 9 roupl ve~e blJ.cked with - 0 .02\ potaBBllml bo rohydride f or
\
2 -.inutes . t~•.'r: were then washed with tap ~.illter f o11wed by
res pH 7 .4 . . ~ . \
4 . ~Specif~.ryugat'; bin(ing was prevented by awJ.lcation o f
50 ul of a 1:25 so l ut i on of noma! rol::bit se rum. i n II 1l'Dia t
I .
chMber . for 10 ~utes. s~e the secord antibody was a nbbit
~t1-11'DU8e reag en t .
5 . '!'he slides were WlllIhed in o.ooa BRLJ fo r 5 lllinutes.
6 . Inclbation wi t h SO U1 oli. the fi rst antJ..bojy (an t l - CIA) a t test
concen t rations to llowil'l9 appr~rlate dil ution i n 1\ BSA. in PBS,
. '
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within the frCIist c hanber for 30 adnutes . ~ative controls
1n:1l.ded were n BSA. and. when eva neere , oont rol ascites a.t the
&arne concentration as the firs t antibo:jy. PoBitive contro l s
1n:luded II known a:A exp~ell8inq cell l ine or liver metastases fre:-n
'" Q'A. prod uc i rq colorectal lldenoc ",rc :lr'la!lo.
7. WlIBh in BRLl 0.001~ fo r 15 ainutes.
8. ~rcl.bation with 50 u1 o f the secoR! an tibody ( rabb i t .anti-mouse
iJmuloqlobul in8 peroxidase conj~ate) t o r :0 minutes . ;. 1 :50 o r
1 1100 dilution . in 1\ 89. . in PBS waS prepared depending on the
batch. . •
9 . Wash i n BRLJ o .~l\ r ce 15 "m1nut.!J!S • .
10. DAB solution was pc epa red and .Umo U a t e l y applied t o t he s lide s
fo r 5 minutes , ~ ge ntly w~hed with PBS ~ c ae ee the slide.
11. 2 drope of Maye r ' s J:laema.lum wece added for 5 Illin utes t o counte r stain ,
then ci ns ed wit h distilled water .
12. Sl id es went pl 4Ced in the s a t u ra t ed aqueous solution of l1th i Ulll
ca~te f or 5 lII1nutes .
13. The s l id es were thei\ dehydrate:l ~C0U9h alcohois to xylene .
U . A cov e rs lip was ~ted in pennount p rior to assesSll"el'lt of the
slide•
II 4. 4 tbUficat.Jpr8
A. m.mer of lf1X11tica~!Q"lS to t he t ec hnique were used when ti68ue
or Jl~raft sections we re stwie:l .
1. Any paraffin~ed section was i nitiall y dewaxed i n xylene and
rehydrated by pa.ss~e t hro1i;lh alcohols t o water, pdo.r t o s tag e 1
".
)
\
\
,\
\
\
\
\ '
I
\
'.. \
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of tse method .
2 . ' xenog rAft sections we re al~ was hed i n 0'.0 01\ .BRIJ solution for 10
minutes a t this point tp reduce mi1(ine ser~ COllp)flent.~.
) . 'Ihe volume of reagents used at each Btag~ was 100 Ill .
4 . Handl.1ng of sections r equired extra care durln9 each stage ,
, ,
especiAlly d ur ing was hing or rins ing t o p revent tt\e sect ion
l ift ing off the s lide.
. .-J" . ' •
5 . Appropriate con trols f o r xenograft sections i no.l ud ed a ~tion o f
" I " .
live r wi th ~tastatlc colorectal adenoc~rcinana exp~~s61nq CF.A
as a posl~ive co ntrol , <U1d t he use of a mouse eecteee a t co rrespond': ' .
inq pro tein co ncen tration to the firs t a ntibod y as a nega:- 1v~ . , .
control.
II 4.5 A8BesBaEnt
.J' Slides were vieowoo urder a edcrcecope Ixl6 objective) and
assessment of staining de termined swjectively by two easee eo re ,
, .
whQ 1s ellpecienc~ a t the technique . The results we re expre6~ tlB II
percent &ge of ae, J stained i n~rison to the .neqa t i ve controls.
Backg rollnd s tain! was alM assessed.
&
Many of the reagents used i n the t est are t ox j c., or have even b:eeJ'l
.' \ '
daronstrated to be powerful c.Grcin09ens, such as. d j aninobenz id i ne .
The investiqator is at ·...ya[ ticular r1sk ....hen the r eagen t is i n flO"'d~r
f orm aOO, theref or e th e preparation of i ts solutiOn arC ' 8ppHCat1~n to
s lides was pe r fo rmed with 'mask arC g~oves a t a sink: ~_
. N
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II 5.1 Imrodu:tion
'I1'le technique of :irnrunofiuorescence has been used extensively to ,
detect cell surface - antigenic determinants since its introduction over
,40 years ago (Coons; Creec?, JMeS , Berliner, 1942). Its use In the
detection of cell surfaCe expressed a.A prwldes a CCfliIl~ntary methcd
of i~OChemisttYto 1fmunope-~idllSe staining.
II 5.2 HllterWs
i .
L
-' ,
Test antisermn (Il-2aS-H)
PBS pH 7.2
Goat anti-mouse imnunoglobulins flooroscein isothiocy~te
(F:m::) conjugate (Kirkegaa.rd & Perry Labl?ratories) 1: ;30
. dilution in PBS
Fl00r~sc~e Microscope
M.?qnU'ng solution - SO, Glycerol in PBS
II 5.3 Metbod
1. cell smears were inctbated with 50 ui of the first
antibody at various concentrations in a moist charmer for
15 minUtes. JlWroprillte controls Were incll.rled ard no
blocking stage lias required.
2 . Wast! for 15 minutes in PBS pH 7.2
106
3 . 50 , ul of a 1 :50 d ilution i n PBS of a goat anti-tlVU5e
inmW'lOglobulins fluoresc~in conjugate, in appropriate
di1~ion was applied to the slide . for 20 minutes arXI
inctDated in the charrt>er. tit
4. ms wash for 15 minutes .
S . Slides were then mounted arxl assessed iJmediately by two'
investigators under the fluo rescence microsc:ope (x 25
rojective) .
..
...
10 7
II 6.0 AHl'IBCJJ!' R1ID1CL'a:1.LIlC
II 6.1 Intrcduct.1cn
The ,fOllQoi'ing methOd of iodination of the rronoclonal anti,body
11~285-14 is based upon oxidation 0; the imtunoglcbU1in with IO:Un:125
using the oxidising agent Olloramine T (Jlt::Conahey , Dixon, 1966) •
. This method minimised protein denat uration. while maintaining maximum
efficient iooination of the antibody.
II 6.2 JlllterJ.a.1s
Phosphate buffered saline (PBS) pH 7 . 4
1\ Bovine seraTIalbUmin in .m5
Potassiun iodide Ing ml-l .in ms
SCdillfl ~isull*lite 10 rrg ml-! in ms - fresh
So:Hun phosphate buffer (pH 7.5, G.SH)
TdchlorllCetic acid (TO.) (Baker, N.J.' 20' w/v
O11oramine T (Sigma, st.Louis) " ngpl-l in ' aodiun phosphate
buffer, pre~red at the time of use.
Sep~ G2S-rrediun (Pharmac1lll, lJp6a:la, Sweden)
2g-standinq i n 20 ~ PBS overnight
1-125 (Allershmn) 250uC1/2.5ul
11-285-14 (Anti-CE1\ monoclonal antibody) 100ug (Stock :
1.1~9mg ml-l)
GlItUM counter, GlIrrM 7000' (Beckman · SCientific Instruments,
Irvine, CAl '
..
~rdorf ncee 1.5lll1
Glass test ueee marked at O. 5ml (12 x 75m)
II 6.3 Method
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\
1. A d isposable 10m! glpss pipette was plugged loosely with
glass kIOO1 an:l;.:,, ~ephadex, ,af te r standing ovemig~t in 'PBS,
poured into the COlUllfl ens~dng hanogeneous distribution.
20 ml of U BSA. in PBS, was used ta.. equilibrate the
colurm. The remaining/["ocedU["~S ,..e["e performed in -a f~
I cuPxlar'd designated "lor the lise of ["adioisot~s, ensudng
app["opriate precautions.
2. 100ug .of antibody was plpetted into 'en epperrlorf tlbe am
250uCi of· 1251 added. QIlorandne T solution w.as prepared
fresh by adding LO ml of S:Odium phosphate buffer to
4.0 ml of the pwder, and SOul of chloramine T sol ution
added to the eppendorf tube which was shaken gen~ly for _ .
one minute . SOul of sodium bisulphite, 100ul of potassium
icxUde and 200ul of 1\ in PBS were then acXIed in sequence,
ard the resulting sOlutiOf.1 appl ied directly to the collmn.
3.. Elution was performed using 1\ B.S1\ in PBS, and 0.5 ml
fractions were collected to a total of 20 ml. RadiO'-
aCtivity present; in each t\be was deter:mJ.ned using a garrma
counter , ensuring that two peaks were present , the first
,..,representing ic:dinated protem an1 the eeccrd, free iodide.
4. Total counts obtainoo from tubes over the first peak were
". expressed as a percentage of total overall counts ~ r ,e , from \
,
109
'-,the sta'rt of the first, . pe~ to the .start of the seCor'rl). to
obtain the percentage of protein iodinated (Amersham).
5. 7he tractions . that CCJllt)cise the first peak of 'radioactivity
were pooled am 5.0ul added to 1.0 ml of 1% BSA/PBS, mixing
well . 250uJ. of the resulting solution was renoved aM
placed in an ewerdorf tlbe labelled -A- .
250ul of 'ICA was added to the initial solution, an:!
following adequate rnbing using a vortex, was allCM!d to
stand for 15 minutes. The ~l.bewas centrifu:jed at 49009
for 5 ,minutes and 250ul of " supernatant [moved ard placed
lnto,an epperrlorf labl!lled -8- ; Both ·~ : . ,and 'B ' were
Pl~' ill the 9- counter .; C01J1l~. .'.
'1'0 c~cu1ate the percentage bolIhd cpn (counts per
minute), the folloving formula was esrp'iired.
Percent age BotJr):l
(C!"l
"'IOO-2BxIoa
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Iodinated anti- <:FAlI'OnOClonal antibody (11- 285- 141
- see prevtcce -eecctco
- calculated antibody concentration: 0.0 41 Jrg ml-l
TEST cn.L LINES CEA positive LS174T ; BENN
a:A negative QL0320DM
2.5 x 106 viable cells ml-1in 1\ r . c . s ./ PBS
l~ f oet al..cal f se rum (FCS). ~n PBS pH 1:4 - Fre s h
CiI\WA 7000. (Beckman Scientific InSt r llrentS , r rv tne , cal
centrifuge, Beckman TJ6 wi th refrigeration uni~ , ard" 'IH4 roto r
Epperd~~ ~ubes 1 .5 ml
12 'x 75 l!IIl glass t es t hbes _
II 7.2 Method
' f- "
, '
1. ;rhe saturation assay en;>Ioyed"seven test antibody ccrceeerectcne, at
200, 1000. 1400 , 1600 ,~ 1000, 2000 an:1 2400 nq/ tli>e , in duplicate.
10001 of the cell suspension was .d f spensed into epperdo rf neee , to
whi ch the calculated venae of icdinated antibody , together with 1\
FCS/PBS diluent t o <btain a total '!ol we of lOOul , was added . 'Ibis
was ~rfO.rrred for each cell line except BENN, enere Mt~concen- '"
tratlon s us e d were 200, 400 , 1400 , 1000 , 2400 I'4"tube. Controls
CallPdJ~ed blank tlbes t o which ,200u! of 1\ rCS/ms was added .
\ -
2. Tubes were then incubated at ~O C for 30 minutes. 1. 0 Ill1
of 1\ FCS/PBS was then added to each of the t ubes, which
were then vortexeel to ensu re adequat e mixing , and then
centrifuged at 1520q, 40c for 10 minutes .
3 •.., SUpernatants ' were t hen retcved and 1 .0m! 1% FCS/PBS added,
tubes voctex ed and centrifuged for a further 10 minutes.
Follwing cen trifugation , supernatants w~e r~,
:...- ':1. 0 ml of 1\ res/rea added , ~ after mixing, the contenta
,_of the e~rf tubes were transferred individ~ly to
glass tes t t tbes . Further centrifugat ioo was perfonned
for 10 ' minutes-and folla.ling removal of the supernatant,
0.5 ml of 1\ FCS/PBS added prior to count ing with th e
gamna counter.
4. Mean counts were oot ained for each cell line at each
antibo:1y concentration, following the sub traction of
control counts fran test counts . Pesults were then
expressed graphically; antiboclY concen t ration (nq)/t ube
.-£'ong the abscissa and cpn along t he ordinate. ,
cell SUSpensiOn
lI Z
U 8.0 IN Vl'I'K) m"lo.a
n 8..1 .InUodlz:tJ. m .
~nsltiVlty of cell lin.. to:~lndeslne 0' ~ n:>ooclonal~
ant 1body-vl rrles 1.ne conj uga t e was assessed us1r~ 4 mic rocyt os tasis -
assay {Srdth (, Nicklin. 1979) with u:::dification IJom son, Ford . Newm8;\.
Woodtouse , Ib d aild (, SimrDrds, 19811.
Essentially ' the test invo lves application of the test [e~t to
cell 1lQ'10111Yers 9'rowinq wi thin well s of m!cro tit re p~es and following /I.
peri~ of r ecovery , ndiOlabell1ng survlv~. c ella ~eterm1ning inh ib it-
ion. of c~ll protein syn thesis. Ii: has been sbcrom that uptake o f JH
~ . uridine in tc! thf: RNI\, precu rso r pool s of surviving ce lls core elates ~ll
with cell adheierce and survival (&n.1th e t al , 19791 Gadiot, Hoedemaek er
.. (, 'lbe . 1982 ).
The meth::d ...~so has ~ aden.tional advantag e that the cell
Il'OnOl ayer is not ae stroyed on cmpletion of th' assiy, permi t ting
additional histological examination.
105 cells ml-l in awropriate medi tm
follOwing t ryps iniza ti on
Medi lD'll - s t e r ile I
TisSue c ul t ure mult iwell plat es. 96 well s I L~rQ' Flow
Labo"to<i es l ' . )
Trichlo roacetic toli d (JT Baker- Chenicala , NN Yo[~)
SCintilla tion Vials , 20 ml (Fi sher SCien tific )
r
(
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Aquaaol 2 scintil la tion fluid (New Resea rch Products . Boston,
Mass.)
3fjJJridlne ( New Dlgland Nuclear, Maine ) SUw lied 1 ue i • 1 ui
VWes ine SUlphate (Lil ly . In:Uanapolis, ~l supplied 1 ng ml-l
11-285:14 Vi rdes ine conjugate (Lilly ~seaz:ch Centre.
Windlesh_ U.K. ) Specific Vlrdesi ne corcen~;atlon ard
in"mUl"1091obul in concentration varied in different batches
(see Awe rxlix A) •
II 8.3 JIethod
1. lh:ier sterile C?rrlitions~ 100 ui of the ~1l sUspensio.n was
dispensed into well s of the - microtitre plate, 8lXh that
"each well contained 104 cells.
2. '!be pla te was inclbated for 24 hours at 370C in a
.& hunidified atrrosphere of 5\ c~rbon dioxide.
3. LJryjer s terile comlt~ons, a sterile Pasteur pipette was
used to [E!lOVe medium f ran the wells and dolilling dilutions
of drlJ;l or conjugate were~ In .a velure of 100 ul to
each well . The test was perfornEd in quadrupl~cate f or
each dilution, with awmpri ate cont rol wells that rec eived
100 ul of nedil.ttn only . 'Ibe plate was inclbated for 24
hours at 370c as before :
. .
4. '1tle supernatan ts were discarded in 8 . similar ~r to
(
..
previously and each well washed three time s with sterile
PBS at 370c . 100 u1 of mediun was then added to eec n well
am a 24 'hour recovery ~r1od fOUow'ed.
--/
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5. Following temoval of the medium under s terile C
/t100
S
af t et" r~overy, 50 ul of rred~LmI cbnta ining 1 ue!(f 3H
uridine was adeled to each well .
6. A 3 hour i ncl.:bation period in the gassed hurnified incubato r
at 370c foll OWEd .
7. The supernatant was then d iscarded and th e wells washed wit h
PE!S. \ 150 ul of 5\ trichlor acetic aci~ was added to eac h
well and the plat e incubat ed on •• 20 minut es . 'Ih is
sto"ppoothe reaction.
8~ 125 ul of the sol ution within each 1 was added to 7.0 ml
of sc i ntillation fl uid, .and each Vial ! mixed t~r~hlt and
l ebelled . .
9 • The vi al s were placed in a Beckman LSfIOO counter f or
counting .
10. Resul ts f rom the counter were expr essed as follows :
Perc entage Cell SUrv ival • MeanCount at Each Dilut~ x 100
at Each Dilution tean cer t ro1 Count
n. A dos e res ponse curv e of pe rc~ntage c~l1 sU~ival (ord i nat e )
against drug concent ration (absc i s sa) ~as th;l cons t ruct ed .
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II 9.1 Introdtrtion
•
'rre growth of h~ tUllOr xenografts in iImlunodeficient latxlratory
animals provides a model, for eseesseene of in vivo d[Ug efficacy.
Animals used 1n such experiments may be rendered irmuncdeficient
by thyrrectOll¥ an:! i~radiation _prior to xenografting or iJrmun~ef.iCiency
may~be a consequence of :an i~rit~ iIrrnunological defect. .such
animals iii "th ei r. own ri~ht have provld~ the irrrnunologiat with Inform-
. ati.on on ene, role of the thymus and T-IYJ1t'bocYtes in the irrrwne response
in addition to ':heir use in graftmg experirents (Davies , 1900) .
The nude rouse was first mentioned in 1962 'am it was. sLbsequently
.shown t.hllt the - normally recessive "NIl" gene was expressed by the
hanozygote (Melson, 1900) . These mice were also shown to be athymic
(Pantelouris, 1968), to account f or the ir congenital imnunC9eficiency .
The fi rst report of xenograf ting- appeared in 1969 when a colonic
edenccerctncee was maintained in the nude neuse rocdel by "'se ri al Passage
fo r four years (Rygaard & Povlsen, 19(9) .
II 9.2 '1'be tbIe IbJBe Q1100y
The nude Il'OUSC colony at Hemorial University was esteblishe:f in
Hay 198 4 by .Dr~J •.!C?rd, operating urder th~ regulations of the
Memorial University Biosafety carmittee.
Mice were sUWlied by Charles River (U.S .A. ) am were obtained
vi a the university of .Toront o Hospital for Sick OIildren. All were
hanozygous nu/nu upon a BALB/c background .
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'!be mice ....ere kept under sterile conditions in an anilllal encloou-
(canadian cabinets Ccr) fitted with high efficiency particulate lIi e
(HEPA) filte rs . All cages and bedding was eccccrever , and changed or; :a
weekly basis . rood and water wa s also eutocLaved and supplied ad
libitum. Multi vitamins lMVI IOOO} were ~ed ~to water bottles under
sterile conditions following aul:oclaving in a dosage of 1.0 ml/lit re
water . Antibiotics were not added .
Breeding cages cons±st~ of two 'f emales and one male were
encoUraged to main~in stocks of mice. OffSPd~ were weaned at 28
days fo llciwlnoa sexing. . , ' . )
~, ~ks and footwear were worn upon entedng the room, and
sterile surgiCal gloves worn for any procedure requi r i ng- handling of
the mice . ~[k surfaces were ste[iliz~ ~ing a solution of 8%
formaldehyde , and 70% alcohol , in PBS.
II 9. 3 Inoculation
preliminary experiments demonst rated th at....mice inoculated with 106
. I
viable tumor cells failed to exhib i t tUl'l'br growth (Ford, 1984,
peracnef communicatio n) . Subsequently ino c ul ation of 10J vi able,
washed tumor cells were used in all experimen t s in order to es t ablish
tumor growth .
Following trypsinization ee a cell line and cell count , the vcnsne
of -cef.l suspere ton containing 107 viable cells, or multiples thereof,
was centrifuged at 200g and t he cell pellet" was hed In sterile PBS~
"'Ibi s was re-centrifuged and fo llowing re-suspens1cn of t he ceil pellet
i n sterile PBS (2001l1 - 107 ' viable cells) , the cell lnoc:ulun was
"
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transferred' to a ster Ue !:o ml sy r inge with A 26 gau;e 3/B- need le
'" (Becton Dickinson . Oita rio ) .
Mice WrE! to be 1ncc Ulated fo llOoling anaesthesia wi th ether
I (m>H O'M!mic A18) . at _~ s LbcutaneoUS s ite on d ther fl ank Or b ilaterally• .
Cal ipe es were .used to se esure tile tun:lr diJrensi ons of maxi llUll
length arXI maxiJlun width in orde r t o quant~tate ' t~[ growth. In
orde r to determine t Ullllr ' vcnne, the formula fo r 'an dJIate sphe roid
was used in view of the ptedi cted i r regularity of ' t UJllOr growth.
- ,
v .• :rt L (0) 2
--' · 6
"
~Evans, .9nith , Millar ; 19831
Iohere V represen ts tlr.O[ 'vol are 1m) 3
L represen ts maxiJllal tlmlO[ l ength 1m)
D represents maximal tl.mI:lr width (m)
II 9.5 O:laracterlBation
'1lJe f ollowi ng hUMn t tm'Or cell l ines were i~ulated fOr
~,' t,~e[r l, ...tl~ ~e:""r"'ts'ln th e "" "', use lIlCdel :C(LOJ~~DH,
B~7" 1ll"29 ,. LS174T, OWl 6 ~ 00116 , A549,SJ<00l.
Hiee bea ring these eercrs -vere sacrifice;d according to the
~ol1Q1/1ng criteria.
1. " .N.mber of .days pcee 1noculation . f'ollowi~ tarot growth ,
.'I
LoVo;
I li B
.r .
. sac rif ices were perfOrmed at var ious tm in te rval s :'
2. 'l\m)r s iz e . When tuno r gr~ r~hed the point where it was felt
that the aniNl would be disabled . or the.. tlmlOr would ulcerate.
the mice we re sac r if i ced .
3 . OIer all host stat us. If a t umor bearing aniJMl o!lf¥8red
debilitated as a oonsequerce of the neor , ex1Ublted potiv:lqeni c
infection , the~ would be sactificed.
Followinq the sacrifice of any animal , ~ d1JTensions of the tuno,:
were taken am it was then dissected noti ng Mrf obvious morpho logical ....
f eat"ures suc h as necrosi s or inv~ion of deep s t-ruc tures • • We, ttimor
was th en weig~ed .(,9 ) m:J pr eserved i n 10\ · formalin in PBS. f t a .lat e r
\. . .
at~e, tumors were washed in ms prior to formalin prese rvat t on, t o
remove Il'llrine se turl carp::ments. • .
Q\araeterisation of sel~ed xenograft tlllOrs was perfonned by:
1• .Vol mne weight correlation,
2. " His tologi eal exandna~ion by haEnat'odlin ~. eoel; .staini~.
3. cr.A expressim by iMllunoperoxidase,
4. CEA extraqtion Md quantitation (se l ected ce ll 1i~I •
.. .
-,~~ .......-,
II 9.6 (Z.\ Ertrction ~[aft8) .
.Xenog[~t s~imen
..
phosphate b~ff~r (0 .05H phos phate i n O.ISMsod iun chlorfde
pIlS .SI ,
Polytron' (Br inkmann Instcl;Ients, N.Y. ~
11'
Ce nt rifuge, server PC2B wi t h SS34 rotor (se rver, Newtown,
Conn.)
centrifuge tUbes (SO ml) I leak Ridge' (Nalgene Labware , '
lb::hes te(, N.Y.)
ef/A rr fibre Whatman fUte r , 25 mn (Ba1ston~} England)
FU t er holde r, 25 IlID (Hillex , Bedford, Ma. )
ultraflltra~ion" Cell (m:xlet 12) , with 000 nerbrane '
(Amlcon, ~f'\gton, Meiss).
', II ~.' lbl _
1. A knolm wei ght of xenog raft- t umor was minced with phosphate
~ (lt ml buffer .t o 1.09 tUlOOr) .us'i,ng the polytron
(setting 11) for 2 minutes •
.2. 1tIe honcgena.oo was s t i r red on ice for 30 minutes and then
c'ent:rr;:ged ilt 20000g -for 30 minut es at 40c, using the server
cen trifuge.
3. The s upe rnatant ....as then filtered through the gl as s f ibre sheet
~ 'its a::A quantitated by ELISA..
4. The solution may be concent rat ed using the ul t rafiltration cell
prior to D..lSA.. ~th the pellet and supernatant were stored ~t
" -20 0e:,~- - '._- '
,"
/
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119.7 ' (a) Mlltedals
Hematoxilin:
(All stock Pi!agent s )
Haematoxilin 24. 09
95\ alcohol ~ ISO ml a
I I Atnronium Alum SUlphate 3609
Dissolve in 2400 ml distilled water end Jpose-to a i r m
light for one ~th. 'Ihen add,
---
..
Glyce rin 600 ml
95\ alcohol 600 ml
Allow to st and unt il the eplor is suffici ently da rk
Eosin :
Eosin (Wat e r so ltble) 9 ,.Og
Distilled wate r 450 ml
rtur lJtion Solution Picric Acid 45 ml
95\ al COhol . 60 rnl
SCot ts Tap Water StDstitute:
Scdlum Bicarbonate 14. 0g
\ Magnesll11l SUlpha~e BOg.
rap WAter 4000 ml
h:id Alcohol: 70\ alcohol 1000 ml
~rochloric acid (H) ' 10 . 0 ml
;
Gr!ded Alcohols :" Absol ute, eo\. 70\. SO,
xyl ene
Acetone
. /
(
I II
II. 9 .7 (b) MetOOd
<,
.
The standard method used for 'haena toxil i n am eosin 'Staining
1nclu.1ed the following stages .
I. xylene (5 minutes )
2. Absolute alcoMI (5 minutes)
00' alcohol (2 minutes ) •
70\ alcohol (2 minutes)
50\ alcohol (2 minutes)
3. Tap water rinse
4. HaBll4tox111n ' (5 minutes)
5. Tap water rinse
6. kid alcohol (4 d!pe)
7. Tap water rinse
8. Scotts Tap Water St:bstitute (1 minute)
9 . T~ate[ rinse
10.' F.o8in (3 minutes)
II. 50\ al cohOl (3 dIps)
70\ al cohol (3 dips) ,/
80\ alcohol (3 dips)
/IbBolute alcohol (1 minute)
12. Acetone (2 minutes)
13. Xylene (1 minute)
U . Slides were then roounted with a coverslip arD "ad.
"
,
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~o.o PIOlLDlIIW!! EIJ'IlIWOlHl'S
II 10.1 IntnxILrtion
t .
Init ial experiJtents using the trIXlel of th e nude souse bearing
hlmlafl tlm'lOr xenograf ts were perforned with limited mJTbers of anilMl s in
orde r to:
1 .' ,Establish the systEm fo r l ater use in assessment of efficacy of
ant ibcdy-dt lJ';J conjug ates and,
2 . 'Ib assess the effect of free vind es lne upon xenograft grO\rith.
RADlOOSATlOO
Four nude lIIie;:e (4- 8 weeks) received an ino:Wlltion of
10'1 Viabfe Hl' 29 cej.Ia In 'eo!llCh flank , bihterally.
Eleven days post ~ulation . the mice were randanly
- .
allccated in to two groupe, weighed and lriUvidual
tumors measured . cne group was to receive treatment
with free vindesine (Lilly, Irrlianapolis) while the
remaining group acted as control.
'nle two mice randanised to receive free -drlJ} were
injected with :?JItIrg kg-I of v iOOes ine , gi ven as a ~ .O tnl
, . . .
intrape ritoneal injection after dilu~ion i n sterile
sas, 'Dle injections were i nitiated on day eleven post
in ocula tion . and cont b,ucd on a biice wef7klY bas i s . for
5 weeks . 'Ibe · vinde~lne dosage was adjusted on the b~ls . «
of weekly weights obtained foc each ecuee, K1ce
cardanised as the cont rol gcoup were inj~terl with 1..0
,t .
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'"ml .st e rU e PeS illtrape dtoneall y en a s i lll.1:la r schedule.
'I\Illor dinensions were obtAined wtee Io'eekly by us ing
cali~C8 t o lreaSure the inaxiJrun t l.ll'OC len;th am maxim..n
I"'..:J width . 'Ibe tlJ:llO[ volm.e was calculated fran these
D'l!!a&urenents as described. ard vas used tetassess ecece
growth. Upon termination of the exper ilrent , f~ tllrOr
II 10. 3 £Iqleriamt 8
I
/
meas ur8llE'ntB were cbta1ned and the bm:>r was dissectEd ,
weiq~. am C:ha[J:b~ised :u pr~~OUSIY described .J '
In th~nd'prel~ry ~r:iJrent, the above protocol was
follorwed, using a di f fe rent cell l ine and mmber;a of mice.
Ei~ht nude lIliee (4 - 8 weeks) rec e ived .bilateral flank inoeulat-
ions of 101 vi abl e ce lls/ flank of the ce ll line 'LSl74T .
", . .
Five days post inoc ul ation ( Ilic;e were randanised into two gr oups.
conslst1~ of four ';ce/qroup, arxJ weighed. The IIl1ce eere "maintained
as two an.i1nals/cag e in ord er to fClCilitate irdi vidull identification.
Q-le group received free viro esine, 2 !'9 kg-I on a t:vice weekly
basis while the cent rol 91"01.9 rece ived 1.0 ml sterile ~ on a s1Jn1Iat
schedule. '>
. Mensuration of tumors 1rt'~:~rfOrmed t wice a week as described.
II 10•• "l':lIc1City BtWy
. .
Thia prel1minary stOOy was performed t o asse ss the toxicity df
free vindesine at high er doses t o those used in exper1nelts A and S,
I ,
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using a limited nurber of mice.
Wive nude mice (6-12 weeks) '<Ieee included in this experiment ,
weighed and r3l'ldanized into two groups. The group of three mice •
cecei vJ individual 1 .0' m.l intraperitoneal inj ec tion of vinclesine at a
dose of 10 l!'9 kc}-l, diluted in sterile .PBS.
nte group of two mice [,eceived vind esi ne ac -e dose of 6 rrg kg- l.
Each 9ro~ was inspected daily, noting any Jl'Orbidity or oortality.
. J
,
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II 11.0 TIoRZI'IIC 8lmIES
II 11.1 Introd\rtim
'rteee exper:i.Jrenta were des igned to assess the effect of the In?~
clonal anti-Q:A vl rde sine conjug.ate (1l - 285-14-VOSl lID.....9r owth of h~"
tlmr xenografts in nwe mice. cell lines studl¢ ~t[ated a
- range of CEA' expre ssion 49 determined by i.n1nunoperoxidase and imnlD'lO-
fluorescent techniques, and in vi t ro efficacy for each cell l ine had
previously been assessed (see results) .
II 11. 2 Exper DEnt 1
• -r cuet een nw e mice (4-8 weeks) were ' inoculated with
107 vi abl e cells from the cell l ine CILCJ320DM itl t o
"right ard left flanks . Qle ro use received a unilateral
inoculation (right flank l . lMking " ~' : total of fifteen.
mice used in the exper1zlen t .
flAIDCMISATIOO~ Three days post incx::ulllt!on, the mice were .r andomly
Atloca~ into one of three groups, consi~ting of fi ve
mice each. 'Ihe mice were weighed and individual eecee
measured, using the dimensions of maximum length and
maxinun width of the t lmOr.
Ole group was to recei ve t reatment with the .free drug ,
v.indea1ne, one to receive the antibc:dy drU';l coni~ate
(cede .8 - see appen1ix A) while the th ird group acted as
a control .
$.+..1: . "1
'I'RF.A'IMEM': The regimen for t:ceabnent with vtraeetne was a
II 1l . 3 Bl:perbents 2. 3,4 and 5
-!
..
!
, ~
HENSJRATIOO:
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2 trg kg-l intraperitoneal injection of fr ee druq In
PBS, given at two-weekly intervals for th ree doses .
The "regimen for t reatment with conjugate \as an intra-
per roneal injection of 10 trq kg-I, with respect to the
vi ndes ine concentration, of the conjugate, given every
two weeks for three doses. Mice in the cont rol group
received a 1. 0 ml intraperitoneal in jection of s terile
res at similar in tervals . Treabnent waain'iti~ted at
the time of randanisation ard the mice weighed ~t
BWropriate int erval s in orde r to cal cul ate the cor rect
dn" do.."i.
'l'\oIice weekly, t umor d1JlEnsions of maxinun l ength ard "
maximum width were obtained using £ alipers, and the
nercr vcnsree ' calculated . t1pon termination of .the
experbrenc , the ' tlm'lOrs vere characterised as desc ribed
previously . se rum fran se lected mice was also ootained
at sacrifice:
The protocol for the follc:rwing exper.lnents differed in t he
following ways.
a) Mice were inoculated unilaterally (cigll t fl ank ) in all cases .
b) cell lines used were: LS114T', experin'ent 21 SWl1l61 experi:rent 3;
BrnN, E!Jqle r!Jrent 41 sscoi , , eWf!' r iJtent 5.
c) COnjugates used..were : ' 8, expe'riment 41 , 10, expe rJ.ment 31
, B. exper1ne nt 4; , B. expe~1Jnent. ' S .
..
', ".
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ImlUloperoddase esseys were performed routinel y on hl.r.lat\ t llOOr
cell lines, using cell sseere p[e~red at the time of trn:siniz ing t heI .
cell cul t ures . . ' 1.
pi ates 4to 9ill ust rate resul ts obtained wrhthes e assays .
For the ce ll lines LSl74T, pl ate 4 and IENN, plate Ii , t he
intense brown st:.?in!ng , which is predaninant ly ~rane assoc iated wi t h
only minimal cytoP lasmic aWning. represents exp~ssion of CFA by the se
tumor cells , as detected tls i ng t he llIOnoelonal anti;O'A antibody -
11-285- 14 at a concentr ation of 10 uq ml-1 . Qlntrol s lides , ' using an
~valent concentration of c:oot rol asc itic flu id ace shewn for both
cel~ lines Ci.sl 74T, pl ate 5 ; BfJ'.N, pl ate 7) .
At this antibody concentratioa, no staining is seee for <ILCJ3 20~ .
plates 8 and 9 • indicating that this cell line is a nan=-<:rA exprFS!:or ;
. within the sens itivity of t he 1munoperoxijase ass~.
The r ange of CEA expression _of the cell lines used in these
st lXlies is show by the histo:Jram i n figu re 1 • where the eeen perceneeqc
of cells express ing a:A i s represent ed 'al ong t he ord i.nate. Two Mtibody
concent rations were used t o t est each cell line, . 10 ug ml-l and 1.0 U9
nIl-l, and thes e a re repr esented :Uong t he kissa by t~ l ef t and '.
rig ht bars for eecb- cell line respectively . ,I,:1so indicted a re , t he
nmber of se rial ~sages. or tryps i niz ations each ce ll line had tnicr·
gene to calculate . their ave~age CF.A expression. t
/.
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Plates 4 (above ) & 5 lbelow) . lnmunoperoxidase of lS174T ce ll
smears using 11-285-14 at 10 ug ml- I (above) . and contro l ascites
a t corresponding concent r at i on (bel ow).
130
Plates 6 (above ) & 7 ( be l ow). lnmunopero xidase of BENN cell
smears using 11-285-14 at 10 ug ml - 1 (above) . and control
ascites at corresponding concentration (below).
131
Plates a (above ) & 9 (be low) . Irrmunoperoxidase of COl0320DM
cel l smears us ing 11-285 -14 at 10 ug ml 41 (above ). and
control asc ites at corresponding concent ration (be low).
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Co\~istently hi gh <:FA expr~sors :We ce f 1l 6 . S( COl, BENN and
LS174T. whereas CXl.0320DH was f ouoo to be a non- CEA. exp ressing cell
: '
line. Altho~h not incl lXled on this chart , the lung t l/llOr cell line A549
was ~~r fouro t o be a consistent non-Q'A expresser.
III 1.2 x-.nfluOreseence
ImtI.lnOfl~rescence \oBaYS wee al so rout1r)?ly per formed following
trypslniz~tlon oneell . l ine s usthg th e test antibody (11-285 -14) At. ~
"sarre.concent rat i ons (l0,1 l)] ml- 1) .
Figure 2 Ie a hist"9 cc;l11 wit h 'S;mrl SC fo~t' to .t hat descr~ in
the preceeding secetco , demonst ratJ.ng . CEk expression of cell lines
; ,. 'assessed using this·, technique.
'" ;A similar range of antigen ~~ess~on to that des c ribed f or the
:iJlInuhoperoxid ase dSSay-..J.S teen, with ~EW, SKCOl,'~116 am r.si.'74T as
consis t e ntly h.i4h CFA expressiQg ' ;e1'1 lines . ~eas ffl"29, CXLCD20tx1
and AS49 l no\S~1 were ~nsist~~ n~pr~SO[8 using this assay. l'
ImlaJnocy~ochmd~al determination of CEA expression of cell lines
ut ilized ' for the lrxl1vi dual exper Iment.s refFJ:;ed to ~n. s~bsequent
sections i.8 sunmarlz ed in 8Ifl ropr i at e ~ ns O£-this.Chapter .
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III 2. 0 ANrIJ!D1f 1WJ1cu.BEU.IK>
In 2. 1 OOculaUm of Pt!~ Protein IcxUnated
m 2.1 Cal Eluted Protein
Total overall counts of the protein peak Cf:mt)ris1.rlg the s ix t een
t 1.bes cct t eceed up to the ~1nninq of the ~on:J peak - see II 6. 3 -
were 364587215 ~.
I
Four of th ese tlbes carpri sed the major peak of radioactivity
eluted f cOOl ue, col\lrltl and the " total counts of these pooled tub es ,
.,
V~lurne 20l(l uf , was. 324736115 qrn .
, .
Ther ef ore , the perc entage of t otal pro te in recove red fr an the
collml ~ p resent in the four pooled t~ "1M calcul ated as :
Q:lunts in .. pool ed twes •
Q)una in pro t ein peak
324736115 x 100 • 89 .1\
364581215
FCaIl the l OOug pr ote in (ant1bcdy ) used at the start of the expe r-
irrent. a y\ el d of 89.1 ug wAS.obt a ined .
'.
'Ihe per centag e b~Und isotope (c pfll l' was de te rmln~01l0Wi n9
.T.e . A. precipit ation (see II 6.3, stage 5)
\ . •.. .
lJ6
COunts in tiJ::le '1\ ' 1 194183 cpn
Counts in tlbe ' B' : 1370 cpo
" bound cpa " 100 - (2 x 1370 x 100 ) .. 98.S\
194183
rneeercee, 98.5\ of the 89.1 u;I ant ibo::ly eluted fr om the collrll'l
following i cdination was iodi de boW'ld. - ~
In 2.2 Qnfir.ation of ,Ant!- (Z\ Binding
. .
To conf i rm that radiol~l~ed 11-28S-1~ retained anti-O'.A blroing
activi ty , an antibody ELISA was performed as out lined in Section II 3. 3
Figure 3 ccepe ree st andard curves obtained for the iodinated
antibody and 11- 285-14 , conf i rming anti-CFA birdi~ had been retained .
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III 3.0~ RM>ICUBElUDARl'IBCm BIJrl)OO 1ISSAY
III 3.1 Bild.lng to oo..l Lines
The range of antibody birding to cell l in es of varying (FA
expr ession is illustrated in figu re 4 • fo r t wo 'CEA. expresecre LS174T ...'
am BDm, aD:l the nee-expresse r aL0320DH./
)
In 3.2 FBt~ of !bIber of B1Id1rJ:j llntJbodies
.--...-;. .. .
Of the l Oq U3'of antibaly used f or the i odnation, 99.1\ or 89.1 U3
~ was recove red from the cc rem, and of t his. 98.5' was Icdide associat ed
or 87.8 ug.
To calculate the ntmber of antibody m::>lecules this represents ,
Avogadro ' s n1.llltler (6 .0 23 x \023). the amount of antibody i n grmns
(87 .8 x 10-6 9) arrl therrolecul a r weight of nceee iJmaJnaglobulin G1
(1 . 5 x lOS) was used.
NUn't>er of iodinat~ anti~ eo jecuree ,. '( 87 . 8 x 106 ) x (6 .023 x 1023)
1 .5 x 105
~, 3 . 53 x 1O~4
This equated to II. count O~4736~lS cpa, ~tion III 2.1 (al. or
3.25 x 108 cpn correc ted to two decimal pl aces .
•
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800 1600 2400
\ Ant i body I tu be (ng)
Fi9ure 4. Ant ibody bindi ng curves for LS174T
aENN.- - and COL0320OH - • - • -
..... .
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'rtereecee , the nUllber of antibody molecules ASsoctaterl with 1 cpn
'" n~r of antibody molecules
/ . total cpn
"~4
3.2 5 x 108
.. 1. 09 x 1.06 antibodyl1D!ecules
~ t he binding assay, was perfo~ 4 days .~ollowing iodinll.t10~
the decay of .0955 was' account ed for , 80 that on ~ day ofassay
1 cpe =1.14 II: 106
. ,
. The nunber of antibody ",,1ooul ea 15 t.en calCulated by multl;'Y~
the cpm obtained at saturabon (s t art of the plateau portion of the
birding curve) by t his figure (antibody molecules as soc i ated with 1
qml
For exa:J'l'ple , for the cell line BDm. t hi s was 125 ,628 x 1.14 x 106
. . .
II 1 . 432 x 1011 antibcdy 1lO1ecul~
'ftle nurrber of antibody molecules bird ing to each cell (ass t#Tlinq
equal antigen density)
'" nurber of antibOdy ro lecules .. 1. 43~ x l Oll
nurPer of cells 2.5 x' 105
5 . 73 II: 105
141
Using similar calculations the nune er of antibody ecrecutes
bi n:Jing t o the two other cell l ines were :
lS174T: 5. 55 x 105
ClL032oo1l .. l.~l ~ ---l04
"III 4.0 IN VI'l'R) lft'ICN:'l
III 4.1 cell Lines
Of t he ten cell lines ava ilable, eight ....ere tested 1n vitro (CAW
6 and,.LoVo were exc lu::1ed). and ef fi cacy of monoclooal anW.-a:A vrrcestne
con j ugat es is i p ustrated in figu res 5 to 10 , wher e dose-response curves
are presented for six t a rget ce ll lines , fo ur C~[ect~ and two l ung.
Pe rcenhge survival of cells" is shown alon g the ~rdinate and drug and
antibody concent ration of conj ugates, using a lO9rrittuniCscal e, along
the abscissa.
, The ass ays pr esented i n th i s sec tion ar e shown to l llustrate
res ul ts using selected cell lines , and re p r eaen]; app roximately one
f ifth of t he total per formed. The eeen counts for each assay with one
standard deviation are al so inclu::led, t al>les 4 to 9.
Ao ef fec t of conjugate was see n for t he hi gh ~ expressing lines
LS174T, figure 5 ; SKCOl , figu~e 6 ; BENN, f igu re 7 : and t he i nt e rmed-
i ate exp~essor, Kl'29, figure a,' whereas no effect was seen upon the
nee-expres se rs CCL0320DM, figu re 9 , o r A549 , figure 10 •
An effect of f ree chug, vindesine, upon th e,s e ce ll linej is also
~een, and is rep res ent ed by the broken line.
~ochemical evaluat ion of individual cell lines used in
thes e assays is shown in tab l e 10. ce ll smears we~,e ; repar ed at passa~
of cell lines used in m!crocytostasis assays , bo.~ those ' from A549 wcr~/
.' ,
not available. ' {
. .". I n ld:lition, s-n1l6 and S<1837 were al so as;;ayed t hree t imes eecn,
noting no effect of f r ee drug or conjug ate (da ta not shewn) .
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Table 4. cnms c:uTAmm FlO; MIcxx:rra:;M'SIS.~ rtUOmG 2( IDJR OO'CSJRE<F LS11.f.T ous '1'0 VUIlESU£
ND 11-2as"'14":~ESIN& a:NJlJ:iAn: (S"l'NI:\AR) of.vv.xlm. S. D. )
VI tI>£SINE ex:wtx:>.TE
'-
VIIDESINE
~'"
ng ml-I
24,000 .
~. ooo
"'i9J--;
••
-'
-HEm~- . PERam7GE CF • ME'.o'.N CDJNI'S PDKDmGE CF"aNI'KL IS.D.)
(S .D .) cnmu. -(S . D. ) (S.D . I
-
9,234 11.1 . 27,810 33. '
(1 ,1 50 ) (1.4) (3,423 ) (4 . 1 1
11.232 1l~5 ...' 52,042 62.5
(3 , 498) ( 4 . 2 ) 112 . 231) (14.7) '
17,100
.-
ze.s 61,394 73. 8
(4,259) ts.u (1 ,40 5) (8. ~)
~O .7'2 37.0 78, 249 94.0
(3,9 50) (,.1) " . 118 , 9301 122 . 1)
t ;. ~
cx:wna. CIlJIll'S: 83,236 t 23587
~
..
•
• I
...
' .:raI?l e ' S . ~JNrs ~NED FRl:M HI~IS /ISSN/. FCLLCWIN::i 24 HCllR f.XPO&JRE CF 9(001 CELLS 10
VIrI)~INE AID 1l~285-1 4 - VIWESINE a:tUl.XiATE \l~ Of.VIATlQi, S.D.}
~, VUlIESlNE: <nllmAn:
. "'-
vnv= MEANCWNl'S P~ECFC'CN'I'IQ., MEAN CWNl'S PERCE:Nr1GE: CE' cx:Nl'flCl.
m<Dll'RA""" . (S.D.I (S.D. I (S.D.I i IS.D.I
fig ml-l I.\
24,000 9'7~ 7 . 1 .$ 20 ,514 14 . 8
(2,334) 0 . 7 ) (4 .0061 (2 .9)
4,1lJO 9, lp) 6.6 29,352 21.~ · · '
(1 , 967) "' (1.4 1 (11,938) . 18.6 )
41ll 11,631 • 9.9 123,966 89.'
(3 ,992 ) '!2.9 l , ~.- ( 35, 313 1 125 . 5 ) '
, 48
. 22~222 16.1 125,024 91.1
18,i04) ( 5 . 9) ( 23 ,96) -{l7 .ll
cnma.. OOJNl'S: 138,374 t. 37,135
;s
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Table 10. ~IC7\L f.V.~CN CF INJIVIDUAL aLL LINES USED
. I . ....
IN IN VITROASSAYS, USIN; 11-285-14 AT lOug ml- !
CEILLINE ~ASSI\GE , PCSITIVITY
....... IMKJN:I'EDIDASE IMMIllO'LlJORF.SWK>:
,
SKOOl SO !J) 00
LSl7 4T '108 35 25
1fr2' 22
<XLC020DH go
5ENN 63 >70 20 "')
AS49 !J)
'M' denO~S missing ce~l smears "fo r tis assay, altlxn':!h this cell line
had consisten tly been a non-a:A expresser,
"
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IU 1.2 Assay Rl!prcdlK:'JhUity -
Figure 11 illusirates the reproducibility of this assay . Dose
. , " response curves for conj~ate • 7 upon two different target cell lines
sca:u erd ' CCl.Q320DH were ~tairled by two different investigators usirq
tne same ~say technique: at different tiJTes. The intelVal between the
assay s usinq a:uD20DM (pas sag es 86 "90) was'S1 days an::I for sscoi ,
(passages44 '" ~O ), 42 days.
III 4.3 Bffl=cy of OJnjugoteo
• The dose response ' c ury: illust rat ed in figure 12 were . obtained
from assays in which each con jugate, , 7. I 8. t 9 and • 10 ves tested
ind i vidual ly against a stardard CEA expressing c ell line, LS174T, in
order to cceereee effiCacy. I
Retention of anti-cr.A birding activity is illustrated for
conju;Jates • 8, , 9, t 10 in figure 13 t as determdned by EI.iSA.
L '
157
-
~ ~
.
~ ~
s , g, !
~ .~
~ .e
5
. ~
~ ~
.
.J,
.:::~ ~ !
·.e
~
·~ ~s
..~ ~8
§
~
I'
e
~
i s 0
"
y E
/ ;' f
;' .,- ~
;' o •
"
~
/
»r--;
.;
"
' -
"/1
/
./ /
I /
'"
. {/
(
/ i
I
7'
\
\ r
r-;
/
§ 0 s ~ ~~
-:7LVAIA..RS a6ilUifJJ ild
...
", .
\\
"-
" '. .<~ " .
r \~'\\ .
\. . -,
'~
.:!:?
. (SOvv ) C1JU('qJOsqV
~ .
15'
~ ~
3 E
~ iod?i
~
-;;
~
0i '
j; i ·~ . I
~ i
! II ~
t
a
~
a ~
::i
}
I( .
IU5-Z~
In 5.1 n-Dr Growth
usi ng an inoc ulum ,of 107 viabl e cells. i t was POSSible, to grow
human t \ll'lOr cell lines as ' x~rafts in nude mice . either bil llte~lY'
• or unillltet"ally,
Cel~ l ines grown. as xenografts for the pu~' of characterisati'on
, '
• prior to perfonning any in vi vo :exper irnents , .e r e listed i n ~le 11 •
Mice bearing these initlal tlD'llOrs were 's acrificed beeeeen 1'0 ,and , 73
days .followi~ inOculatio? of the various cell lif'les , and' t.JJm:lr'd.uren-o
etcne were available for ,,; of a possible 44',tumors.
~ Figure 14 ,is a sc\tter :graplj, relating turner- volume to 'weiqht for "
these initi.tl ~rs. with 'iinear ;egression '~~iS . ~ corr~lation
. , . . '
coefficient of weight ~o volurre for all funor s was 0,85 , witl)
coefficients for i rrli vidual tumor lines as follOW& : ffi'29, ...0 .85 .
(f ou rt een t~rs); LoVo, 0.65 (Sill, t~rsn LSl74T. 0 .98 ( s~ tUTOrs )
and BI!:NN, 0 .95 (five tLJm:lrs).
The weight-vollb'Ile .ccrreraetcn coeff icient fo t all turrors in th~e
s t ud, i e.s: ~ncl1rl~ tnOse" fo~r Charoct ,edsa,tion pu~es , only ard~r"_
obtained from ta[(jeting experi.ml;nts w~ 0,96 (154 tu;:ors) . , : '
. '1tIr~ turrora did r)ipt exhibit growth at sixty dir)(6~t in eetcn ;~arinq tl)e 'cha,act er&ti on of cnese t"';r" two fr",,~ 11n. ). " I
S0r037< arrl one' from the c;el~ l~e 0l.<D20bM,~ there€~CI~ th e overall
Percentage of.~umor -take- was 93 .6 percent, USing th~~: tumor ceU
inOC~"', . . 'II "', .... "<, -",,---- .
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'11le tlmPrs grew as discrete su:-:irt~eous nod~es that could e~Uy
,be palpated &rd tll!aB~red ,loitf'n :.the inocUllml ~ame eBtabliB~ . Until
this point, IrrtIlch was of a variable' interval 12-10 days), the inocUlum
~ared diffuse ~ plaque-like with ill-defined bo~de[s. ,\G rOW~h
proqreeeed irregularly in three planes, often giving the inp ression ~f
individual -lobes within the tUlfOr bulk. Satellite nodules were not
• seen \or ' MrJ xenograft tlrlOr; although it was' not uncamon to see tllrlOr ...
ex t erd Plg partially along the"'n~e track used for, the inocatEion.
When' this was present, the tUlOOr was noted to be in contin~ty with the
·inain t~[ mass" aro was not existing. as a d iscrete ncdul.e.
~ Upon dissection, · the t\Jll),')rs appeared ....ell b:ef1n~ although the[~
was no evtderce of a discrete tlJm:lr capsule. '1\Jrro[ .s~rface ~ared~iny ArxJ 8IlOOth, although the ' I ~obed '. ~araJX:e gave fiGe' 'to overall
lrreqularity ot.st..ape. I , '""
. 'lbe degree of v.ascularlty of .the tercr was extremely val\abl e and
incOMistent. Ov.prall , the tumors appea r ed grossly avascular, with
occll8i~mal .visible biood vessels noted Jver the tl.ll'lOr eurrece, but
rlIrel y invading the bulk of the t UllOr ltself.Q'leo t\llOt rowever. CXLO
~2ODH excised 42 d"post inoc ulation, tq:rpeared h4em0nhag ic ard gelat-
inous thrOlJ;lho~, with no evidence Of' necroeis or cavitation, making
". .
d isseCtion difficul t .
Tether inq to skin was a finding .that was Also variable and of, -
, ' .
~ared to be unrel ated to t~r type. ;tUs uncocrm::m finding cecurred
,\
' \
,'"
in two or three early tunors II.oVa) and ""as probably related to the
method o"f..i noculat i on.~ J
Frank ulceration of the overlyJ.J:l9 skin occurred with one tUll'J:::)[.
'uNo, after ' 49 days , inoculat.ion . Mice exhibiting ,any suggestion of
impending skin "br eakdOl«Uwa:u1d g~rA11y be sacrificed prio" to its
cccueeeece~.~. This parfl~~a~ ,~umor Also appeared' quite n~ot1c
vitl1!n the centte of the tumor !""Ss. and cavitation ~ 4160 been
est~lished in continuity with ' the "Skin breakdown; · va~ing deg rees of
ce ntral tumor necrosis were not.ed with all IJJVo tUlOOrs, although no
others had cavitated at the time of dissection.
Spread to deeper layers, . in particular of the ' atdominal wall
. ,.
musculature and the proximal muscles of the hind-linbe was not ed _on two
c:ccasi~ onlY', with ~ tlll'lOrs ~o, after 28 days inoculation and
HT29, a!ter:30 days inoculation. In the latter case, spreoXlhad occurred
thro}Jgh the proximal rrw;cle bulk o~ t he right hinl lim down to the 'eight
funur, resulting in an iocQ'lt)lete dissection. as the lower limit of the
t..mor could not be adequately defined.
\ 'Generally, all turro~ bearing mic e aWea~ed to retain good general
health, with no deaths prior to termination of the experiment. One
i " ,. not abl e exception however, rela"ted to mice" i noculated with the cell
line BENN. Of 'the three mice inoculated , two bilaterally . and · one
unilaterally, two mice appeared extremely cachectic at t tk time of
8<C~iCe 53 days post inoc ,ulaUon. Bo~h mice carrh!~ bilateral tlmOrs
. am total ~um:>r burden for et¥:h eccse was 1.359l1"ancl 1.1409, conpared
to the unilaterally in~ul~ted roUB~, . with II tumor ~8 of 1.138 Cane
Limitecf llutopoy perrl:mlled on selec:ttd mice bearing repeeeenteetve
tllllOr& fran each c oll l'tne l~i8tentlY f~ll~ to dEm:ll'\8trate
..... .
, "
.'
-.. ~
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aetaatatic tllOOr deposits, with particular reference to the peritonelml
and lung.
In 5.3 Bistology
. ' .Haenatoxllin and eosin stain~ of xenograft sections dlmmStratea
~t tlmOr .tectur~ ~ beep maintained~ : and this WillS Confirmed. by.
two ' inde~ ,fItaff ~thOloqistS. Histological in~tPretatio~' is
sumnarised in table 12, ard illustrated in plate 10 bY LS174T, a mcx1erat-
ley well differe!1Uated ad~noc~~inor.:.a.
. .
, The his~logy of xenografts frau mice in the 'fa[qet~ experiJrents
t , e , those treated with' vfndeadne or antibody-dr1J3 con jugate was
contrasted to 'their cmtrols and this is referred to in subs~uent
sections.
IIIS••,-~ / ".
, ' .. ' ." .""-.- " --~.---
Irmuloperoxidase staining of a section of 00116 xenog~af.t, wttF-
i ts eeeeeer slide, Is illustrat,d by plates '11 am 12.
The ~istribution of CEA. similarly r~resentedby the brown
staininq WAS found .to be predominantly peri-ll8llinal, a1tho~h.in -eithe r
.. sections 8tud~ed s;ranal 8taining was' aJ.80-praninent. '" '. '
Tabl.e 13 Slml\/:ld:;C5 .1JmIunoperoxidase resUlts obtained with~
x~r4ft8,~th C9rrelauon to the' aA expressio~ of the inoculating
cell line. "-.... . •
... ImmunocytochemiP,try.tf xenografts from tar;eting stuiie8 is '
• , cOO8i~red in Subsequent sectioos .
,
Table 12.
UNo
BENN
"'837
r:
carcmcea, un:Ufferentiated .. widespread necrosis•
.
.: Ad~oc4rcinqna, poOt~ifferen~i4t~' 0011-
infiltrating , ~tchy necrosis.
Meno:arc!nQlllI. /poorly differentiated, non- ' .
infiltrating: m:xIet'llte necrosis.
Adenoca~iJlClll!l. lIOOerate diflei'entiation:
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•
and debris.
1fl'29
LS174T
calu'
AS"
M116
""'----
I
non-infiltrating; little necrosis : cribrifom pattern
fran large llJI'OWlts of fibrosis .
AdenocarcinQlla, Jroderate differentiation: ncderete
... necrosis .
.
Jldenocarcinana, lIIX1erately 'well differ~tiated;
widespreo!ld necrosis: larqe amount of lLmi~ nucin
,--
Adenocarcinc:ln!l, poorly diffe"kentiated, 'lit t l e
fibrosis. •
M~ocarcinanat ncderere differerlr.atton; noderate\
fibrosis .
Adenocarcinal'lll. , ecdereee different1ation~
. 0 .0'-"" - 1
.I if
)
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Plate 10. Haematoxi1in and Eostn stain of LS174T
Xenograf t section ( x25 objective; dO eyepiece )
Plates 11 (above) & 12 (be l ow) . Irrrnunoperoxi dase of SWIllG
Xenograft sections , using 11·285·14 at 10 ugml- l (above) and
Contro l Ascites at cor res pondi ng concent ra tion (bel ow) .
168
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Table 13. (DRRfLtl'I'IOO CF CELL LINE 'Am XENCGRAM' ~IS'1'Ri­
IMI'IJN:PEIO(IDASE ASSM USUl; 11-285-14 at .1 0ug rnl-l
aIL LI Wxm:GRAFT , PCSITIVI'lY
'- ~' ~
/
., m, <10
LaV, 30 <10
LS174T 70 30 ·
\BENN '0 30
CCL0320DH . 0
9<837 20 20
00116 >95 55
' cal Li 6 <5
AS" '~ 10
."
! '
. :
"
" ' ''':'' '
I'
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III 5.5 aA Quantitation
'Ib establish the range of (FA content Qf x_enogcaftS, five tunors
lnderwent Q'A extraction: LSl74T (aA positiv~) . th ree tUllOrs; BEW
(CFA lXlSitiV~) 'r one lumor; &1.549 tCFA ne9ative )~ one · t~r . xenografts
J
of <XLC820OH (CFA ne9ativ~) were not available for processi~.
'1'UIoors were se~,~ted f rom control groups of targeting experin ' Its
or fran initial characterisation stwies, with the exception of one.
LS174T 'lI:enograft (ind icated by ·"I:s~iow J which was" obt ained from a nLrle '\ I
eccee trea~ with 11-285-14 vinde~ine coojugate in- t he second
targeting experiment .-
CEA content, qualJtified by ELISA, . i s Sl.mllariS~ below . A 1 :50
dilution of extract was used and results corrected for ,t hi s dilution.
xmt"","" erA CXM'EN1' Ina 9-1)
LS174r ' 15834.5
LSl74Tt 14107.1
r.si74'l'* 11427.6
")
BENN 9574.5
./1549 4083.3
. , .
• Extr8Ct~,.by S.Butt, ~r stooent, Faculty of Medicine
-. , ',. " ~
, .
1 I '
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Figures 15 am 16 illustrate the growth of indi1tdUaJ. -tUJrJ:lU ~
mean tuoor. vOllJl'lll!s of each treatment grolil"'for the ' prelWnary
experiments A 'and 8 respectively. '1Umor vcnnee and their means af
presented in tables 14 tQ 17 for both expedllents.
\
III6.l ElqJe[~A
From figure 15 it is seen,that, graphically, there is a d it'ference
in grOlolth between control group tUllOr~ th~sJ treated with free
vindesine. In ,view of the limited n\Jlbers of turoors used in this
experiment, no atterrpt was made to interpret this data further, altho1J3h
in terms of the time required to reach a fixed tUlTOr vcjore (500 nm3l,
, .
the group receiving vi rdes in e"'hOO a growth delay of 8 days CQI'{lared to
~ c~trol group .
. .
Ole virdesine treated 1lOOSe, bearing bi1 4teral tllTlOrs, died betwen
3S and 38 days post inoculation fraa unknown reasons, and th e
experiment was tetminated at this point. No toxicity was Been in mice
..
treated with ~lrdesine dur~ the expei1Jrent'.
Loss of this neuse made it difficult to meaningfupy contrast
~IlTIO[ weights of dissected xenogr8;£t8 at the termination 'of the exper-
iment, and in:Uv1dual xenograft weightB are H~ted in table 18 •
. '
. \
\
. ,.\
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• 'QAYS PQST INXIJt,ATICN
,
'l'IlFAn1ENl' GIalP
MEAN~R' VCl.aIES (~ I
"\tImFSINE. cnma.
- \
/
n·
14"
) '8'
· 21"
25·
28'
38
"
15.8 '.0
37 .7 67;2
70 .8 l lSJ••
54 .9 177.2
.1.0 377.6
\04 .2 408 .8
99 .7 1156."
..,
219.5 1323.3
628 .0 1795.0
' t
T5:)1e 17 . MEAN 'IUK>R VCLlIiES, EXPERI~ B (LS174T xmo:.;IW'TS )
,
~..""
178 •
DAYS Pan' IOOaUT!W VIKlESINE a:NrRCL
·5" 67.0 73.1
8" 82.1 190.4
" 12* 99.7 724 .9
1. 118.9 1173.S
'"
'\
·Tabl e 18.
./')1.
I
ecose
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~R WEIGffl'S . (g) AT'l'f.3limTION ·a OO'ERIMENr A
(l!1'29 XEH:X;RPn's)
.'"
VUD ESl NEGFQIP .. \
WEIGHT
!'IlJSEI
FLANK •
.,
. ' ~ ....:.........__'-:-ii
\
WEIGHt 0 .12 0. 084
I
0 .24 ' 1.34
. ~
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,
'!'he; duration of t he " second pr e liai nary experiment ....as lrUCh
. , . .
B~rte~( l u t ing ~y 14 days, ,eflec.~ the t ap id gCOlith of. LSl74T ' .
. xenog r~ts ". Supe r ficial -t umor ' ul ceration ~llS . not~ at this . t ine,
AM therefore the experhent vas. terminated ~ .AltMuJh mice received -oiu y
. . . -'-". --:...
: th[~ injectionS of free dru;, II. (J~ference be~ the . two g,ou:PB -i s
seen in f~gu[e 16 , both for ' the rate ' of , ~[owth ~f tnJividUAl t~r8 .
~ fo r me·an . turror Yol ll!ll!S 0.£ ~h gooup •
.~ v!ndes 1ne 'to xic i ty was seen in thiB , exPe~iment. 'w' the dl7i!!1th .
of one roouse i n the control group at 14 day8 _ ~as anaestheticalIY . telat ,e:l.
In:1ivldUAl am rrean tlnOl vol umes ace recorded in tables 15 and 11 •
_ _ _ .__~~_~ ~~hta at the~!.etlon··Of t~~_[1Jrent. in table 19 •
Mean. t trllO C veig l\t for the cent rol group vas O. ~33C) (S tlmrsL:~ f~~_
. In 6. 3 -.city Study " •
t-
Following: the lntreperitoneal bolus inj ection of free vindes1ne at
15 aq kg-I (2 mee) ~ 10 Ilg kg-I (3 mice) , all me:-appea(~
r
8ltl j ec tivel y cecbecere by day 2 poet-injection. At . day .' ). one dea~
I;llId occur red in each group aM the [Bllll.1ning mice awea red more cachectic
than on the previous day, especial ly t hose rece iving the highe r corcen- .
ttatioa of f r ee drUj . · This prel J.minary exped trent was t e rminated at ~i8
...
.,. .~ ....l' .. 18 1
. t
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~ .
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III 7.0 'l2Ulm'IRJ EXPERIMEkrs iNVIVO
•IIi 7.1 Experiment i - ' aua20IM
Individual tum::lr volunies of ~20DM x~og[afts ~e listed in ~
>'. ~ tables 20 , iJ.. and 22 and figuxe.i7 contrasts grOwth of these xenograf ts
. ..- " , '~ ' , \ .
in eot:ltr'ol, conjugate and vindesine . treated groups. It was found that '.
one t~r f~iled ~ g~ow. at ~1;. ~o~hciut tha exper.inent- ~use n~r' : . ,.
./J, lef~ flank, vindesine treated group. · Although fo~r ' tumors were not
present in'the c~trol group at the 's tart of ·t reatment (right agioleft '
flanks of miqe 5 aIJd 6 of control .group), all ewrcrevere..sub~eq~tly _ .,
present; 10 days post InocuJ,.atlOn. 0'lE! tumor Imcuee i, ri9hit flank,
contro~. groUp) becaine undetectable by day ,,2~ ' p>St - inoculation. "J '
. . I
When mean tumor volune, table 23 , expressed on a :l oga rit hmic
( ;
scale aloo9 the ordinate, of xenograft tumors in each group Js plotted
. , . . "'.... .
against tine ..post-inocula~ion, alcng ~e .ebectesa, it can be seen' that
little difference exists graphically between the control and conj~atll! •
treated group, figure. 18. Despite no conjug~te e~fectupon· l:.hese non
<;FA express.ing xenografts, a margincll"'effect of ~ee drug '."i s
represented on this graph bY the broken line.
The. sinii,l~~:ty of these' hlDllall tuoot xenografts at the termination
of 't he experiment is ,i llust rat ed by plate 13 , which shows
repreeentettve n~e mice fran each 'Of these ~reabrient groups bearing
tunOrs. and ~lllt~. 14 ShowIng· dissected ~Urors frern each group. _The
weights ""'0£ individuai tumors are' recorded In tllble 24 , and 'mean tunor
weights, for each 9r~up " ~re sUTmllris~ in tc;Ible 25 .' . Histologicllr
, tJ eXMlination of xenograft, sections from each ,group · revealed little
.~
•o M I' e- N~ ~ ~ i § ~ ~ ~
'"1
N,... ~ N .n 0
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'nlble·21. IIDIVIIXW. 'IUK>R VCIJJH&S (1IIIl3 1 EXPERIHEm' 1 laI.C82ODt1: cact&.TE TRFATm GIIlJp
JOlSE
; Fl.W<
Days "P06 t
Inoculation
3" 13~.9 58.3 78. 5 74 .2 23. 6 18. 8 131.9 41.9 31 .1 ".8
33 .5 SO.3 78. 5 32 . 1 25 .7 54. 4 • . 110 . 9 18.' 62 .8 18 .5
1. 110.9 74. 2"r 104.7 32.1 95.0 141.3 230.9 91 .6 58.6 62. 8
14 '"><0•• 160 .2 269.3 65. 4 131. 9 351. 8 654.4 111.2 150.8 91.6
,," 448.8 301 .6 385.) '" ' 41 .7 160. 2 6lD. 6 950.. 2 294. 5 230. 9 104 .7
21 508.8 575 .6 779 . 2 78. 5 309. 2 759 .1 1846.9 692.6 466 . 4 ) ) 5 . 0
"
654. 4 402. 8 1055 •• 53 .0 466 . 4 1206.1 2636.1' ' 934. 6 823.5 385. 3
28 600 .6 628. 2 1130.8 28. 9 654. 4 . 1871.1 3762 ~5 1766. 8 823. ' 551.2
n- 785.3 855 .1 2389.6 4l ~9 105S. 4 2600 .3 46~~ ~~~. 1846.J 1766. 8 1145. 2
"35 1107.1 1011.7 4260. 0 65 . 4 1526.5 34TI.l 4535 ·, 6 2345.3 2422.9 1526.5
38 1356 . 9 1431.1 3607 . 2 53 . 0 1898 . 2 4157.6 5830.0 2296 .9 2005. 6 1816 .1
~
'-.
t.. .
"".:.
t ~ • ~,~\
Tabl e 22 . IIDIVIDUAL 'JUK)R VCLVHES lIm3) OO>E:RIMDlI'l ICXU020DH)s VIIDESINE TRFATfDGKlJP
I<IlSE
fLI\I« R L R L . ~
Days Post ~
»: Inocul ation <,
3" 63.6 37. 7 18.8 85. 1 72.0 • 65:4 8.' 72 .0
91. 6 78.5 14. 1 33.5 18. 8 • 6. 3 SO.3 25.7
I. 122.5 58. 6 104.7 . 78.5 18.8 • 72. 0 150. 8 50. 3
"
98.2 41. 9 188.5 179. 6 53. 0 • 98..2 424.0 33.5
,," 118.8 12.0 265 .4 131.9 65 . 4 .. 188.0 779. 2 41. 9
21 192.4 53.0 732.9 368.5 122. 5 o 732. 9 1459. 8 85.1
2' 58.6 33.5 1013.5 628.2 113. 1 • 837.6 2002.4 10 . 8J
2600. 328 37. 7 14.1 1431. 4 602.0 131.9 • 1246.2 179.6
31· - 8. ' • 1769 .4 600.6 122.S • 1545.4 3404 .1 1S4.8
35 • • 2355.8 667.0 · 179.6 • 1453.9 3916. 3 179.6
38 • • 5574. 2 732. 9 279.7 • 2591.3 6049.7 268. 0
' 0/
-'
• I
~.
l!.
l~·.
Figu r~ 17. Graphs of i ndividual COL0320OH xenograft t umor
"' vol umes. cont rast i ng treatment . gro ups in Experiment l.
. . ,
. . ;
.'
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Table 23.
-" .~~. PCST
. Ilo:IlIAT IQl
I ,
VItDESINE
'-" 3' 52.9 68.2
< L '.
. 39. 9 60 .S '
10 82.0 100'.2
14 139.6 232.7
''''' ~'~ 360.5
'V. \ 468. 4 . 635 . 1
24 603 .8 861:8
I
28 790. 4 1189.9
31'
<,
?60 .7 171?:3
.,'
3. 10al.5 2264. 5
38 1937.0 . 2525.3
33.1
46. 5'"
106. 1 ..
200.6
, 393.9
786.4
1231.0
". U7e.•
19~ .S
2~1 .1
3109.1
...•
' .
r-
..
.~ .
",
r.~·
.:
100.00 :.
: '
.,
1000
.
Me 100
• §
~
j 10
0
~
.I InjectiOn .
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Ftgure 18,. Mean .TlIIlO r VOlu~s of CDl03200M Xenograf t s ,
.Eltper..tment 1. t reated with Vtndesi ne - _ _,
. J l.' 2~ S. I( V l ndes i ne c~nJ uga te - . • an"
Cont·rols _
..
' " \.,
.'
.... ~ .
. ..
14 28
Days Post Inoculat i on
42 .
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Pllltes 13 (above) & 14 (below). Nude mice bearing COl0320DM
Xenog rafts , Exper iment 1. from. Control (lef t). Conjuga,te
(m1ddle)•.~nd V1ndest ne trea ted groups (r Ight) : pla t e 13.
Dissected tumors, tn correspondfng ord e~. pt~ te 14.
Table 24.
\
1UK>RWCGHI'S (9 ) AT 'Im'U Ni\TIQi CF OO'EIUMDtl' 1 ICXLC020Dt XDQ;P.AM'S)
\
IOJSE
FlNf(
WElQlT 1.655 0 .305
VUDESINE GRlJp
c.rss
cr.wlG\TE GlUJp
~ -.
1.478 2. 44 0 .16 4
IOJSE 1
FlNf(
WEIQfI' 0 ..74 0.566 2.175 0. 005 3 .07 1.38 0.83 1. 58 1.38 0.86
<Dn'RL GIUJP
IUlSE 1 2 1
"FlNf( . • L •
WElQlT 0 0. 09 0.5 1 0.63 0. 884 1.2 U 0 .15 2.42 5.03 4.68 1.161 2.26 4
:g
)
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Table 25 . MEAN 'IUK)R WEIGHI'S AT TElMINo\TION CF EXPERIHDlI' 1 (a:t.0320Df1)
TRFA'I'HENl' .GR:UP MEAN 'Itll'()R
WEIGIlr romn. WEtGIft'
...--:-.
,Virrl eSine 0 .689 42
cOnju:;late 1.260 10 77 ·
conercr 1.639 11 100,
.. /
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difference between groups, all eere undifferentiated eercrrcees , althoug h
generally greater eecreere
eceere,
in sections of conj\.J3ate treated
No toxicity vas ex111bite:l · by mice in these group> throughout the
course of the exper1:tent.
Table 26 , 8lmMri.ees the 1JmImocyto:hem1cal charaeteriat:1cs of
.....r;;,ts l'B<ld in each targ~ting ";"rlo-en~. and cceereare these t o
the (FA expression of irId~vidual JnocUlating cell l ines" used in each of
. these exper~t8.
Table 26.
19J
Q)RIlELM'ION CF xmxRAf'T SEC'l'ICNS wrnJ mXXlI.ATIfC Q:LL .
LINE BY DHJN:PEFOUDASE ASSAY 111-285-14 at l Oug ml-I )
TAIa:TINj EXPER!MEt'lI'/ , POOITIVI'lY
'l'RFA'DIENl' GRDP ~ ClLL """"'-S
, 1 --!.CWJ320DM
Control 0
CcnjlJ3ate
Vindesine <5
, 2 "" LSl74T 70
Control 30
Conju;JlIte 40
Vi rdes ine 45
t 3 -BENN 90
Control 30
Conjuga.te 65
virdesille 20
' 4 -SKan 90
control O ·
COOjtJ:jate <2
Vi rdee ine <2
, 5 - 00116 1control }COOj\J3ate} otGlIl<:VWesine)
ID 7. 2 E:lper~ 2 - LSl74T ..
194
Individual tUlOOtvol unes of LSl7 4T xenogr.afts ;fre listed in tables -
27 to 29 am cootrcsted graphically in figure 19 .... Mean tUlfOr volumes
~ of xenografts 'in each treatment group are -lis t ed in tat,le30 and eepree-
~ ented~ gniphically in fi9ure 20 • Two mice in the1group .'t ec e i v i ng
viOOesine- died early In., the exp!rJJl2nt lIB a consequence of ~esthesia,
and no d rUq.c r coojlJ1Ate tox icity was: Seen durtDg the experiment~
It ' can, be seen "fran fi9u~e 20 ~at ' a difference exists between the
. . "
vi ndes i ne and the eonjugate treated groupe CQ'IP!lred to contr~ls.' ~ilJnif¥':'
. .
ing an effect of both 'Conj ugat e and vindesine up:m ~eriograft growth. The
' . I
effect of virrlesine appE!dCS to ' beqin "to diminish t,owards the em of the
experiment however.
Plates 15 aild 16 iliustrate the difference in turror growth between
groupe .!lt the t erminat ion of ' the . experi.Jneht, for ~ce ~ar~9 tUlfOl:S.
and dissected eceeee,
Weights of individual turrors a re recorded in table -31 , and ' mean
tmlOr weights a~ oontr'aated in table 32' . :
Histologically, in9reased necroai? ~as seen in secti0'.U' of
. xenografts fran the conjlJ::jate treat,ed group , with otherwise . little
difference between xenograft s'ections 'f rc:n control am vin::1esine 't~eAted
groups: represen ting moderately well differenti~ted adenocarcinanas.

Table 28. OO~ 'IUMJR vCLUMES (rmil) EXP~MENI' 2 (LS174Tll CDUOOATE TP.EATmGFWP
KllSE i 2 3 • 5 s .
Days reee
Inoculation
.'
160. 2 126.7 165. 9 230.9 179 .6 192.4 141.3 141.3
179.6 117.8 265 .0 192.4 243.7 230-.9 340. 4 165. 9
11 131.9 508.8 750 .3 424.0 230.9 141.3 I 445.2 207.3
14 131 .9 732.9 1168.5 523.5 320 .6 199.1 628.2 245.0
i .. 179.6- '1908. 2 2546.3 696.8 1013.5 243.7 "1621. 9 624.1
21 235'.6 2709.1 5540.7 785.3 1725.2 294.5 2238.0 826.8
25. 179. 6 3933.' 84'3 .0 1459. 8 2881.3 466:4 4479 .2 1125.5
28 235 .~ , a584.9 ~1l324 .4 1981.2 4120.4 654. 4 8798.5 1635. 9
32' 268 .0- 14252.3 17903.7 2600.3 4920.9 1235.2 10262.7 2473.5
35 268.0 17903 .7 23373.8 3561.9 6334 .~ • 1168.5 10142 .8 2079 .1
38 301 .5 20123 .3 22076.3 2993.0 7839.9 1431.4 - 14088. 4 3121.4 ,
.
~
:.
..:
. 1 ~
Table 29. ImIVIDUAL 'IUK>R VCLUMES (nml) ' EXPERIHEm'2 (LSl1 4T) VIWESINE 'I'REMU) GR:JJP
' "MaJSE , (
Days Post
Inoculatioo
-_.- ,
"
119.0 :335. 0 4{1~.9 . 179. 0 156 .... l SO.8 131. 9 188.5
201 .3 169.6 230.9 • 201.3 156 .8 98 .2 142.5
.11 421.Q" 269.0 H H 282 . 2 ~~30 . 9 169.6 256. 5,
14 811.4 335.0 ' H H 593.6 368.5 282.2 f 466 . 4
' 8' 1013.5 791.8 H • 2355. 9 614 .2 785.3 91ll. 0
21 890.0 10SS.4 H • 2355.8 969. 3 1076. 8 1130.9
25 1432 .3 1884. 6 H H 3328.4 1327. 1 1691.0 1356. 9
28 1169..4 2345.3 H H · 4TI1 . 5 1590.4 2355.8 1096 .6
32' 2257 .3 3025.8 H • 111)5.8 227 8. 3 • 3816.3 1813. "1
35 7709. 1 Jln .l H • 8433.0 . 2211.3 48.16.2 2003.6 .
3. 2650.2 3206. 4 H • ;11'.5 2002 .4 5025.6 2308.6
:0
j ~i
.~
t~
-~'~ '»
'- . ' - '"
. .
. .. .,
Figure 19. Graphs of lnd1vtdual LS174T )(enog~aft twnor
volumes, 'con t r as ti ng t rea tment groups In Ex.per illent 2.
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Table 30 .
199
I<l'I\N'MIlR~ (!<IV) """'RI!':Em ' l~~'
;...:::::-
TRF.A'IMrnl' GIOJP tnV (rrrnJ)
. VOOESINE e:autX>A'l'E o:::M'RL .
"
215 .7 167.3 124.1
172. 4 217.0 286. 3
~1l 212. 4 355. 0 771.6
14 476.2 4.93.,.1 16eS.l
1" 1090. 1 1~3 3858.9
21 1246. 4 179-4 ,·4 6085.8
25 1835. 1 2871 . 1 8625.2
"
2322 . 5 4667 .0 11692.1
,,.
.~ -("99.5 6749 .6 12017.2
l5 I 3891 . 7 8104 .0 13256.5
J8 "".-1".s.s 8996. 9 170 3S. 7
10000
.~. 100
I
j 10
1
14 28
1Injection
42
100
. Oays Post Inocula tion
Figure 20. : Mea n TUllor Volunes 0: l Sl14T Xenografts .
Ex pe r~ment 2, ~reated with · V1ndes1ner- , - -, n -285- 14
Vlndesfne Conjugate ,and Contro.ls~
."
•
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Plates 15 (above) & 16 (below). Nude mice bear ing lS174T
Xenoqraf ts , Experiment 2. from vtndes tne , Conjugate and
Control groups (left - right ) : plate 15. Dissected tenors
shown in plate 16. below.
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Tabl e 32. MEAN'IUI'OR WEIQI'I'S AT"'I'ERUNo\TlOO CF EXPERIMENI' 2 (LSl 74T )
'OJ
TRF.AM:NrGllWP MEAN 'ruMOR lIJH8Dl: CF p~AGEa
WEIGn' (g ) "'IDIlS cr.tmllL WEIGlfT
.\
Virrl esine · 2 . 50 6 21
I
ConjJgate 5.66 ..
I
Control ' 12. 19 · 100
J'
,
204
III 7.3 Elpert.nt J - BErIf
Wividual tUlOOr vol umes of BElm xenografts are recorded . in tabl~
33 , 34 .am 35 , and contrasted graphiCally in figure 21. Mean tumor
VOl~8 of xen09rafts fran each treatment group are recorded in table
3~ard presented 9[~cally "in figure 22 •
An effect of conj~ate is seen upon xenograft grcwth throughout
the exper1nent, awarently greatest within the initial 2S days but
persisting until the termination of the expe[~t. 'l1le free drlil also
had an effect lJIXXl tUl'lClr grOltth arx1. the gr:owth curve of' these
xenog'rafta is seen to lie between that of the control and ' conjl.gll.te
treated groupe .
At 20 days pcee-mccuree tcn, one 1lCIU8e in the control group
(nU!tler 1) appeared extrenely cachect1c'~ was therefore sacrificed. At
30 days pcee-mccureetcn, a further mouse (nurber 4) also appeared
cachectic am by 44 days, all mice in.the .control group exhibited this
#
state, arx:J a further death had occurred tecuee meeer 71.
Cachexia ~ mortality was also seen in the group ' treated with .
viOOesine, one sccse awearing ill at 6 days post inoculation (nmber
4. virdesine treated group) and by the termin~tion of the experiment at
61 days, only two mice remained alive. Q'le death, h::Jwever, was a
~ cceseqcerce of ana-:sthesia, and this was ecccuneed f~r in the survival
chart of-mice in these qroups, ' figure 2.3, " All mice rec eiving
conjLJ3ate appeared well W'ltil 44 days, at which time, rouse mmber ~
. . . )
aweared to becane ce,che:::tic. although even at S8 days, the de<Jree of
cachexia exhibited by three mice in t:hJ.s groups (ntJl'bers 3. 4, am SI
"t . , ' . ' .
was lI~jectivelY . much lese ~an that seen in the other two qroupe, An
. . .
, ~ ,
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TlIble 35. IJI)IVIIlUAL 'ltlKlR VClJJMES (rrmJ) txPERIMDn') (BmN): VlN)ESINE 'l'RE'M'ED GIOJP
II1ISE 1 2 3 • ' 5
Doys ","t ./
~ati~ ,"-
.
2· 131.9 110.9 57. 7 179.6 154.8 91.~ 41.9
98 .2. 67 .0 48 .1 41. 9 91.6 23.6 61 .0
i llf3 25.9 58.6 ' 33.5 . 65 .4 1) . 1 28.3
-13 .. .1 41. 9 104.7 33.5 ".1 0 91.6
l6" 41. 9 ) 46 . 1 104.7 8.2 38 .5 14.1 95 .0
20 23.' 18. 8 98.2 16 .5 18 . 8 18.8 • 131. 9
23 65. 4 91.6 221.2 21.2 10• •1 41.9 , 11~~6
-; 26 113. 1' 98 .2 323 .9 8.2 117 .8 65 . 4 ' 359 .3
3D· • 114.2 418.8 33.5 169.6 104.1 606.0
3. • 282 .2 466 .4 14.1 l SO. 8 2~1 .2 Sl l .S
31 • ·...- '--593.6 785.3 33. 5 294.5
' f07 . 3 1055."
41 M 1076 .8 918.5 33 . 5 416 .1 323 ~9 934.6
'\ _ ...
-
..
"
755 .9
"
37. 7 466.4 307.8 1)21.1
'.
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Figu re 21. Graphs of individua l BENN xe nograft tu mor
vol umes. cont ras t i ng t rea tmen ~ groups i n Expe riment 3.
Table 36 MEAN'IUl«)R VCLlIm) (!'nV ) EXPERIMENT) (BENN xnn:;RAF"I'S)
212
TREA'IMW1' GIQJPMIV (trrn1)
DAYS POSI' I~ON vnm:SlNE a:w= . COOI'KL
2· 109.8 139.9 94.0
62.5 76 .1 67.5
36.2 34 .8 84 .5
13 52.0 36.8 124 .1
16· 49.8 29.5 144.8
20 46 ~7 42.4 191.3
23 103.7 54 .2 134 .7
2. 155.1 74 .3 . 202 .4
ao- 251.1 140.5 318 .0
"
276.4 199.8 553 .0
37 494. 9 270.6. 629 .0
41 617.2 372.6 945.0
.. 579.0 432. 4 1073.2
•• 952. 1 501.2 1513.0
SI 1119.S 611.8 ) 1550.4
S5 1329.6 601. 1 1719.3
S. 1277. 1 701.3 1913 .6
'1 . 2175.2 786 .6 2161. 6
:ll ~ .
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..~ attempt to quantitate cachexia was made, usinr:J ' body ~ght as an index,
arrl this 1s sunmarised below , cont rasting neen body weights of mice. in
each treatment group at the start an::l termination of the expe riment.
TreatnEnt ~y 2 POSt -inoculation
Group Meon Body ..-,
Weight (9) of mice
COntrol 25
conjugate 25
vtrdeetne 25
Cay 61 Peat-inoculation
, \
MeM BcdY NlJrrbe[
of mice ' .
. 18
23
21
Plate 17 illustrates .eep reeenee t ive a ice" {[om' eac h gr oup bea ring
ecsore and pla~e 18 i llust rates the dissected usrcee, -
Individual tUl"llCfr weig hts- are reco rded in taJ;lle ~7 , an::! mean uecr
~ ,
weights contrasted be t ween groups in tM>li 3~ "
Histological examination of
o
xenograft secttone. i ,ran eac h g retlp
revealed qreeter turro r nec rosis in sections fICIn the conjlJ3a t ed trea~
group, canpared to control or ~indes ii.e t rea ted . grqups . . Plate$ J.9 : /
20 and 21 j.11uBt~ate histological sections troo "th 9 " three ,groupe ,
the t umor being -a poor!y ' differen~lated adenocll.~Cinara •
..
216
Pl ates 17 (above) & 18 (below) . Nude mice bearing BENN
Xenoqr af ts , Exper iment 3. from vt nces t ne , Conjugate and
Contro l groups (l ef t - right ) : pl ate 17. Dissected tumors
shown in plate 18 . below.
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IlEAIj 1t1HOR
WElGm' (9)
tueER CF PE:R<1NOOE (J'
Vindes ine
OJnjugate
OJntrol
-:
"
1. 01
0 .4
, 1.08
7 _
94
37
100
219
Plates 19 (above) & 20 (be low) . Haematox i lin and Eos i n stain of
BENN Xenograft sect io ns from Contro l (above) and Conjuga te (be low)
treated mice in Experiment 3. ( x16 objective ; xlO eyepiece).
Plate 21. Haematoxil ln and Eosin stai n of BENN Xenograft
section from vindes tne trea ted mouse in Experiment 3.
( x16 objective; xlO eyep iece )
"211
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Tables 39 ,40 and 41 list tuoor vcnees f((Ill the three treatment
groups. in this experteene , ~ these are contrasted graphically in
figure 24 .. Mean tuoor vcnsree are listed in table 42. • m:d
represented grilphic&ly in figure 25 •
It can be seen that although a steady nO--qrowthstate was reeched
by all tumors in each of the treaboont groups, . a conjugate effect waa
also seen throughout'the course of the experi:rent .
cnly one IOOUse died during this experiment, number 6 of the
C2njugate group, between 20 am 24 days, with no apparent explanation.
Pl~tes 22 aDd 23 illustrate the size of the xenografts at the
termination of the exper1Inent, and the tumor weights are' recorded in
t abl e 43 . Mean tumor weights at ~ tenninatio{l of the experiment may
be cont ras t ed beween groups, table 44 . .
H!etology falled~ to deronst[~te arrt turror ~el.ls In ,( any,.elide
studied , the only tissue present being of a calcified, necrotic, I!m)rphus
. nature. As this ....as the only cell ~ne previously not grown as a
xenograft in the preliJn1nary characterization expedrrents , no further
hi stological details were available.
. . '
In a slbsequent experiJrent aJ.tred at establishing growth "of this
cell line as xenografts , nooe mice were inoculated in 'th e usual manner
with 2.5 x 101, 5 x 101 ard 1.4 x 101 villble SKCDl tlmlOr cells. t:b
xenograft growth was seen at' 21 days poet inOCulation aM indeed there
w¥' no detectable nroule at all on the flank of the IIOU8e that Qacl
received the largest inoculation. 'these results were also confirned at
31 days poet i~ocu1~tion. I rtese mice ha:J 4160 _previously been
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Table 41 .
i"~t
Ina:ulation
t 2* to .8
.-J-< 67 .0
10 57 .7
13 84 .'
17" 41. 7
zo 62 .6
24 58. 6
V 01.0
31" 46 . 1 .
34 ! 58 .6
]8 ~3 6 .5
41 58 .6
~ I
, ....
IK>IVIDUAL'I\lK>RVWHS (1lIlI!1~ERIMmr 4 (SRCOl) : VDl>ESINE 'I'RFATmGIOJP
78.5 03.8 • 132.0 · 58.6 .... 58 .6 76 .5
25 .7 03.8 SO.3 84.' 65 .4 72 .0
16 .5 54 .4 41 .9 74. 2 141• 9 25 . 7
•
14 . 1 62 .' 63 .6 58 .6 74 . 2 21 . 2
4.2 23.6 28. 9 41.9 41.9 \ 4.2
1.8 67 .0 41.9 54. 4 SO.] I ' .B
1.8 38.5 38.5 32.1 35.3 14 . 1
58 .6 SO. 3 58 .6 56 .6 23.6
23 .6 37.1 50.3 41 .9 4. 2
44.9 23.' 41.7 16 .6 2 .4.
35.3 33 .5 35 .3 23.6 7.3
•
54.4 41.9 . 50.3 2~] 6.]
~
Z17
,
- '
Oays Po!:t Inoculati on
Fi gure 24. Grap'1 of in dividua l SKCO l'xenograft t umor
vol umes . contruti ng tr ea tment group s tn Experimen t 4.
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Plates 22 (a bove) .& 23 (be l ow). Nude mice bearing SKeOt
Xenograf t s , Experiment 4. from vtnceatne , Conjugate and
Cont rol groups ( l ef t - right ) : plate 22. Dissected tumors
shown in plate 23. below.
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Table 44 .
133
MEAN tu~R WEIGIfT AT '1'ER'IINo\TIONCF OO£RIHEm' 4 (SCOll)
t
Vindes ine
Conjugate
Cbntrol
MEAN'lUK)R
WE IGHT (g)
0.014
0.009
0. 020
"""ER CF
nJI<lRS
I
I
70
4S
100
r
•
\•
13'
inoculated with 107 viable SK<D! tlmt)C cella (oppos i t e flank ) :),.DO days
previously, which had failed to grow•
-135
ill 7.S Slpertment S - 00116
This final targeting exper1lllent is ongoil19, and therefore data has
. ~
been asserrbled up to 71 days post inoculation of 00116 tl.lOOt cells .
, .
Wividual tlJll'Or volunes a re recorded in table6 45 , 46 and 47 • as:ld
mean tImOr voneee of each treatnent group in table 48 ' . This is
rep[~n~ graphically in fiq\ue 26 , where ~t is seen that there is
little t<»o, g,"'f'h '0' """"01 "'" conj;".t. treated g,o",," . whe,.as I"
growth of x~nografts in the vindesine treated group appears t o be
. proceeding at a greater rate, shown by the broken line .
oie eccse died as a consequence of anaesthesia (eccee nUllt>er 5,
control group. 50 days p>st inoculation),~ two ~i ticn'l
deaths, one in the control group ard one In the conjUCJate treated
group, occurred without explanation.
No toxicity has been seen in any treatment group to date•
•
"Table tS. .-~ 'IUM:>R VCLlH:S (D'Ili3) EXPERIMEm' 5 ( 00.116) : a:wRCL GKUP
2 3 , , 5
' Days I'o6t
InocUlat.ion
1
5" 122.5 ~209 . 4 192 •.4 150·,8 117.8 144 .0 141. 3
84 .8 183 .2 188.0 lSO. 8 169 . 6 216 .7 205.2
12 10 .5 263 .8 74 .2 54 .8 98.2 111.2 72. 0
l5 50 . 3 190 .0 131 .9 78 . 5 53 .0
"
78 .5
19" 63.6 163.6 130.9 98 .2 78.5 .
"
50. 3
22 78. 5 100. 5 169.6 102.9 113.1
"
78 .5
2. 13 4 .6 176.7 158 . 4 142 .5 150 .8
"
78 .5
29 62.8 132.5 243.7 98.2 122.5
"
78.5
33· . 91.6 226 .2 256 . 5 117.8 205 .2
"
91 .6
3. 63 .6 254.' 256.5 111.2 188.0
"
131. 9
40 104.7 170 .1 307 . 8 158.4 176 . 9
"
134 . 6
43 104.7 117.3 368. 5 160. 2 301.5
"
113.1
~
--......
".
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Table 48. MEAN 'IUMJR VCLUMES (MIV) EXPERIHENl' 5 (SflU 6)
DAYS POSl' TRF.MMEm GMJP mv (11m3 )
IlrolLATlOO °VIm ESl NE a:lUUGATE a:>m<L
5" 135.0 106.8 154.0
177. 1 129.3 171. 2
12 113.1 116.6 91 .8
IS 71.0 86.9 97.0
19" 93.0 86.8 97 .5
22 113. 1 92. 1 107 .2
zs 138.9 -110. 1 - 1,,\.3
29 1e.1 104.7 123 .0
33" 242.6 139.8 164.8
36 244.7 ' 114. 2 1~.6
10 319.7 177 . 2 175.4
4J 429.2 199.3 194.2
0-
47, 523.5 199.9 179 .2
50 708.6 IlJ1.4 197.2
,.
54 ,828.9 213.2 " 173 .4
57 1006.5 197.6 216 .2
61 1177. 5 284 .) . 266.6
64 1436.5 301.9 229.9
68 1464. 8 32.1 .3 284.7
---.,
11 1921. 4 341.5 243. 4
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.. Grovth of ~cnies was no~ in ,ral wells follov i nq both
fU81c:ns , ~ ,--:en supema~t;s ~~ thtse wells were tested by ELlS' .
anti-a:A activity '~as dEmlXlStcated. -nds 1~ illustrated in fl9ure 21 ,
• hlstoq, ...towing "SUltS)""_ In";;'"",,,,,,l1., ELISA_ of ee1set"
vell~ fm ~th f~~. A. ' ..
I . In this ex~le, screeninl of fusl~ 1 supernatants was Performed
;t 27 days poet fusion : 'am was the last sc:r.eeriing of - wells f~an the
~ . :d~~~ Plat~. tb 'int;-Q'A d l Vity .;.,u.oJe~e::tEd i n thes e rema~ .
- ~ ~1l8 . · as ' Ul~~ca.ted .~ . the histogra:n~ ' ~reas 8eleC~ed ~e.ll B ~om
fusi on ' 2, ~re 8upe~tantB ~re tes~~fO~ flret tbe at. 10 days
post f us i Cl"t ,' were" gene,rally peeretve, .rn pa rticular , strongl y poai ,t1ve
resul ts were ~tai.ned !ran vella d.~i9nated AlO , ,Gll , .Al;o·, B6, D12, 86,
. • Hll ard Al. "CM.t rols lrcl~' ihe"llOIOClonal aptl-crA antibcdyll-tSS-U
(positive),~. (negative) Nil ilr-Kl-.fl'i.,ilE'dilD lneg~tivel .
', . .~ the - supein4~tB ¥ece '~e-testecl in .fI.} SA aft.er \1psequent
elonlnq of the8't~po8it1ve wells by 11rdtIng ~ution, All anU-cv.
' er;: t 1vl ty hlJLdihppea~r ~esplte ·9rowth of ~ral 'colorUes.
In B(IlIMry: ~th fU8i~ ~id ~t yiel4 ~lond !"'~-<V.
ant ibod i es .
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In 9.1 lntrod1£t.icn
Statistical advice reqarding the presentation of data obtained
EtOO the in vivo targeting experiments was obtained fran a name, of
sources (see acknowledgenentsl,. and the wirlely .di f f e r ing opiniona offere?
reflected the.,eatplexity of the problml. which also 1o'aB apparent in . the
literature.
An IltterrqJt was therefore fMde to interpret the data using . statist-
ical methods of increasing 'cmplex i ty , ard slK:h results will be consider-
. \ . , .
Ed in this section. A full discussion of the problens of statistical
'interpret at i on will be: considered' in Olllpter IV.
In 9.2 Growth Delay
For" a 9r~up of mice bearing xenograft tcecee and receiving Il
part'lculll[ treatnen~, 9rO\ith delay ccreespcrds t o the time taken for that
pd[ticulJ. groups nean t urror vollm'e to re~h a pre-deeermdned fix~ tlJl'Or
volume in carparison .to controls.
.
'Ibis growth delay .may be represented as .f o llQro'S for cell lines
. .. · t . .
CXL03201»'l, LSl74T am B£NN, where-the fixed tllllOr \(olume was taken as SOD .
, ",,3 ,
XfNXlJW'lS DAY 500 nmJ REAQlfD Gmmt DEW
a>Il'RCL =OOATE (DAYS)
'--. 0::u:020DM lit 19
LSl74T
. ' 9 14
BmN 33 . 8 . IS
/'
0' '.
...
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It can be seen fum figure ~ that i n experiJrEnt .. (steal) , the
IlO""9to\rith s tate reached did not all~ meaningful C<Xl{)llrisoo to be 1M&:!
between groups .
III 9.3 OXlparisoo of Qlrves
Di rect. vis ual assessmen t of the f orm of t he growth curves for eac~
t[e~tment group ~-, mice be ari. 'lg xenOqraft a, compared t o c_ont~o181
cOtdned in each expe t'iment was a [!:liabl e inlti~ lT1Cthod .of anseaa inq -
the "efficacy of tre~tlre~,t . . I
Growth curves are i llustra t ed i n sec tion ~!II 7. 0 by figures 18,
20, 24 ~ 26, where mean t uoor vol lJlle Is expre ssed in ~J lcn a 1oga·
ri t:hmic scar e alcng t he ordinate , with days-.post turo'i- i~ulat lon along
. the abscisS a .
M al temative oethod of presenting these results would have been
, . ,
to plot the mean tlm)[ vol~ di [ect~y along the abscissa without
logadtb:dc t ransformatioo. 'rte fo['Jll of the curv es is'visually qu ite
di fferent , although~ of ..each treabnerl": roodality , t oo, Is ~
' ..s t rikingly~[ent . Growth curves plotted in this manner are contrasted
in fiqu res 28, 29 and 30 f or aLa32ODH, LS1'4T Mel BbN. ~es~tivelY.
,,$tarde.cd er ror has been Incl w ed "i n these ccrvee, although. i t wOuld not
be meaningful to tnc l w e s uch val~s en t he loqa ritbn1c .Plots .
,
nI 964 Hearl 'l\m::lt Voluae lUI eo Perc~tage ot Q:lntrol
"" me", "."" ~...;: of mice treated ~I th tt~ ";t\bodytr~
cal j ugate (e onj ugat! MlV) was expressed as a perc:entoge of t he ir cere-
t ' . :'1-
(
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Figure 28. Comparison of fonnat of growth curves for tOl0320OH.
Mean tumor volume expressed along crdtnate i n emJ below; on a.
logarittvnlc sca le, in 1lI1\3 ebcve. Groups receiv ing. V1ndesi ne- - -
Conjugate - - Control~
249
1
i "
-I
J -
t .- "''''''''''
J •
F1gu r~ 29. Comparison of fa nnat 'of gr owth curves for l S174T.
MeaD'tumor volume expressed along ordinate in cm3. bel;wt on a •
10garft lvn1: scale in rrm3 above. Groups rece~<ov.f n9 Vfndes1u - - --
\ Conj ugate --- Cont rol
; ..
,,'
) 250
i"I
(
'·'1
!5 ae
"
F1911rr"JO. Comparison of fannat of growthcurves for BENN .
Mean tumor volume expressed along ordtnate in em3 below; on a
logarithmic scale in nm3 above. Groups recei vi ng V1ndes1ne _
Conj ugate _
"- -,
Control _
/
, .
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spondi ng con trol rrean t1.m1Or vcnnes (control MlVI...at vertcue t.Irres
throughout eech experteene , viz . at the start of ereetaene , weekly for
fque weeks arrl at ' !:he termination 'of the experirren t t experillEnts 1 am 2
terminated at 5 weeks, exper1nent ) at 9 weeks, experiment 4 <!lit 10 weeks.
experiment 5 is ongoing .
This is shown as follows for each ·c e ll line.
~s PCSI' . ClLC!l20DM LS174T BENN SKlXll ,00116
\ TREA"JENr 203 135 149
"
69
116 29 30 51 90
81 30 22 ;. 86
81 40 37 37 85
8. sr 36 27 68
TEOOfMlOO 36 59 140
(see t~t)
III 9. 5 St ldent 1B t 'test ..
Thestwent I S t test was used to cpcrpare the t1JlT()[ vcnee means of
~trol and conjUJate treated groups of mice in each targeting experr-
ment, as t hese were ,normai populat~ons. calculations were pe rformed
using a Tl programnableS9 ' calcUlator (Texas lni:ltrUJrents) . -
/'
'I'l¥! f?llOW'ing lists the d~s p:lSt inocUlation of ear::~ cell l1n~
used in experirr£nts 1-5 arrl the significance level as determined fromI . .
. t~les of significaix:e levels of the St udent Distribution (2 tailed tes tl
(Documenta Geigy, Scientific Tables) .
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DAYS J
"
21 28 35
a:L0320DM <,
rc
,
0.01 0.7 0.7 0.7 0.7,
DAYS •
,, ) 21 28 35
LS174T
, p< 0.8 0. 1 0.005 0 .01 0.2
DAYS 2 13 20 26 3. ~1
8!>O1
sc 0.05 0.3 0 .2 0.1 0.02 . 0. 02 ;,
DAYS 2 13 20 27 3. 6'
, ~ SKOJ1
P< ' . 0.3 0. 1 0 . 1 0 .2 0. 1 0.8
0 .5
00116
DAYS 5('
P< 0.05
, 15
0 .8
22
0 .7
29
0.6
~
of
0.2
In ,Order to IlSSesS the co~tribut10n of a variety of different
fActors upon the vari at i on of data te, inte r.: and meee sl.bject variation,
. time etc. an att8l{lt WAS IMIde to opply the statistical t~hnique of
analysis of vlu::,tarce, uslng the 'HANCNA. command (r epeat ed measures
ZSl
multivaria te analys is of variance) . as out lined in O'Iapter 28 of the
SPSSX (St a t ist i c al Package f or the Soc ial SCierces - ext ended ) data
analysis system manual (SPSS Inc , Olicagol .
Accord i ngly , data files were cons t ructed for each experiment
lis ting irdividual WJrrO[ vcueea, i n the fennat of tables 20-22 (CCL0320-
OM; exped1l"e nt 1 ) ; tables 27-29 (LS114T, experinent 2) , t abl es 33-35
(SEMI, expednalt 3) ancI tabl~ 39-4 1 (SKeIn , experiJTent 4) . using A
vnoo tertnfnal (Digital EtJUiPrent -Qlrp. , Mas) . connect ed to t he central
uni vers ity CCct{luter, w\x-lV700 VMS V3.7.
An exarrple of the format of t he cc:npute~ procltame des igned for
. ,.
the data of experiJrent (cxx.c61184.•DArI. as designed -by R. Cornish (see
• ack nowledgements) is- listed in awerr:Ux B , and was . ref er red to ~
PRX>.DAT.
This prDg[(was mxUfied accordingl y ehencther data .files ,,; re
used . ' ............. .
To run the SPSSX MANOJi\ progra:me, the followi09 coorrand was typed
in t o th e VT100 terminal when the dollar sign was showing :
SpSSX/etrr .. PRIm' Pii:c.DAT.
PRINI'.OAT. 'IY
A printed co~,of the results Coul~ be cctained witht~l
' "
r
. }
Interpretation of these resUlts (refe rred to as PRINr .OAT) was
performed at the stAtiStiCal Consulting Laboratory (see 4cknowledge-
ITIlilnts), Md fo1101011nq a f urther Manova 3 Wi!lY onalys1s,' the fOll~ir'19
•
,
results were obtained for experirrent 1.
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1. '!bere was no difference .!llOOll9 the means of the three 'g roups
(Tr e a tllEnt groi4J6: V~Mesine, ConjlJ'}ate. Contro l) . " .
2. There was a si qni f i c5It difference alTOng the means of the tine
per acde ie . this ....as a tirne-dependent process.
~
Attmpts were m<l3e to apply th is programre to othe r dat a files of
the renaining expermerue, but the progranme was unable to take account
of missing data i n the analysis, followinq the death of a eouse ,
'Dle Statisticians proposed that in order to overcome this, ....mice
dyi.n9 during.._t he COurse of ' an .expa rImerrt; Shoul d. either be tota1 ;Y
excIlXlecLlas the progral'lfl"e did ) or tha t an extra~late<l mean tumoJ:
volume, based on t he last value obtainei, should be slbs t i t ut ed.
As neither opt ion was biologically , valid. and in the eceerce of
alternative prcsreeree , this awroach was aborted.
A full d i scussion o~ the problens encountered with the statistical
interpretation of results is fcurd ~ Olapter IV.
----y-, .
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IV 1.0 INlKDJCrICif
. Prior to a t t et{lting t o ass ess the e£f iQacy o f t arg e ted c~. . f'l
ther~. it WAS necessary to evaluate ce rtain aspects of the various
components of t he ~~~tin9 system ~lOjed ~ these stlDl~• •Thi~
wderf Iee the rationAle f or ~ inclusion Of...~ initial experimen ts
aimed at characterisation of the targ et , hllnan ttJm:lr cell lines express-
ing the antigen (EA" ~ the carrier ; the. m:::ncx:lonal ~ti-cr.A antibody
11-285-14. AlthoUgh pot a pr~iple ~_im .of ~e stldiea, ~"atteupt w~
also ~e t~ generate further anti-<EA tnonoc1onal- antiJ:xxties for a:Jdit..
.
tonal characterisation. . ~ ~
Evaluation of the warhead alone, it must be stated at the 'outset ,
was not at t ertpt:ed ~ the se 8tu:1ie.:' f~t 6~e ra1 r~aSons . ' The vi nc a
alkaloids , as dfecuaeed in sect ion I 6.5 , have .iur e<dy received extensive
' charact eri sa tion and cl in ic al (rial and: in " :kU t iool the re i s no exact
.anal ogue of the vtece alkaloid (<< precursor ~f .v iro es in e) con jugated t o
• \ 1 .
. this antibody that exists in ftee s t at e , al though vi ndesine represents
the neares t chemical relative of any pr actical value. rteeer c re virrles -
me has ~ ircluded ~ .many of · these s t w ies as .an ' '1nt~resting a.nd
relevant par41lel rather thAn as 1I stric t fOnt ro l in view of the diff -
icul ty-correlat ing efficacy of ' free d,:U9 to that. of 'CQnj ugat oo drug~
I,;;
The s t ooies outlined above enabled logical prcqrees t cn t o evalu--
, .
ation of conjl,JJate efficacy proper, which was perf orned initially· i n
. ' . . . . ' .... "
vitro using selected cell l ines in an established rnicr~osta!!l.is assay .
However , prior to assessment of in vivO efficacy it was necessa ry
to establish a Bultllble lllld rel evant pre-clinical roodel.· Accordi~lY,
.,
",
\ ."
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cell lines sejeceed on the baSis of <:FA express ion fran illitial stG:Hes
we're: grown :: xenografts in mile mke·. an; .ch8t'actedsation ·~Qf, these
xenograft tUlIOrs performed confirming the .sui t ab i.U ty of ' the m::::del fot'
later st udies. Ie, t hat turror his tology arx:l imnunocy:tochern1c~ cnereceer-
i s tics . had been maintain~ Preliminary experiJrents usin4 this n.me1 ·
were, desigf\ed to ensure t tia t the system would work for later ta rge t ing
experiJlery.ts.
Although it is somewhat artific ial to div.ide the 'preceed ing
' . st~ies int~ st:es as above. this has been aon~ for c~enie~~ an: . ~- ::..:. . ~
cl a r ity Of discussion. .In facti eneee st~ies formed a cohes ive w,!'tole
whi~ event ual ly l~~ to 'an .eValiJ~tion of ' cooj ug~te effiC~. ill 'Vivo~
where the~ of; h~ tUll'Orxe~rafts wi t h.a r~e of CEA expression
was~ assessed fOllDW~ tcea.~t ri the llost - witt! ecooctoner anti-<:F.A
antibo::ly vfrdeai ne conjugates.~
The results obtained at "'eac~ of th~e s t ar;eIl wHl .be the ~lbj f,lCt-
of di .5Cussicin ill this chapter .
/
There i s little dolbt that t his approach to cancer cheoo the rapy is
llppealinq i n vi~ o~ the iWtat1 q,ns ~ed by IT03tlY present day ey,ta-
toxil; agents , arxJ,that it offe rs poten t i al - iltProv,ement OY~r t radU.ional
\ ' ~ '
intnunotherapy. :w cur ren t ~tll1;USOf . ~henotherapt was outlined i~
/s ec tion I 7 .0, where encouraging resultS: were presented f r.OlII a n\l!tle r of
• I . .' . ,- "
s t udies enp loying a range of targeting systems, alt-h0u9h it is still
_. . ,
sThat su rpris~ tha t s~l1.~tle inf Ot1llll.tion. exiS\& on th~s' awr~h. of
, twentY-~eVen ye,rs fOllowi~ Mathe'~O~i~inal ~i:ation ~~g~~) . • •vi
r :
- . /
'2 58
,...... ' :' . .( .....
1heSe ·sti.zUes ,ar~ end,uragJ.nq ·~ ~lr SURX>rt of ·tid.s ~rapeut1c
'awroach,' where effic.~ and selectivity ~f IOOOClonal Mtl-(E', M~itooy
".drug . conj'~ate8 has ~' dEm:iis~rated i n vitro ~ in a relevMt pre-
~U.nlC~ in vi vo incdel. 8OoIever,-6eVeral questions have '-a!Sot!een r~'
.t~ ~ stll:Ues tll"ld these will be iKHresUd Inthis chapter. .
. .
IY\ ..0 .~sMIQt CP~.~ <DP<Hms
. .. " .
.~ .
".
. 'lhe avaibbUity of · ten hl2llall 'l:unO'r,ce'l1 lin;s provided sufficient
• ; . ' _ " . f
'm t ed al upori which to baU th ese sl:u:11es, and 't o se1e:<;t key cell lines
. . . ,. .
r f~r f urther·· eo.:a1uat i on. By~ta1ning these ce ll lines in culture as
descr~ i n section ' II 1.0, sufficient cells.sere gene rally lIValllb le .
for 6j!eriments .t;o~ per£o~, pr.j.,,~ded t hat ca re 'vas taken in. the~r- :'
hancUi":l. especia1~y in ' the preven tia'; of infecti on. cnIy , two flasks of
cal turcd ce lls ' ,o::un2ODKJ ~re disc arded dur ing thece stu:Ues followi ng
~f~ticn w1t!\.~~lOC~ aur,eLlS, which ~t likel y, occX,-ed f,OIlOW--
irig" ,'" breakdown~ sterile ~ectni(Jue. ,- e: " .1 .'
.. .... . . . ( ' . . ' .
• Imunoc:Ytochc:~i.cll'l s tud ies of the a,:all~}.e ,)ceU linQ8 ~~ngl
11-28S-l~ er:abl~ s inW tanto UlJ evaluation 'of~ ta~get and antibody, ~
both~e"ts 'were C8sent1~ly inter--dePQ~enl:.-.'1bo.SPCC1fiCil:~ ~, ~ ,
IflOllOclonal ant ibody 111-2 85"',14) f or a:A Clpitopc!(s l,' wit h litUe 'tq\ .e e
,. 'no n , l ', cr o~.- ~e;"tlvity .... qUAlified In Sc\:tlo n I M, moklll<J I t '
pol:e~tlal1Y Il suitAble- ca rtier f~[ !lUCh .4I\ aw rOilch. Its usa M a:':t ool
' I .
. to 'chl:lrbCter,J.se the d.lstribution o~ the utget ant igen . "';'J" Ie thor~foro
jUlltJf il!d. '. ' .
..
.~
'13 r:
~ .
intemediate antigen expres sion .
--~
'-: .
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The Immuno~rOxl.dase te<:hnique WA.8 prefer red, becaus e eore
info~t1oo regard i ng the, ceilular .distribution of aA (cytoplasmic 0'[
Ilurface) could . be gained over 'the bm.i1of l UJl'escerc e t ee .....lque, which
,onl y '~lted 8urf~e . relICti;:: 'I'he 1a~~r ' eOqeia~entl)' gall' a i ow'r
~man perc~t.,ge ·Of ~el1s exp[~S~ the an;i~en for each' .~rresp:xdil'l9
cell l ine tested , as Is apparent frOlll .fi qut'ea 1 '!'f'ld 2. In DJi tlon ,
. ; 1.bj ectlve .ls!1 SSllent of ~fllJO[esce:rce ' slides ~¥ more d~ffJC~~'
ani the permanent nature of ,the immoperoddase reac tion , enabling
sl id es ~ be stored fOr later revtev , was a d~t1nct advantag e .
Figur es 1 am 2 i llustrate the range of a:A expression by cel~
eac h cell~ine, Md cons i8ten~lhigh ~[esSO[8 (by either ~ecMlqui!l
. .the ref·o1e i~looe ' ~16 , SKCm. B~ am LS114TJ tntennedlati to l ow'
. 9P!~SO[S. ILNO, ~~~sl837 1 and non expreescre, cdm2.oai Md A549. -.
;:-- ...
In the eval uation of the selectA.lty of ta[geting~ it would ~
Jr!p:)runt to cont ras t re8t1lts obtained using cell 'Unes .of qUite differ-
ent a;A expressivity, 8lJ:h as arrJ o~ the high eepeeeeeee 100116, .!lJt00l,.
BENl, lSl74T). wi t h ,non-exp resso cii (QL0320 DH, 1.549) . A further re fine--
rrent would be to la ter evaluate the respOnse ualnq a cel ~ Hn e of
'\ . .
' . Bi rding BtucUes, using t adiOlabellJ 1;-285-14• .kre er ec perfo rm-:
ed to ,'coofirm the bi rd i ng of IlI\tibody to ) rAng~ of cell une8 exp,e"i~
, . , I '
. CEA, M selet;:tcd fr om ilml..lnocy t:~hmical A8Me~nt, ' and alob t o attUTq)l /
t o l3:w:""titat e tho nl.llbcr of 4I'lt~ nOl,ecul eo birding. . ' .._......
. several fltt urpts were' rrade at [adIOlabe~ling. ~ follOlllng the
~LlXe8s£ul icdlnation of' one batch;.of , 117285:-14, ~lth 'con fi rmation of Ita
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I , ' .
antibody b~ act1vi~ ~ a.~SA lsectl~ III 2.2 ) . this was erp!C7fed.
in a binding 8tldy UB~ selected ce ll llnU to illustrate the pdn-
• "' • ••P-::.- •
• c!~e" . Fi gure ' 4 clearl y Ulustr~tea the dlfferenc:e in birding of ~
Mt1bo1y t o two Q7A expressing cell lines , LSl74T and~, ca:pared to
the ncn-expressor , aIJD20D1. · 'IbeSe results were consistent with 'tho6e
oota!fIed prevl~lY ~ ~ OlCology ~earch 'Laboratory. \.
\ Quant1ution of the nlr.ber -of antibody birding ecreeaes reveal s a
s imilar nurrber bi nding' v> the Q".A expressing cell lines liP4T and BEm,.
'N!S' a forty fold red~tion ' of bi rding t o aLro20~ . This ;esu1t !MY
!'-- awear surp rising lilt firs t Si9~t, as i t ~1:>uld .be expected thal. ant1~
. ... . r .
tJin!ling wou l d no t be d et ected with ~~-\Pr. ~or. . This may be
~ explai ned , however, by t he relative insensltiYl~: 'Of the l lm1unoc yto-
\. chemical assay , ;;-t\ich !MY not detec t b i rd ing at tth'is l evel of Mtibody
~ . ,
oAturati~. '1he/essential. featu re illus t rat ed ~re is that ill range of
bl~lng e~lsts ' aver this ~entratiQ"l r~e USt'd.'o, .evi~e f em
other work in Chcoloqy Pesearch irdicates the ' background ' level of
. \
birding of a nctt-specific IgG ( fr~ the Age Sf()USe myelcrna line ) i s \ot
t hc level of 3xlO. rolecules per cell ~ which Ie consistent with the
,
It should al EO be noted at this poi nt that such st.U:Hes D.BBume
t hat D.nti~cn density i o equ"t f or edC~ ce~l. It maybe derronst rated t h1,t
this 18 not tho ceee howeve'r , lind antigenic hct o[cqencity My bo "dcntln-
dtr~t'd by 1JmIunocytochc!.m1~al st~ie8, DeG 'pl atcD 4 llnd 6, ~here it i~
peen that not w ert cel,l 00 the slide has been st ai ned, and tha t this i 8
....On hetecoqentlOUS within ~he c.ll 1t.8elf" . ~,......
I. . #
. I
\..,/
I
-. .' ''''-
IV 2.1 _ to~[ate ~~ mtti-alJbioclcnal Ant1balies
. Two fUSl~cl'~~i"f;nned in 41\ atterrpt to geneclte aaUt!onal
Mlti-CFA rrcnocl~ ~~S ' fO~ ' chacllCterisation as potentill1. carr~
I •
eld . ..
- ~
It can be seen frau 'the hisl:ogrMl of 4 representative screening.
fLIS1\, figure ,27 , that several \tells tested exhibited anti-Q'J\. ,~tivi~Y,
although this disappeared on slbsequent cloning and r~testi~. The
non-viability of these crcoee was also,il.warent on microscopy.
,No fl[ll1 'conclusions CM be drawn f;an these attempts at nooocional
antibody proouction'in view Jf ,t he limited ntrrbers of fusions perfomed. '
I The dmonstrlltion of anti-o:A activity at an early stage 8~ge8t8 that at
, least initially the fusions had been successful, an:1 it 8fPellrs as if the.
problem arose at 11. later stage, in maintaining villble hybrid clones.
r-» cloning waS performed to prevent overcrowding of. cells, but
appeared to beve little influence on outcome. ,
'ltlese two fusions i'::~trate th«: difficulties that eeree In the ,
generation of ll'OnoclMa1s using hybridoma technolo:y, and indeed several
• invest1gtlt~rs ' reported many initial attempts prior to obtdn~n9 a
_, spccessful ,f us i on . The reasons for this, too, are ' W'C~ear as _rrM'/ ~.
factors may influence cceccee, No furthe,r f~iOllS were att.ed as this
IV 3.0~ IN vnro
was 'not a centra! ehere of this thesis.
\
(
•
-- "\ In, keq:ling with the theoretical predictions of targeti"9' ccnju-
\ .
gate efficacy in vttrc ' is clearlY' dUl'lONltrated in figures 5, 6, 7 ~ 8,
• • \1, ._) • -"'.
/
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Whe;e dose-response curves shOw a ptCXJfe9sive reduction In percen~e of
. _surviving cells to inc[ea8ing·.antibody"'C1r~ c(W:entra.t~on, ~ eech of
tre;J...CEA exptessing 'c~~l 11,008 L5l74T. $~l. B~ am the intermed: \
iat or ffI'29 a"reevaluated. . , .
. . .....
selectivity is confirmed' by the abse:ooe' of conjugate 'response upon,_
the non-exPressing cell lines CCL0320DK 'and A549, over a similar conc:etI-
, ... -
tration range , figures 9 MId 10.
Table 10 shows the a:A expression of .the inUvidual passages of
c~ll linea used i n each of.. these experiments, alt.l'lo!.J;Jh cell smears of
AS49 were rwt availab)?: " ,
Interestingly HI29, an intennedill;te / lOW" Q'A 'expre8so r (.17\,
figure 1 ) (passage nlrlber 22) used in this 'particular ;~~l:!!~trated­
in figure 8, was not detPnsl:rated toexpreas Q:A, within the sensitivity
I · ..
of either iJmIUnocytOCheriti~al assay, (table 10) , although a convinQJ..ng
reaponee~o c~njugate WAG still cbtai~ed. 'l1le reason for . ~.i~.: is unclqr
as prevtcca experterce showed that on average up to 20\ ~9 cells on
ce~l smears were antigen expreasors when tested usir"19 U~-14 at 10 lIg'
ml-1 by ~roxidase. It is possible that' for t his partiow:~ cell
, , pasS~lB -Were 'stripped' of antigen ~ ex~essive trypsinisatio,':!
during 'preparation of ,lls for assay and that a§ter 24 hours reco very 'i n
# cureure nedium, suit-icient target sites had been regenerated for a
conj~ate affect.
,
~ther ieature of interest Wicated "by,tilea;, ..resulbt' is that
regarding the effect of tree drug. Although the limitations 'of .its use
. . ,
- .
---
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as a .control or for a direct ~<lTPBfisoo to cmjugate .were addressed in
the introdu::::t1on to this chapter, section IV 1.0, it can be see.P"frOOl
each ·Of .. th~ dos~response curves obtained t~t vindesine used alone
caused cytostas!S with six c:ell liness~~ the vinca Alkaloid was
eff~'tive' upon a .range- 'of h~ torcr cell lines despite their source
. (colorectal or lungl and that effects were seen in ?eneral at lower
ccecentreejcee than for conjugated drlJl. '!herefore, eben a cell line was
. ..
s~it1~ to free drug, II conjugate effe<;t was only seen with cell lines
expressing the target antigen. This is in contrast to results obtained
• with 00116 (high expressor) and.-Sol837 (law expressor) which" were both
insensitive to free drug and..C~equently also to coojugated d;uq. '1lle
explanatiat of the observation '~~j' vJ,.ndesine is effective at a . lower ,
cooc,ntrati~ __ ..range i~ ,specutau v.e although it !My be that the smal~e[
vindesine molecule is internalised faster by the cells in this assay
system, .('':lnpa~ed to its conjugated c:;olJllterpart. '1llis byp>thesis asSlJJDCS
thll.t intemalisat.ioO is required 'for the drug to' exert it; effect, which ..it
is likely but tlot pr6Jen.
Tho valt're ~f .'a m1C~£~tasi~ ~say I'WIar to the c\re ~~ .1n
these experimentsl as a predictive teat of hllTlM tImOr chcrnooeAaitiVity,
. " , ,
in canparisoo to other avalleb1e assays such 8!l ebe clooogenic ansay
, - .. - ~~ , .
(~I 19841, bee ~~ess~ (Wilson, Ford, Newmnn " Ilowell, 1984) .
~th the Clonotnic dpd monolayer llSSays were found to be cOllP'1,r6ble,
sugges'Ull9 tftatonon-elonogenii:: assays have val~e :in in vitro pred~ctlvC!
teoting• .:..In order to 1Jtprove the consIstency of reD~t81 tests inclUded
I In this , thesh. were performed throlJ;lhollt in qll~r~licatc rot:hec thnn
t.ripJ,lcate,
OthM qroupB, too, have r~ported sitrdlar reB~tD ,Of , conjugate ,~
r
..
•J
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efficacy in vitro, and the efficacy Of . pplyclonal anti-a:A antibody
v~nd~ine conjLJgates has been well docurrented using a similar ntceccyec-
staBle aa~y to . that used in these 's t trl i es IJoMSCI'l et ai, 1981; ~land
ee. ai, '1982) . With noncclonal ant~ ~arrie", in vitro efficacy has
J . '. ( .
been reported for conjugates conpda1ng adrierrriCiiI and an anti-sp4 (rat..,
rn!II11llary carcinomal. l!OllOClonal an~ (Pm ee a1l, 1982) and using·
COlony inhibition assays and 7S~selenarethlonine !ncoq:orat!on aSsays ,
RQwla,rrl has recently reported tIe efficacy o~ vtrdeetne conjugated to
rron~lonal anti-n-elanana~ plti-=OSte,?genlc sarcoma ard anti-cEA antibodies
(bflard, Axton, Baldwin. BrOom, COrvalan, erbleton , Gore, Hell strom,
Hel1stran, ' Jacobs , Marsden. pInin, Sinrtor'M:ls & 9nith, 19851. By elIF1oy!n9'
I cell linea of both positive am neo;jAtive tArget antigen expression, thi
in vitro ~tlXllesout11ned in this thesis have also conf im!d Belec~lvlty
of the ilmlUnocoojugates in ad:!ition tp efficacy .
, t . ~/ ) ,~
Ileptootx::ibility of this assay was r~rted in section III 4.2; arrl
, figure 11 ~-\eArlY sOOws that the assay was reprcducible not onl y when
~Ormed at ,di!fe~ent. tines ·, but eree...... ;hen performed by t¥ different'
investigators . Result.s have been incq uded for two different CFA express-
. "
ing cell lines I SKOOl, a high espreeeer, where conjugat~ 1fica:y is
aqain demonst.rated, ~ <XL0320DH a non e.xp~es~or, vdemons t rating .no
conjugate effect w hence the selective nat ure of tat9otirig •
..,r~ \' , ' , I
. AD .all .invi t ro ass GYS were performed at ~1fferent times throlJ;)h-
out the year, different batches 9f 11-285-1.4 vfrdeetne conjugate were
, . ,
EIfI=Iloyed. (iqUr~ 12 illustratos the . c~p4rl1tive efficacy of f our.
.'_\ different Clon~~y=) ,~eB t.ed against LSl74T, a Q'J\ expreesor . 'nle
. '.";.
.
•
, .o ,
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var i ation !it the ~e-- ('esp;xl;se curves likely represents the in::1ivldual
variation of (FA exPress i on by the cell line, l58 these assays were not
perf ormed 8imJltaneously~ Id~lY: U\,is exper1Jnent would be [epeat ec\
using a ce ll line of ttJe same passage m.rrbe r , perfcirmedon, the sese date,
Md. testing' each . of the conj ugates t:09ethuo fbw'ever , the s~lat1ty of
eac h curve d~trates the efficacy of each of t hes e cmjugates , as does
...~ demonst ratia: of tIle! r anti-crA birding aCtivi ty c0rrp3red' ~o the
a
parent antibody 11-285- 14, ~ tested by ELISA, figure 13 • . •
These s twies ~e also dem:mstrated that c~jugate eff icacy I s
'if maintained for at l eas t several, roonths fOllW1ng t heir p repara tion, when
stored as outlined In awendix A. Periodic evaluaticn of the con j ugates
'"in vi t ro .has cont i nued the efticacy of these IlO'lOClooal anti-<:FJ\antibody -
v!OOeSine conjugat es for up to seven mon~ post-coojugation. and th~
\ /
"'''''
~ never previously been addressed .
lV,4•• mE IN V"jO ItCDEL
As alluded to In seetlal I 1.3, the ~tlng of !"t"'~liy new
anU""Car'I7;[ drugs has been ~ject to crit.1ci sm in Vi -=", ~f the cateb-
11ahed practice of sc reeni ng these agents agai nst.. rodent t umors of
debatabie r~evance to the human. Although D1l accept.ablf'tmor rro:lel !MY
~fNC'c' be canpletely agreed upon, the use of xenografted hlll'iUl tuno rs i n: "
, !rnnun08lq:pCessed mice or ra ts i s becoming inc reaslrl9 1y used_ !~r, such
ptJrpJsea : (Lane'et aU t.orial , 1978) and has al so recei ved furt.her reccn~
suwn,t l'tasSI : 1984) . .. :/ '
IJmunoeuwrt8cion IllIIY be ach ieved G9' a consequence ot cCJr'I9Cf1it.Dl
, . . . .' . .
' ,.
.,"
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thymic aplasia, . as in the nu:le mouse (Pantelouris, 1968), or following
inmUl'108uppresalve me~u.ft!s such as thyrre::t~, the administr"ation of
8rlti-l~te serum., eYEotoxic drug ,trea~t and woole body irradiat-
ion (castro, 197,21 .Steel, COurtenay' Roetom, 1918) . 'n\e increasing use
of the nude ncuee in such a ", ol e is evident by the establishment of
In~emational Workshops on NIJ::le Mice , although the ~uppressed mouse
Is favOl;Jred by many in view ~f its ease" of han:Uln9 and cost (Steel ,
Courtenay, Peckham, '1983) .
'Ihe methDd ",of xenografting. tcy.I, TNl'f vary from the sl.bcutaneous
inoculation"'of ttmlOr cell. suspensiC7.1S as perfonmd in these stlxUes am ·....
~f others (Fogh, Fogh , Orfeo, 19"171. to the , direct s~utaneous 1Jrpl~an- -
. tation of fresh surgically resected ~1Iten8• . which rMY then b:e main-
tained by trM8plantation between mice when the tLmOr reaches suitable
proPortiona, a proce~s of serial passage (HotJ:jhtoo & Taylor, 1978a) .
,Using these methods, a wide va r i ety ee tUllOrs' ha'ie been xeno-
• ' ~ I into iJrmuncdeficient hosts 1rcllXling ccrcrecear tlJll'Ors (~iQJ<.ard.
Cobb' steel, 1975, Houghton et al,1978a) " bladder tUlrOrs(~
. ' KfFlazis, ltCorfbs , Peterson, 19841, lung turrors (Mat t e rn , . _waY~ , Haag,
'Ibanes "Volm, 1900), breastt~rs(B4iley,Gazet, sni.~-","Steel, "1980),
rtiabdonVosa~COfMa (HOl.Jlhtor:, WUliaas, TouanC~ , HoI:4~ton, 1984)' and
&lAnCl)'lM (Fod8t~, Ma~ , _?hil , t1900')~ oddi~ion-<:~ varie ty of c:ell
.. ~-.--"
lines, ~l~i~ ~)' (St,~~.' seegertat " White , ~anson & Drewinko"
19(0), SW.UI6,. _(X1(ig, salziMn, QulNh -Melincoff, 5edmak,,_'l\bba & ,z~rawsk i ,
1984), HT'(.9'; lii174T M::t ~4g' :-(F09h et al, !!nn: ' -," f t( . ./' ' . . ,
~ y Much attention ~ ~ given to the ~~eac~edsat1on er . tl:!ese r
~~anted .'t urc rs , e8pecial~ with #~egard to the mah\t~e~4{l.Ce Of ' •
" , . - , ' . ~
, i ~ .
~ ' ) :.,
.~ , 267
Ori~inal t~r hi~~Ogy ~Hooghton , Taylor , l-978b1. Kyriazls et a:'
1984), tlm\Or markers (Thans~ Neville, Phelan, sceneenc , Vandevoorde,
· 1981) i ncJ.trli ng CEA (Lewis, Snith , ~eep & Boxer, 1983) and eerce kinetics
. (sprang-'1bomsen,Nl~lsat , ViSfeldt ,~ 1980; "'Spra~g-Thomsen & Vinde~ov ,
1984) . The ~tent t o which these charACteristics are bintained reflects
the usefulneSs of t he tUlTOr ITOdel, and this. has been addressed in JOOSt of
the stlrlies referred to in addition to reviews (steel ' Peckham, 1980) .
cceseneue is that s~{ xenografts do maintain . the r biological
ttml)~ characteristics , for at least up to 10 serial ~5ages if trans-
plantation is employed 'I. (HOughton et al, ,1978a : Steel et aI, 198] ) and
this includes the 1IIaintenance of histology, tumo~ ,marke rs, inoenzyme and ~ __-,=- /
chececsceai patterns. Host : reeponae t o the xenOgraft is essen,tially
minima l and inf requent , with eurcr i nfiltratioo by host · tissue and
me~tases being :mc~ findi ngs. Steel comnents on reports of host
' response to t UllOr occu ring in 1.nIwnosuppressed mice, po;;sibly followi ng
inc~ete i~osUHJression, and the uiccencn OCfurence Qf this phenom-
ellen in the nude rouse (1983).
IV ".1 Xenograft Ow:llcterisation
.'1 , ' .. .'~5pite ~t\\init~aJ. prcb~of establishing a nu:l~ neuse COl.ony
and 'the precautions necessary tOi the handling of these mice, it was fel t
, ' :
that it was more convenient to work with the nude neuse rroclel rather t hM
. atterpt inmunoeupprens ion at this institutioo.. .
Pre limi nary expe riments - (Ford , per s onal eommunicationl had
e~tabl.1shed t hat "h i~ocul um of 106 viab l e tunor ceils did not [(~sul t in
established , t l\,..~OW~h and thetefor~ 107 cells were usid as the
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1nocultm 's u e in fut ure exper iJrents . '!be overall ~~e· Qf 93 .6 ' 'for the
1n1tia: ~ tlElOrs gram for Charact~sat100 was~[able to t hat of
90' lIChieved by Fogh establishing xenogratts f CQll 127 t tJ:lOr cell l ines
(}977) . '!he range of t tm)[ -take- ~ seriall y transplan ted ttr.'Ots is
· [~~ted quite vadabl e but averages at l ess than SO\ (steel ee aI , 1983)
:- a , f urther re asoo for direct inoculation of t lllOr ce ll l ine s in this
mle1 .
Of the ten Cell lin,es availab le f or charact erisa tiCll. nj.ne were
grown as xenografts for Ch8.ract eci-"oo priot . t o expe rhoont atioo . with
,th e eeeperco ' of SKCOl . The cell l1ne SKCOl was inocul at ed i ni t i ally at
~ 'outs et of experiment -'4,- -and--as_tbe res ults f rClll t hi s experment
indicate, th ese t llnOr8 f ailed to grow. 'Ibe . growth curves of individual
SKCOl. t ll'lJOrs are shown i~ fig ure 24 . Follo"'l ng t his t expe r ime nt an
atterpt - was made to grow these tuncrs by using inocula of ~reasing 7
cell nU'!'ber , up t o 7.S .J: 107 ..q.abl e cells , and ~8 'too, faii ed t o
achieve t lbOr -take-. A c d tl ci6ltl of this l atter exper1Jlent rel ates to
the prior lnoc ulatioo. Of.. mice ~l~ 107 Sl:COl t tm:lt' cells ' , am ideally
inocula of increasing cell nurber sho uld be injected in~ ' fresh ' nooe
m.:e . It is, b::lwever , lmlikely tha t: prior i nocul at i on .looW1d be respons -
ible f or agy tlJlClr 8t.Wrees iCl'l ~ollowing a l ot er chal lenge, and· it i s
possible t Mt 9fftlter-thon 108 vi abl e c el ls, will eventually be requrr ed
to ',establiSh9~ of th:ls cell line ~ xe~ro.fts i n the futu re .
Alte rna t ively it 'IjollY t>e.a cell line that: is 'resistant l to 9 ro.lth i~ th e
nu;1e mouse . ' ~:.,
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reco rded were that of tltnOr vol uZ aro weight at the tilre of sac ri fi ce.
'!he necess i ty of fOllOlo/ ing u.e gr owth of tlllClrs in prel imina ry ard
targeting exper i..mslts enabl ed 9r~urves t o be cons tructed for the
C~ll lines used in t.hese elperthnta. 'rneeerc re for trI'29 , LS174T~
CCL0320DH, ~. and SXOOl, the growth curves of contr ol tlm:l rs frm
expe rb:ents ut ilising these ce ll l ines. .are represented in ' figures 15, 20.
18, 22 and 25 respectivel y.
Particularly . striking was the SiJll1la.r1ty between g rowth curves
obtained f or the ffl"29 F 'Afl:s in experiment A (figure 15) Md t hose
r epo r ted f or th e ce ll ine HI'29R (Wuenius , Freedman' Blee¥n. 1900) .
Tumor growth approxirna well , with the Gcmpertzian function , and in
addition, the spontaneo us regression 9£ cccasional tImOn corresporrled
with pblished find ings (W4reni~et al ,. 1980, ·"sp.rarq-'!\loosen e t al ,
.199J1. The expl ana tion of the latte r phenanenon 1s not knCMJ, although
vasculari ty at the sit~ of inoc ul ation am the rOleJff local trauna have J
been proposed AS contributing f actors • •
r:
Figure 14 co rrelated t Ul'Or vol~ to weigh t At the tenninatioo Of
the characterisat1«f studies , where a co rre lation coefficient" of O. B5 We3
~tA1ned for 41 of ~ pose1b.1e h t\llOrs grown. '"'": fOOr correlat~on of
wei ght to vcnere for ttle aix JAVO. xenoq r afts studied (COrre l a tion,
.coeffici en t 0. 65) ~as Il'I06t likel y II re~lection of the high propor tion of
tUllOr necr osi s ·exhibited by the setlllOrs, as has / been report ed by cere ee
. ( at raqa~ ,It al , 19lKi>." 'I1ie overal l cor ~e~,~tion of these two'tlA!'lOr .-
~paramete [8 obt ained for a total of 154 tUllOr8. inc l uding eeee used in
~
,'('>,2) . 'rfe ee resul ts Buwort the view that -t'
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turro[ groo.:.th in Sl.X:h a nodel .
The me~urenent of tlmOr volume~. in erese studies followed
~t of Evans (1983) , who. used the fonnula fOc. an oblate sphero~d to
eatpIDSate for the f~t ~t bmlors d id ~ q~o:.. as tt:Ge spheres . Measur-
I . 0 0 ~ •
in;I the lMXitnum tun:ct" length (L) am maxinm woor width (Wl at right
anqies , itw"'AS possible to calculat e tuoor vol urre (V) using the formula:
i
v.~2
\ 6 .... . ~ . . ' ...... ,
/ several otJ:!er fonmJlae have, been repo~~ed__in the literature, and
Although the- final vcnees derived by each are all of sWlar magnitt.d e,
they eaaure that growth 1s equal in all dirrensions. suc~ exlmPles lire
listed below, where D represents tumor di,ameter, and ~ tl.lflOr heig ht .
v · (D) ) x'C'l/6r-
V. Lx (W)2 x 0.4
V= L x W x H/2
V ... L x (w)2 x ]/2
(Warenl us et al, 1900)
(Kyriaiis 'et ai , 1984)"
(fbol1~ et al p 1983)
' IFods t adt et al , 1980)
rte irregularity of gross tUllx:lr morphology has been mentioned , and
it was felt that the site and depth of tunor cell inoculat ion was
, '
InportMt in determining final t umor IOOrphology. Intradermal Inccufe-
.'tion. either at:cidental or fran thet.is -track , lqp!ared to account for
. ",,- . i 0 0
'-:he skin tethering oc:caaiohaliy .8e , And poyibiy for skin .urceraetcn,
~though this IIII!Y ~so have resulted, in t~ cas e ~f J.ll.rg8 t ':M'Ors , f rom-a
prea8~re necrosis effect upon an area' ~f ~ready dimini~hed 'vasCularity .
o , i ' ~ 0'
(f ' 2n
In only one case wAs there apparent invol vement of the abdontinAl wall
. " "
musculatu re, lhOBt likely -rei at ed to 'depth of t lll'lOt cell, il'\ccul lltfon, an:! .
? r ' " /
in no c~es. vere Il'll!tMtas~~tr.at~ . . . . ' . '.
... . . .... i . , ~ .
. : Haemato,#lin and . ec s n 1 t atn,ing of xenograft tumortr;ections .
'docarnent ed tha~ -the hi stolOgical architecture had. ~ mainta ined , :and
this is Sllll1llarised 10 t abl e 12 . Pl at e 10 Cle~r.ly illustrates "th e preser-
va tion of ' glarrlular " rchitect ure ~ wi tli LS174T, a nrXlerately ' ~ll
differ~ti8ted adenocarcinana of ccrcreceaj odgin .
Exprf!s sion of .(FA. lliustrated, by plate 11, . was 'eval uat ed for
each ce ll l ine, and table 13 contr~ts tAe results of " immun~pe rox - ."
.
. ~ldase assays perf~~ on' representative xel"lC?9raft aect i oMy l1t h the i r -'
inoculating cell l in es . 'n1is indicates that express ion of.. the antigen by
the xe~[aft fa '~[ally re::1LX:ed, ~ keePing w~t~ . ptbl i shed · r~ul bIJ\
(Lew1~ et al, 1983). with the exception of A549 where 10\ ·c~ ce lls· ,
appeared t6 expres s crA on tlflOc sections , carpa r ed to. no expreeetco by
~e inoculating cell 1ii.e. There is AS. -Y.~t no explanation t o ~~unt for '. :
t his obse rvation.
t ,
I
• r ,
' r
, ..
\,"" ".
" ,
A fu rther obser:vation of interest i s tha t of the pattetl1 of ev.
expre;s!on-' by these xenogr~t8 (Cellu,lac; I.t rCl'l'lZll, glatdular), cud 'J:hE!' ~ . -~' •
·considerab) e heter~neity' that exi~ted among i::he~e eecefcne ,
I
, , L . ' . " ,Extraction 'of, cr.A. was .perf ormed from a limited 0 nUlber Of , ')Itdrs
'onty to i lluStrate t!;le range of ~ ·cont ent of xe~raft8 wi~h dif!~t~~
CE!' expression.. Hig~, a:A.~ ~onte~~ was _ ~fOurd f.OI:, ~'hi.?h . exp~re ~~or ~
L9174T and BENN, W..reaueed cont ent fo r ·rq4~ . I t awear8 the refore tr.at
~ - " " " ' . ~ .
• II ~ of 'i:EA,' expre~,lon ~ ,proooctloq .pxlsts ~ eel.~ lines And {
" . ~ , ' , .
" ,~ , . " ;', "" '~'I': " , .' " r , -, '.
_ .: L~~ -"oS". '.( ,.' .. .. 0'
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-their xenografUi. and tha~ even though cv. may not be det 'ected 1n ¢ert.aln
\_,; cell lines by inmunocytOChemical techniques, the antigen may be produced
in vivo, as eviJ::1~nced t; the extraction data. "'& [\11'\ <:FA was not evaluated
in,the; studiesf 4,
Results obtainr.:d from preliminary ~pe[iInents ace surrmarised by
figures ,I S ,.and 16, where it is clear ~hat g[~- of Hl'29 ~""'Un74T
xenografts was sow'ceaSed by ' f ~ee vindesine at _this dosage ,and schedule.
In vieW of . the ·'i~tcd nurrbers of mice used in the~ expe~imcnts. no
further conclusioos~ are made. These expedments c~firmed the 'f eas i -
bility of this rrodel sY~tem to assess therapeutic response .
)
IV 5 .0 TAREJ:I}(; S'11DIES
Having est~l1shed a suitable model with which to evaluate the
efficaCy of targeted chEmOthera~, hllllafl ewer cell lines, on the basis
6f their -'la cl & ' charecter reaetcn, ~re , selected for asse"ssment· iii
~~ individual experJJrents• .
Statistical adv ice had suggested that treatment gr oups. each
contai?1ng no less ~ six .mice, · WOuld be an <adequat e population size
from which ccoctustcoe regarding therapeutic efficacy could confidently
. ~ . ~
be ljI!!lC1e". Therefore, for each experiment, sufficient mice were inoculated
\ slJrultancously so that n~t · leSE than six tlmlOrs would be ~~loocd into\ . . " .
-' \ each of three treatment group; at the start of the experiment:
\ , In experiment 1, mlce were ihocwo!Ited-bi b t e rally , wooreos in the
ker.aining targeting experiments, uni1o!lt.~al inoculatiori was peeronrcd,
F
.'
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'It wat:!' initially proposed that the use of two ecncr e per animal would be
,;wjvantageous. in that a saving of animals ,could be mar;3e, am thiS ' was
. '.
based on the experience of others (Rowland, personal corrmmic2Itionl and
~ {ron the' lit~rature (l,renius, et al, 1980). 'nle latter proposed that
statistical results were similar regal;'dles"! ' of whether the animal
supported one Or two uecra, if each tunor was assessed individually.
~ ~;rc~etion of ~riment 1 it was appareflt' that the use
of two t1l'llOtS per animal had several d~sadvai,tages, u4.lXIing ';ar lier . "
.d iS~~l1 i ~Y" of the h~st ' as. a \esul~ o~ ~ t .lDlO: massf.~" .req~iring · .
~t1fice eaerter than if only one tlDlDr hCJ3 been present. Furthermore,
the" i-nterpretation of ' res ul ts posed additional questions, ~ 'Wi ll i' be
discussed . : As" a res~t of exkr'ience' ;~ fran expeori.rrent I, Unt-
. " • l
lateral inoculation of mice was performed , fo r all slbsequent experurence,
, rnree treatJrent groups were lnclliled 'in each. experiment. Control
mice received a\ intrapedtoneal Up) injection of 1..0 m1 sterile
pOOsphate buffered saline, every two weeks for three doses. Mice, treated
with conjugates of 11-285-14 VDS, were treated on a simibr schedule, at
doses of 10' ~ kg-l with respect to dr\.J;l concentration. The vcnee of
,
cooj\Jlate injected va ri ed between 0.5 and 3.0 ml, depending on the weight
, .
of the ecuse and the batch of conjugate used ' .
This regilren was se!ec:.ted on the advice of Rowland (persona!
coomunieation) who fiad used a similar regirren to treat idee bel!ldng the
MAWI co!orec:tal xenograft, lI'Ill.intained by se~ial passage. HoW'eYer, the
only plhlished regimen in the literature was that: of a dose .of 6 rrg kg-!
(wi th respect to dr\J;l concentration) given twice weekl.y fo r 5 we~ks
..
.I
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~~d et al, 1985) . An ~rtant differerx:~ rega rding s~edUling
. used i n these st~ies rela ted t o the time of t he initial injection. It
....as ,elected for thes; ~tu:Jies. t o wait ' unt il t umors w~re vi sible (tlnOr
volumes between 75 and 150 rrml) ·before !:!tarting t reatment to ensure 100\
"take'" on t unars, whereas :RoIo'land began t reatment .at the time of curer
. ." ..... . " .
initiation, when t ymor bUrdeJl was lowes t . The ro1y exception. to t ills ·
. .
bei ng t hree mice iri experimen t 1... whe re Erea~nt ' was in itillt~. with ..........
inpalPable t unors, two o~ whl ch subsequently g rew i(see ' seCtion IV 5. 1) . .
. ' "\ l ' •
Mice recei~il'l9 Eree vinde~ine " were t reat ed ....ith 1 .0 m1 of t he drug
. at' conC~ntration of 2 ng k9-~ , gi ven on a similar sc~ule.
The intraperitoneal route was chosen over t he intravenous rout e
for its eese . of acc ess and reliabil i ty , . and no adverse physical effects
....ere noted with this vo1une of solution. Repeated injections of up bo 3. 0
ml of a so lution , via the small tail vei n o~ ,th e mouse was not a suitable
al t erna: ive, al tho ugh in gener al the int ravenous rou~ is , to . be pre f er r-
~ ed . The t oxi c ity s t udy, section II 1004. with res ul ts HI 6.3, was
'perfOl'lOOd in view of t he m~h higher doses of conjugate over free drug to
be ,in j ect ed , with respect to vindesine ccncent ration . It confitrnCd that
using doses of free drug ! t 10 and 6 ng kg-l to xic ity and ITl()rtallty was
exhibited within days of i njection , and was not t ol er a t ed by the mice,
. " ';.-
At the te rmination of each experiment , t he xenograf t t'unor£ were
characteris~ in t ne usual IlI!lIlner ee confi rm t hat the rro:lel was still
re levant and '" at ter¢ t o detect any d...ffe rences between t he t reatment ·
gr oups of each experiment . Tabl e 26 correlates' t he inmunocytochemical
cha racterist ics of xen'O;)ra fts from each ta rgeting experilTent with nntigen
expression of the inoculating ce ll' l ine.
.. ·x. , . 27
Consistent "'~th pr ous· .
findings lire the results. thIlt expr~ssion of a:A by the xet"Ografts, fran
. W'hatever ' t reabDent group s tudi ed , is l es s ,than tha t of the cells used for
i nocul ation, The absence of antigen expressi«l by the · SKall xenograI ts
Cexper :LJrent oil ref l ects the ab&erJ:e of sufficient ;";"teci al avauable for
tes~~- .
IV S.~ E:lpert.:nt 1 " . : . , _•.
~ ". sc conj ug.at~ ~ff~ upon the ?rowth 'of ~2OtI'I xe~ was
seen i n this experirrent , as shown by the similari ty of grCMth curves in
figuce 18. Figure 28 al~ cont rasts the fomat in "'lrlch these curv es may
be presented and thi., t oo, . """. no conjugate eff~t. . . ,. --- - \
This wOuld be the predicted "result for a ncn=-cr.A expressing t l.lOOr , l,..
. .
am" inmunoperoddase of xer\lJ9raf t sections prepared -f ,?llowi.n:3 t ermination
. ' of the expe rJ.Jr2nt conf i rued ~ lack of lIntigen expression•
..
Whenmean"turrer vol \lle of CC!'jU3ate treated IlIice was exp~essed as
a" percentage of control , section III 9.4 , i t can be seen that although
these'tlm:>tS reached about eo, of .control values, thIs was nOt. statlst-
~ 'i c ally s ignif i cant when eval ua t"ed wi.t h ... St udent ;a t test. 'Ihese
findings were also reflected by "the t uro r weights at sacrifice, t able 25, .
"'her e the wei~ht of conjugate treated t urors reached nt of control. •
An effect of vindesine was. seen in this expeeteen e, "and this i s
IOOst cl ear ly ~een in. the l ower grllph of figure 28. '!be t WOr w~ightB ~f
the ·vindesine t reat ed t UllCl t'D were 4100 noted to be less than 50\ of
control t unors , al thoug~ no h'istological diffe rences between the ~roupa
_./ .
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were noted . .As no dea ths of mice OCCU[[~rinq this expe r1rrent,
. analysis of va rdence could be applied to thes\':esults .,..outlined in III
9.6 , revealing no statistically sigltificant diffecercE! between groups.
seve ral questions arose as a result of~ ,the bilateral inoculation
of mice ' i n this exper1nent, . t!ll'ld. in the statistical interpret-.tion .of
these res~~ . For calcUIation of 'mean tUmor vcnees, each tlmlOC" was
considered as a diSCrete entity a,nB ' was i ncl Uded in the c~cula~ion ,
unless of 'eccree the tumor was physically missing as may have occurred .
for ~~e tprough the death of. an ~1ir\al . '¥ h tlaOOtS were denotEd by
" . ..
'M' in the- tables of results. whereas tumors, that becere unmeasur:able .
during an experhent , S~h as that ' on the right flank of~ ,IIYJuse 1"in t he
control group of experiment 1 , table 20, were s t i ll slobject to the same
experimental conditions ' as the measurable "tumors and w.ere therefore
i ncl uded in .calculations. .Thi s reason ing was also applied t o the turoors
( of mice ? ~and 6 ;f the same group, whose t~r~, although not measurabl~
at day 3 P;st-inlt:ulation at tJ?e start of treabtent, ....ere inclu::1ed in the
calcu.l a~tiOn of eeen t1llTCI volune because they were still Blbj ect to
" <
.~.r.eatment He , an injection of sterile PBS) and i ndeed all did ev~tua.l1y
gtOW' by 10 days.
', Qle exception t o 't his was a tl.ROOrthat did not establish itself at
al l , ' the left t~r of souse nurrber j of 'the group receiVing Vind~e in
~riJrent 1, bble 22. This turror vol1.me of 0 was not inclLkled in the
estimation of mean t lm>r vcnnee for this group as it never awe ll.red
during the cou rse of the ~r1ment ard llUSt be aa~1mled ( reas~1Y) to
have not -taken- . However, the eoree yplumes of 0 that were recorded ."t
days 31, 35 Mld 38 for eccee nlllber 1 were ioo100ed 'in calculat ions, as
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pr evlow:ly explained.
'lbese prcb lm.s 'IIe,te not ercccnee red .i n sl.bsequen t expe'tiJlents as
'al l tUllO'S ~re pr~t at ~ start of . t reabnent atd were ipcltDed in
the caicula t,tCn of man tmro r vol une, unl ess de ath ~f a!lOOSe. occu rr ed •
. .
cJe cr it!c :t8lll of us ing one animal> t o s uppo r t two tUllOrs ' was
r eg a rdi ng t he exposIJee of each tlft)[ to the a.e amamt of drug or
, ' .
tonjugate . It ass~ that a t such concent ra tiCll'\8 ; both ~lZlOr8 were
. eq~llY "exposed to el~[ druf or conjugate , and 'to !!Valuate th18~ cu rVeS
were constructed 9£ t l.llO [ , burden of mice ~ each gcOl:JP. fe , ~ Sl.IIl of
. the we t1.lllOr vol..J.lll!s car ri ed by each ecuse , When graphs .t mean tlmr
burden of mice in each group .were constructed, they were seen to be
alrroat identical t~ ' that of figure 18 . In addition, ~urther g raphs
_ _ _ _ . _.~~t~~~!~~ML_ ~_l,lllO r _v...QJ.~!...~!...!~f:l3__i._lmCIll__
. (exc l tXIlng the left . tuX)[S to tally) between ~roups , and .v f ce ve r8~. _~. ~.
&ssenti ally thl; final ~[aphiCal fom was silllilar to f~re 18 : th at
the~ of conj lXJ4te effect was fo~ no matter how the resUlts were
present ed. -• .
fborever. l deaU y it would be nec~sary to [epea~ this ~rilrent
usinq ' a unUateral :~ 1nocultlll. eo JM1ntA1n consistency , with t he
other "expe r 1Jrents .
IV 5 .2 B:l:per t.nt. 2
'Itle grllPhical representation -of the res ulta obtained f ran expert -
rrent 2;' figures 20 am 29, convincingly s~ that .t he conjugate i s
prcducing a ,reduction in the growth of LS174T xenoqraftB wheft carpared to
controls . It is per~ pr:e~erence as to which . nethod ee g[aphi~
,
Mean tlmOr vol ume of mice treated with conjuga te reached 30\ ..of
. cOntrol during t..ilIJ secord "';k"of treatment (ie . 21 days ·post-inocl.l1at-
\ . e , fonl , .which was :significant (P<O .OOS) ~ evaluated ~ St 'went's t test.
. . ' \ .-
. \ ' .
, Cha racterisation of .t UlOOrs fran each treatment group conflnred
4 ~CEA ~ress'i"cm"by these X~;aft8, ~e' 26" ani the ~nl~ a!ff~:e~e
~ between g roups when exam1ned histological l y w~ that of inc[e~ .tUll'Or
nec rosis in the sections of tumor obtained from mice t [eat~ with
con j lJ;Jat e •
.'
- ., - --.------------ "/'_ ...
~ExJ?e[iJrent 2 .confirmed the predicted efficacy of . targeted cbero-
therapy u;:>ing ,t hi s i n 'vi vo nOde!. "When taken with expertsene 1, selec-
tivity of this C!WroaC:hmay be . s::orclu::ied al so.
IV 5.3 Expe [1Jaent 3
The results obtairied when "experiJrents 've ee performed .usi ng th e
hi gh ~ expresser ~Em al~ conti~ the efficaCy-.af~_~roach •
. figureS 22 and 30.
,
However, i t ' was also d~nstrated that survival of mice beadng
this particular t llOOr was prol onged fo llowing t reat:nen t with conjugatef
as shown by the 6ucvival cha rt: figure 23. The cceerverrcn tha t mice
bearing this tllllOr gene rally became .cecbec utc W48 . i ni tiaJ,ly made during
7·'. .
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• '{r .~
the course of the xenograft "characterisation studies" and was confinned
"" this exper1Jrent. The Lnc~e~ survival resulting from conjugate
ereeerene is, likely a tBlqX)n1[y effect, as mice in this 9r~ too, at ~e
. termination of the experteene were beginning to show early signs of
cectiede,
When growth delay was CCInJldred bep.;een the. first three experi-:,
nents, 'i t appeared to cocrel~t;e- to . the degree -cr. ~rget antigen expees-
\ sion', aI:! outlined in ' section '~Il 9.2 • .
" , ' . /- .
I IV 5.41'.l:pedJII!IJt. ~ • .... " .
. 'n1e SKCOl~ine was th~ only cell lin~ not pr.eviousl~p~ac-
terised by earlier in viv~ st.udies. · Despite ' a' no growth state having
been established, c~dson Of. g~owt:h curves between different trea~nt
groupe suggest~ that there was sti~l a ' conjugate effect oper~tl~ in
this syl:ltem, figure 25, which presunably would haW occured eariy after
the start of the _experiment before the tumor 'died' as hawened in the
•
control gro\lP .
.
Histology of tUll'Or remnants ·obt~ed fallowing sacrifice 0: t!l~e
mice revealed ' only non-speclfic fmJrng~' arrl vas unhelPfUl in attE!l1i>ting
to determine ~e reasons for this -growth pattern-.
..
IV 5.5 £lEperbaent 5
'this experilTlent is ongoing an1 it can be seen frorn. fi9.uce 26 that
a d.iffecent trend qf t~r growth is ~urrin9' Minimal tlmlOrgc~ of
the control and conjugate eeeeeed tumors is .oc:cuning, whereas a steady
I<
I
/
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. progressive increase in growth is seen for the .xenograf ts of the vfrde-
sine treated group.
This . expedment i s particul.arly interesting as 00116 is 1Io high
CEJ.I expresaor (90\, ' figure 1) and one might have expected a targeting
effect . Rowever, in vitro reeuree (not sholm in thi$ thesis) ,clearly,
irxJicated that ~er\;'! was no eff~ of ·~[ee drug on this cell line, Ie , it
was 'resistant' to ~¥Desirl~ in the uridine assay. In view of this, ' it
was .at surPriSing that. conjugated drlJ3' was ~~effective in vi t ro. With
. the in vivo 'expe.r~~ of c~~~ate effect .coul d be ~[edicJi
fem the in vtfr;;-assay, ~i~ its ;lv~ue asa pr~in vivo 't arget ing
. J .
sysf en. However, while lack of response to free drlJ3 would similarly have
~n predicted fran the in vi t ro data, the increased rate of growth in
t he vlndesine t[~ated animals was surprising . 'lbere is no ccvtcce
explanation to .account for this , other than retardation of gro..rth in the
,::ont rol m:J conjugate 9[~, or possibly, a stimulatory effect of free-- · __.""'-
drug ~n the resistant 00116 cell line when C1rOWTl in viv o .
'lbe re l ative efficacy ~,f fr~ dr~ Upon, _three other cell lines
(CXL03 20DM, tsl74T, BEm) in vi vo is ease quite different as seen by
• • I
contrastil)g figures 28, 29 and 30. Vfu:l~ine efficltCY in vivo i s noted to
be greater than that of ~ conj ugat J against ce ll lines COL0320DH '
(figure .28) and LS174T (Figure 29) weteas for SEW (figure 30), ~t has
i
intermediate efficacy between control arid conjU3ate treated groupe . ' These
. I
observations illustrate .that there is a "relative sens i tivi ty " of cell
11nes to vi ndes in e , ~ 'Although ' not the ideal contr ol , allows results
obtained with_conjugates to be i nterpreted on the ~iS of sensitivity to
the vi nca alkaloids .
In v ivo efficacy has aI.so been reported fo r con:fugates carprising
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warheads of da~1n (~ et al, 19~)~, ~riamycin {Pim et .al .
19821, am for vindesine cmjlJ;lated to rronoclonal ant i-<EA. anU·rnelanana
. . .
.vii anti-oateogen1c sarcoma ant1.bodies (Rowland et al, 1985) . ~rtant
differences ~ methodology errployed in testing the latter have been
addressed in section 'N 5.0, and the studies outlined in this thesis have
not only d~t[ated efficacy uSing a different m:xlel CEA targeting
eyeeen , but ' in addition. conjugate selectivity by B!1?loying cell lines of
. .
different tArcJet antigen expreeetce . "
IV 6.0 .IJIIJlUEBII:1IE, I PIO,!t'ECJ'S
The ' testing of any new ther~utlc approach allred at eventual
clinical use should logically progress ~rough severer stages des.lgned
to assess its efficacy, toxi~ity etc ., ar.d incltrle testing in vitro and"
in vivo using animal sceers, proceeding through Phase It II and III
Clinical Trials.
\
'1lIe studies in this t hesis report preliminary results confit'lldnq
the efficacy ard selecti~ity of ' inm.rloc~ther~py. in vi t ro- a.Dl3. in: vivo
using a. relevant pre-dinica! rro:Jel, in : keeping with the theoretical
predictions regarding this awroach. Although these results supfOrt the
~the8is of a targe:t1ng mechan~Sm, they do not prove it .
'll1e use of Q:A as a target in this targeting system underlies the
belief that this awroach has potenUal clinical appl1catioo, arK:l this is
sUfPJrted by parallel studies where a:.r\...-has been used as a ' t arge t for
inmunodiagnosis (Gol denberg ee e.l, 1978J Machet Al, 1900). Il'rleed st:eh
studies h~e progressed well beyord the level reached by irmuncx:heno-
therapy am the administration ·of antibody radi oi sot ope conjug8tes to
. ,
-,
\
\
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& patients is wefl documentoo for both di~noslS 'And therapj ( Intematio~
Syrrp:lsitJll on Lab@'lled an:! Unlabelled Antibody in cancer Diagnosis an::!
nterspy, Baltirore, 1985) .
\ In add i t i on , collaborative studies, 'pe r f ormed in 8irminghllll. U.K. ,
' - - e:-al.~t'lng the use of the lI'OIttloo .al anti~ antibody 11-28S-U, as a
carrier o~. ~~onUC:l1dea for i1m'unodiap1oslS have confinned the feasi1:l~l­
it:Y of adminis tering such conjlXJlltes to patients (lUllmI et al , 1985a, ~ ,
~ are proceeding wi t h f urther clinical eval uation.
'., .
'SUch ' st udi es , in ~ition to being of i1rp>rtance 1n their CM\
right . di agnostic all y , provide confirmation o f the rationale fo r using
such an ' atProach, as evidenced 'lr' the selective uptake of antibooy-
isot~ conjugates at "tar13e t s i t es , ard prcv fde additional confiden:e
with the admini stration of other iJrmunoconjugates to patients •
. The use of anti-neoplastic drugs as . warh~S ~nderlies t he
conviction that this approach has clinical appli~abilily as eoee d[~s
have already been administered to patients and have rece i ved extensive
ctmtcerevarueefco, Although toxins have not seen use clinicall y, i t has
recently been reported that approval .has been granted for clinical trials
of irnnunotoxins to proceed IIntemati~al Symposium on Labelled and
t1n.labelled AntibcxUea in cancer Diagnosis ~ Therapy, BaltillO re , 19851.
am preliminary results are to be expected in the following year. Ho..te.....
er , the use of vinca alkaloids as warheads may receive criticism if th~e
antibOOy drU3' conj ugate s are used clinical l y , fo r exempre, t o treat
ccicreceat cancers , which have been shown to be W'lresponsive to this
c l as s of 'agent (o r indeed any othe r), deaPitt'convincing effic3Cy "9ainat.
colorectal cell l ines dEJOOnStrated in this roodel. I t should be et{lhasi a-
ed however tha~ the conjugated form of thes e agents may well eventually
..
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be shown to be ef fec tive against a range of hi thecto unlikeir tunors (by
today' ,s standards) in view of ti}e sel~tive nature -of trils therapy • .The
coupling of many othe r ener-c anc e r drug: to a variety of antibody
ca rriers (section I 6. 41 Is encouraging in thi s expanding area. .
several f l.llldament al question,s regarding this approp:ch are out -
standin g , and although extensive furth er i nvest'igati on .is·requ i red, ' i t
eeee not necessar ily preclooe the' i ni tiat i on,of clJ,nicaJ. tri al s . Indeed,
. . . ~
awroval for the adminis t ration of ~tibocl:;t' drug c¢njtigates ' to patients. , .
~ recently been granted t o sane workers in this area by tlle Food and
Drug h3ininis tration (F.D.A.) and pre limi,nary results a re to be expected .
4
i n coming years ( Inte.rnational S'.fnt:'oSi~ on . Labelled and Onlabelle<:I.
A!,1tibody in cancer Diagnosis and '1tl~rapy, Baltimo r.e , 1985). in t hi s
regard, it is worth noting tl'lat a prel imi nary ' f eas iq il i ty and t oxicity
clinic al stLrly wi th .po lyc lonal anti-crA ant~ vindesine conjuga;.e .
demoostrq ted t .hat such 'conj ugat es eould be administered to peetence with
colorectal and ovarian cancers wi tho ut. cdverse ef fects (Ford et ' a l,
• c · ~ ..
19831• .Jl"k~v.IY lIttl, is kncsn of too phydcc>-ch..,dcOi ch.,actedst;e.
of the ant fuooy-drug conjugates tested in t hi s thesis, even thoug,h much
infonnati~n has been generated on th~!J; t wo ccepcnenta , the .monOCl on al
antibody carrier and the d rug warhe~. The exact details of preparation
' . ' .
I ' of these conjugates have bee n retained by th e drug company invovl ed fn . ':.
thtUr ~ntifac ture (S irrmonds, per s onal communication) , for reasons
regard i ng patents etc . although the method ha:> been outlined in reCent
publicat ions (RcI.>l and et er , 1985). Studies to fully document the
physicp-chernical cha r(K:tetisyc8 of these conj ugates , a[~ urilerway . It
28'
has -been suspected however thac : stability of the cenjugate 1&' .11. -
. . 1 •
dependent (through - an effect upon the vinc~ alkaloid CQJ!V>~ent l ~ it'
is f or this re ason ~t conjur;1ates Are sccred.tn the dark at "4oc.:. CARJelld- " •
-fr~ . As little i s known about ·t he l ong-te rm stability of c~~ates. ,
every eff ort was made to use th~· as soon 'as poeetbte after preparation,
.' . ..
although these studies ' have shown that .J:,lleir efficacy ' and ant i -CEA.
"bi nd i ng act~vity is maintained .fOr· at least ' sev~ral m::at hs. fOlld.iing, ·
p~parat1on (roo~ A) . . . . . ' -.,'
.. The earl1 c r iticil:iill of conjuga te dissociaWon in vivo (Davies et
'- , . . . . • - ' .
al, 1973) eppears t,p be less valid with t he use of covalent l1 nka<je,
although \the fate ' of t hese ~omplex~~ followi'ng sy stemic ~inistratiori is
still not known with certainty. r.c:caiisatiil>n studies . f or example; .
. .~ - ' . _ .
indirectly slJlllOrt -the asstmlption that the cont>lex reac~es its - .ta re;,p t
site- i ntact, . al though . t hi s is not proven and i n a&Ution , evide~' of
nOnOCl6nhl ~t~ local isation in ' solid tuno r has _- now been recen~lY
documented (Old~ et al j ~964 ) . ' The !~te df t~ ·C~lex foil~ic9' ~ts'
.. ' , . . , . .,~ ar rival at th e target s it~ i s also open t o speculatiori and ~ SUCh, •
con¢exes ectdeve t heir therapeutic ~ffe:t req uires u ::qe~t investigat-
i on . It i s still not known with '~ertainty whether ,the cOIlpl,ex ' i s . ~ 0
~ , - ,
in ternalised intact by the cancer ce ll • or whether dissoci<'!,tiOn occu rs
fo llowing antigen-antibody interactio l'lto wit h Subs~~t local rel ease clnd' . ~
- C- ( .
build up o( the warhead , follCMed by l ocal ~t!ll kil~. AftIo. · the ,~
amoun t of con,jugated ' drug required fo r : ell ki ll i~~ known~'i~h
ce r tainty as the .effect of conjugation upon the cl ;~ ~rlent r~uiren .
f urthe r stUdy. Howevec; (ro,m the, in vit ro ~iel) of, this thes is .
es timates sugges t that' a 50 , cell kill i s aC,hieved~ t he cpn juga te is
in the 1-10 ug ml-l c onc ent ra tion t ange (with respect ~. vindeo~nc
? .
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j ' . •
' ccncent r llt i on) •
. : ; The· fate· of the conjugate fol1~ing sys t emic administ(at1on , t oo,
'i; uncertain. Thec~exing of conjugates with ci rculat~CEA en rou te
to the ta~et s i t e was a prob~em encounte[~~ i n ear 1y attent'b .at tumor
~ing using antibody rad i oisotope c,onjugates, and may have rel evance to
~ v, therll0' also. 'Ibe, concurrent adm.inis~ration of free , .blocki ng antibody
may become a necessary nencewre in patients with high circulating target
. . ~ .
~ ar.',t:lgen l eVels . In addition, t~e threat of renal toxicity exists if such
carpl,exeS" become d~:t:ed in the glomerulus, aOO eucb aspects will .
req uu:e ' eva~ natiori. simuarl~ the .ext ent .Of the host 's 'owl'l imTIJne
response to t hes e. murine ant~ies also requires cons~derat.!on, but
cunently avail'able ,evidence suggests that this may be of less in'port-
ance t han previ ously suwosed HJewtran , 1978; Oldham et al , 1984; Dillman
et ~. 1984) •
•
',.
oie key area of fu rther investigation l !s that: ?£ the effect
of antfgenlc heterogeneity of the tUllOr upon t he efficac:y of the conju-
g~te . silch. heterogeneity of CEA exPression was danonstrated i~ these
studies bY inmunocytochemis try and ' is a wide ly repcr eed (hencmenon, being
.~e~ent on the epdtnpe recogni sed by the ~tigen and poss~ly on the •
• '" . t lf\Or -.qell cYcle• .The selective killing of target ce lls within the tl.m'K)r
may ~ll accoun t for the initial response seen to coojugate therapy,
. . -, wh~ . cor:tin~ ~r~ of cells not expressing ~he antigen may be
~. ... .
l:espons~le' for "conti~Ued ' t umor'grOwth and refepee ,
Although the h!gh1y specific monOclona l ant ibOdies offer the
grea test p.dvantag~ ,as carrier s , it i s conceivable that the use of
o
.mix tures of conjuga t es may offer further the ro!lpeutic advantag e, especial-,. .
Iy i~ey ere c./lpable of . re60qnising aQjition,al epitopes:of the target
an tigen ( t~erefore d"elivering more wa r head ), or rec:ognis,i nq other
Mtigens expressed by the tumor (therefore theo reticAlly rec:Qijfli s i nq a
greate r proport~on of cells) '. 'lhe latter approach has ~ expjcred in
imnW\oradicdia9nosis, where enhanced~ of tlJl'l'Cts ~ressing (f.A 8nd
co lon spec ific an:ige~p ((SAp) has been obtained (~~ar, Pant , SOOchat,
BeMett , Goldenberg" 19811 Nelson, DeLand, Shcx:ho/It, Bennett, Galden-
o be rg, 1983). The use ,of conjugates wi th 'other types of warhe~ , incl oo-
. .
ing different d r ugs , may a llOw Ito ·combination 1Ilfnun~hel!lotheraP'i·
Antibody on i t s own hea also been demonstrat ed t o inhibit the
gr owth of c:olo rectal cercer xenogrAfts (Merlyn, Steplewski , Herlyn ,
Koprowski, 1900) : However, the eva1~tion of antibody alone was n,ot an
objective of this thesis , as exper ience with ~I .cct orec ear xe~rafts
had indicated thatwhUe sane suppres s ion of tumor ,growth could occur
l at e in the" 'expe r inEnt with 11- 285-14 alone , i t was in contrast to the
statistically s ignificant suwression obtained with ll-285~14 vtrdeerne
conjl,)34te (fbrrlarxl. e t al, 19,85). As noted previously, the major aims 'o f
t his t hes i s wer e t o eva luate conju;Ja te efficacy' and selectivity in
. e
rel at ion to 7arget antigen de nsity . 'Fur t her s tUdy wi ll have t o be
ume rtaken to evaluate the rol e, if any, of antibody al one
J
i n vitro and
i n vivo with the cell l ines used i n this thesis .
Of o::Jual irrpor tanee is t he requi rEment of <!II proper evalua't1on of
the se t ting in which irrmunoconjugllotes should be used. It i s ~81bl(!
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that with other tUlTOr targets i rmunochE!oothe rapy lMy achieve the status
as a primary therapeutic modality in the treatment of selected haernatol-
ogical malignanc ies, where access to disseuinated t arget tUllJOr cell
populations would allow a p[Oporti~ally greater cell kill. An iJrp:lrtant
potential ~lication may be ~ the ex vi",? eliminatiol) of leukaemic or
\ cancer cells .f rom~~e marrow prior to autolOg~ marrow rescue in
patients receivibg' sht!motherapy. studies leading to acch a goal incll.de
the in vi t ro elitnination of C;lll'ICer .cells fran hlm'lan bonE! marrow with a
pokeweed anti-viral protein irrmunotoxin (Uclwn, Rmnakrishnan , Houstcn,.
1985) am the, ex-vivo treabmnt of human bone marrow with antl-T cell
iirwunotoxin' for the 'prevention of graft-ve~us-host disease ,' fOllowi~
bone marrow re-1nfusion ·(Fili pavic h, van eee, rene, QuinoneS, Neville'
Kersey. 1984). I t s role in the treatment of solid tumors (addressed
principally by these stl.diesl, ard in the systmdc treatment of m;tastas-
ea (e!J?eCially micranetastaseB ) requires an even more careful evaluation,
as in:leed does conventional chE!lXltherapy.
Using a relevant model'systen it is felt that the results present-
ed in this thesis have' contributed as part of the . intematlooal evaluat-
i on of ~CX:hen'OtMrllPY. At "present, it is unlikely that illfflU'lochemo-
therapy wi!! replace current conventional chE!lXltherapeutic awroaches to
cancer treatment, but lMy offer ldvantage as an ed!:Ut.i2Ilal therapeutic,
option to the oncologist. It is !JTp:lrtant that unrealistic cla.1Jns as to
its potential are not llI!lde early in its evaluation and that careful,
systematic evaluation · in vitro , in vivo in pre-cl'ica! models 8JX1 in
ctlrefully crooucted clinical sttx.!ies is performed if this iMOVative
aWroach to chE!l'lOthe rapy is to be exploited lMX!mally...
2BB
IV 7 .0 Ft11t1RK SltDIES
Altho ugh al l of the aspeets di sc ussed in the previOUs eecetcn I IV
6. 0) require evalua tion, irm'edia te futu re st\dies, which are presently
belngpuJs ued in t he oncology Research Laboratory, us ing the nOOel
develoPed in this the s i s , in c1u3e the following.
1. Fur ther e~a1uation of a range of cell H nes', inclLrl ing those of
in~ernediate CFAexpression and of diff~~ent t issue origin.
2. An eva1Uatioo of theoptimum schedule aM dose for the admmist ration
of these conjugates , in cl uding the t 1.llle t hat t reat:rent, is beq un, In this .
regard. sc hedules ut ilis i ng"stral ler doses of .conj ugat e give n twic e weekly
are being investigated wi th encouraging prel iminary res ults .
3. A f ull assessment of conjuga t e tox icity with detcnninatioo, of IDSO.
4. Eval ua: i O!" of the ef ficacy of rnfxtures of d iffer ent conjug ates, each
rEcogni s i ng differen~ antigens or thei r epitopes tiOih 1n vitro and in
vivo.
5. The use of addi tional control s for i n vi t ro and in v~vo experirne~ts,
when ava ilabl e , inclooing corijUgates cOlTllrisi ng vindesine and a non
specific irrrnunogl~ulin , and uncon jugated anti- CEA antibody.
6. St udies t:Q inflfcate t he fat e of coojugated vrrdeetne, For eX<l!rPle . on
a ce llUlo,r l evel, i s the conjugate internalised i nto the cell or is t he
drug ' split of f ' outside t he canc er cell?, and in vivo, what i s t he
el imination of conjugated radiol <bell ed vinclesine when administered t o
mice?
7 . Devel opment of a comput er progI"a~~ specifically to hmxlle t he
pre-clinical in vivo data.
.f·:J
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APPEmIXA
11-285-14 Vindesine Conjugates
The monoc lonal anti -CEA ant ibody v i ndes in e conjuqctes
prepa red ~ supplied by the Li lly Rc~earch Centre, WindIeS T ' Sur rey ,
England.
Det a ils of conj~ates used in targetin!/ experirrents are s hol.m
below. 'l1le conju9ates were sto red in s terile centrifuge tubes wrapped In
\
I-(rrent of its efficacy i n vi t ro using a standard cell Hne LSl 74T i n
a 24 hour expos ure rt: ass ay was pe rformed . .
Age of conjuga~e at t he time of use was al so not ed unci var tcd {rom
t lfO weeks (experirr.ents 1 and 4 in vivo) to t hree month!l (expe rin'Cnt 3) •
.-.
at which titre efficacy was also demonstrated . Similar res ults fro m t he in
vi t ro assays. con firmed. efficocy·...Of con j ugates at five ~ths (allowing
preparation (dat a no't shown).
. .
al uminum fOp and refrigera ted at 4 degrees, ce lsius•
. ~jugate _t9 , altoough ' pr epared f rom ti"..J same batch as con:j~~te· -- ,
• . ' .. . ' - ' 0 ' \.
" S. a t t he Lilly gesearen centre; was sent sepa rateley . Upon a rrival "1
however, it appeared turbid i n contrast to the USUally clear solution 'of
conjugate . It was the refore filterd under stedle conditions usir'l9 a
sterile 0,.22 um Millex - ' G\;' filter (Millipore , Bedfo rd . ~tA l and its
con jugation ratio (Ml es l~esi~e to troles 'inmunoglobulin ) recal c ul ated,
fo llowing t he detenninalion of its optical abso rbance using a dual, beam
spectropho tome ter and use of simul taneous equations (Li lly Resea rch ·
----
centre) . Anti -CFA bind i ng act ivi ty was coofinned by ELISAand shown t o be!
\
greater 'than 90\ of unconjugated antibcdy activi ty . In addi tion asscsc-
/
Jl5
~ A - eattinued
COnjlJ;Jate Allti body Virdesine Conjugation Date of
Q>de °Q:lnc:entrat ion Concent ration Ratio - Coo.jugation
,~Jfl1·1 lJ;Jml- 1
3. 862 151 s.s 19-7-84
5 .9 00 190 5.' 24- 10-"84
.s 6.2 10 141 4. 0 . 24-1 0- 84
1. 4.810 124 4.5 22- 1- 85
/
• J
.,
\
--L -
group 1 ' vds ' 2 'e onjugate' ~'c9ntro1 ' 1
/
3 1 ~
COtplter programre (PR:G.DATl for data from ExperiJTent 1 (a:LC61184 .DATl
designed for Manova llIl1ltivariate analysis of variance ISPSSX l
A
~it1e 'repeated measures analysis of colo 6-11-84 data'
file handle rnice!name- 'col061184.dat'
data list fileo"1llice rec:ordsaS
I I group I id 3 sex 5 strtwt:~f1nalwt 6-11 tvoll to tvo1l9 12-74
12 tvollO to tvolll 1-13
var~le labels group 'treat1nent group '
s t rtwt •s tart ing weight'
. . . .
final~ 'f inal uecr weight '
value l abe l s
~
missing val ues 9tr~ to tvo1~1 ( -1)
eencva tvo ll to tvolll by group (1 , 3 )1
wsfactoptime(ll f!
wsdesi9O"'tine/
print's1gnlt lave," / ..
noprint=pararnetecs(estiml signif (nul t1v ,eigen ,di rrenr , univl l
analysis (repeated)/ ·
netOOd-sstype (unique) 1
design
fln,ish
. ,1




